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  The purpose of Phase I of this research was to construct two homology models, 
one each inactive (R state) and active (R* state), of the orexin-1 receptor (ox1r).  The 
ox1r is a Class A (rhodopsin-like) G protein-coupled receptor (GPCR) that couples to the 
Gq protein.  Homology models were built using an existing crystal structure of a Class A 
GPCR.  The ligands 1-(5-(2-Fluoro-phenyl)-2-methylthiazol-4-yl)-1-((S)-2-(5-phenyl-
(1,3,4)oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone (SB-674042), and the orexin-A 
peptide [pyroglutamate]PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2 with 
residues C6-C12 and C7-C14 disulfide-bonded, were docked in the ox1r R and R* states, 
respectively.   
  Another orexin receptor (ox2r) subtype’s x-ray crystal structure was published 
(Yin et al., 2014).  The high level of identity between the ox1r and ox2r, and the release 
of peptide-bound neurotensin crystal structures (Egloff et al., 2014, Krumm et al., 2015), 
led to the latter being used as a guide to dock orexin-A’s C-terminus into the binding 
pocket.  The ligands were docked in ox1r models created by directly mutating ox2r’s 
crystal structure, only using Conformational Memories (CM) (Whitnell et al., 2008) to 
select an R* TMH6 that kicks out.  The new ox1r R* model has orexin-A hold the ox1r’s 
toggle switch residue, Y6.48, in a trans 1 and has part of orexin-A accept a hydrogen 
bond from the ox1r R* state’s H7.39 as per Darker et al., 2001 and Malherbe et al., 2010.  
These interactions promote the ox1r R* state.  The new ox1r R model has SB-674042 
 
hold the ox1r’s Y6.48 in a g+ 1 and accepts a hydrogen bond from the R state’s Q3.32, 
as per Malherbe et al., 2010.  These interactions promote the ox1r R state.  New IC3 
loops and termini were created with Modeller (Sali et al., 1993, University of California 
San Francisco, San Francisco, CA), and the receptor models were palmitoylated.   
  The purpose of Phase II was to examine the homology models’ behavior in a 
simulated lipid bilayer environment.  To do so, CHARMM force field parameters were 
created based on SB-674042 and on pyroglutamate using the global minimum structure 
of each, all calculated at the HF 6-31G* level of theory using Spartan (Wavefunction 
Inc., Irvine, CA).  The result was a list of new parameters that were used in the Molecular 
Dynamics (MD) simulation, and in turn, the results of the lipid bilayer simulation of each 
ligand/receptor complex indicated that each complex was stable and retained important 
GPCR features.  Furthermore, each complex was compared with recently released ox1r 
crystal structures (Yin et al., 2016), and the transmembrane helices match almost 
perfectly, with an RMSD of 0.5383 for TMH1, 0.2374 for TMH2, 0.3416 for TMH3, 
0.3731 for TMH4, 0.3839 for TMH5, 0.2851 for TMH6, 0.3074 for TMH7, and 0.5060 
for Helix 8 between the Cαs of the ox1r R model and the ox1r crystal structure 4zjc.  The 
residues in the ox1r R* model’s EC2 loop that bind to orexin-A’s residues L16, L19, and 
L20, after running MD on it, match extremely well with the ox1r crystal structures’ 
corresponding EC2 residues, and face the same way as well.  SB-674042 in one of those 
crystal structures accepts no hydrogen bonds, as opposed to the complex.  In fact, orexin-
B was docked in the ox1r, and the binding interaction energy thereof was calculated as it 
was for the ox1r ligands, and the results were consistent with experimental data. 
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CHAPTER I 
 
INTRODUCTION 
 
Definition of Orexin-A and Orexin-B, and the Orexin-1 and -2 Receptors 
 The neuropeptides orexin-A and orexin-B (oxA and oxB), created by cleaving the 
peptide prepro-orexin,1 are heavily involved in various activities in the human body by 
activating the G protein-coupled receptors (GPCRs)2 ox1r and ox2r (the orexin-1 and -2 
receptors),3,4,5,6 which are in the β-branch of the Class A subfamily.2,6,7 These 
neuropeptides are given their name orexin from the Greek word όρεξις (orexis), which 
means appetite.8,9  A GPCR’s general topology can be seen in Figure 1.2   
 
 
 
Figure 1. Structure of Rhodopsin, a GPCR, as Seen (from Left to Right) with Helix 6 in 
Front, with Helix 1 in Front, with Helix 4 in Front, and with Helix 5 in Front.2   
 
GPCRs are proteins that cross the lipid bilayer, beginning with an N-terminal 
portion in extracellular (EC) solution.2  The protein then crosses the membrane seven 
2 
 
 
times in order, forming the seven transmembrane helices (TMHs), which are grouped 
together in a closed bundle,2 ending with a short horizontal helix (HX8) connecting 
TMH7 to the C-terminus.2  The helices are connected by extracellular and intracellular 
(IC) loops, and the GPCR ends with a C-terminal portion in the cytosol.2   
Binding by the Orexin-1 Receptor to G Protein and to β-arrestin 
  When ox1r’s R (inactive) state binds to the Gq/11 protein,10,11 GDP is bound to the 
α subunit,12 but the GDP leaves when orexin-A binds to the ox1r to activate it12 
(changing it to the R* state).10,11,12  GTP can then bind to replace it, causing the G protein 
to leave the ox1r, as shown in Figure 2.12   
 
 
Figure 2. Cycle of G Protein Activation.12   
 
While the β and γ subunits increase the activity of GPCR kinases 2 and 3, the α 
subunit with its bound GTP upregulates phospholipase C, which can produce further 
messengers that increase protein kinase C activity and intracellular [Ca2+].12  The ox1r 
can also activate phospholipase D via PKCδ.13  When the ox1r is activated, whether via G 
protein-dependent or -independent means, intracellular [Ca2+] is elevated.12,14  
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Furthermore, PKD1 and PKD3 help modulate Gq/11 protein-mediated increases in 
intracellular [Ca2+].11  The downstream effects of the Gq/11 protein are shown in Figure 
3.11,12   
 
 
Figure 3. Gq/11 Protein-mediated Cellular Cascade.11,12   
 
A phosphorylated ox1r can also bind a β-arrestin protein for signaling purposes, 
mainly via a TSVTT cluster at the C-terminus (418-422), of which any 3 of the serines or 
threonines are necessary,15 as well as to be internalized into intracellular endosomes if a 
sufficient signal is delivered, as shown in Figure 4.16,17 
 
 
Figure 4. The Process of β-arrestin Signaling.15,16,17 
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The ox1r and ox2r ligand discrimination may depend on the system that uses 
them, leading to the use of receptor-specific antagonists to determine the receptor 
responsible for that effect, as well as the fact that ox1r binds orexin-A much more 
strongly than orexin-B.3,4,5,6,13,18  The ox1r can homodimerize with itself,19 or 
heterodimerize with other receptors, such as the cannabinoid receptor CB1.20,21  Mutation 
and/or truncation of orexin-A and -B can actually change their ability to bind ox1r and 
ox2r,22,23 with the C-terminus of each as their most vital part.22  Furthermore, mutation of 
the ox1r may alter its pharmacological profile.3,24   
The Orexin-1 Receptor’s Role in Energy 
  The hypothalamus projects orexin throughout the cerebrum, and the ox1r and 
ox2r are found in differing ratios in the various parts of the hypothalamus, as shown in 
Figure 5.25,26   
 
 
Figure 5. Expression of Ox1r in the Hypothalamus.25,26   
 
The ox1r’s many functions10 include, when activated by oxA, increasing feeding 
and drinking behaviors27,28,29 as well as causing glucagon release30 and gastrointestinal 
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muscular activity.31  Ox1r can even increase obesity resistance32 by increasing lung 
activity33 and spontaneous physical activity.34  Additionally, when energy homeostasis is 
disrupted, when drugs are administered, or when a noxious insult (e.g. arterial occlusion, 
change of pO2 or pCO2, or inflammation) is administered, the expression of prepro-
orexin, oxA, and oxB are altered (increased in some cases, decreased in others), and ox1r 
and ox2r expression tends to increase.25  Orexin even has a thermoregulating purpose, as 
heat acclimation can decrease the concentration of orexin, among other molecules.35  
Orexin can even stimulate hypoxia-inducible factor-1 activity, which is important for 
regulation of hunger and wakefulness, yet can stimulate angiogenesis in hypoxic 
tumors.36  Fasting can even increase the levels of orexin and thyrotropin-releasing 
hormone, as well as decreasing cocaine- and amphetamine-regulated transcript.37  Orexin 
receptors, along with histamine receptors, are even necessary to maintain seasonal cycles 
of energy metabolism.38  The orexin-1 receptor is also responsible for increased glucose 
production (via sympathetic means), which is also a side effect of atypical antipsychotic 
drugs.39  The ox1r is even responsible for promotion of gastric acid secretion,40 and 
cholinergic activity resulting in ileal contractions.41  Food deprivation may even regulate 
the expression of orexin receptor mRNA in many parts of the brain.42  The orexin 
receptors may even collaborate additionally with ghrelin and gastrin to regulate food 
intake and energy homeostasis.43  Orexins can even promote stereotypic behaviors, 
glucocorticoid release, and metabolic rate, as well as affecting luteinizing hormone 
production and inhibiting the release of prolactin and growth hormone.44  Orexin-A’s 
induction of gastric acid secretion is also mediated by the neuropeptide Y system.45   
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The Orexin-1 Receptor’s Role in Sleep  
  The ox1r may even modulate neurons in the retina responsible for the circadian 
clock.46  Insomnia affects 20% of the general population47 and burdens the US economy 
by $100 billion due to fatal accidents and other problems.48,49,50,51,52  When the orexin 
receptors are knocked out, narcolepsy caused by cholinergic activity results,53,54 as well 
as a corresponding rise in accidents.55  The ox1r can also delay the onset of paradoxical 
sleep, as well as reduce the amount of paradoxical sleep.56  Furthermore, polymorphisms 
on prepro-orexin, corresponding to H21A and G22R on orexin-A, were found in many 
people with early-onset narcolepsy.22,57  Orexin may even play a role in sleep apnea.58  
One novel treatment involved the use of a bis-amidopiperidine derivative (SB-649868) to 
antagonize both orexin receptors and treat narcolepsy.59  Almorexant, a dual orexin 
receptor antagonist,3,47,60 can even cause sleep without damaging the capacity of learning 
and memory acquisition.61  Other dual orexin receptor antagonists, such as DORA-1, not 
only promote sleep, but also block drug-related reinforcement and relapse behavior.62   
The Orexin-1 Receptor’s Role in Pleasure and Drug Addiction 
  Ox1r also reinforces activities of pleasure, such as food, sexual behavior, and 
drugs,10 and is responsible for learning and memory functions,63 drug relapse,64 and (in 
conjunction with ox2r) causing wakefulness with exposure to light.10,65  Furthermore, 
prenatal exposure to nicotine can greatly increase orexin expression, especially at the 
dopaminergic system, and significantly alter behaviors of food and drug reward.66  The 
ox1r may even be responsible for alcoholic relapse.67  Additionally, the ox1r can even 
mediate alcohol preference68 and cause morphine withdrawal symptoms when it occurs.69  
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Not only that, the ox1r can activate the CB1 receptor by activating diacylglycerol lipase 
to produce 2-arachidonoyl glycerol,70 as well as creating an allosteric coactive 
relationship by heterodimerizing with it,4,20 to activate it and trigger its effects in the 
body.4,20,70  Ox1r activation also supports higher breakpoints for cocaine use.71,72,73  The 
ox1r even increases long-term potentiation, a form of synaptic plasticity, in the brain’s 
dentate gyrus.74  The ox1r also plays a role in amphetamine sensitization and its effects 
on dopamine activity.75  The ox1r and ox2r also participate in two opposing means of 
regulating depression-like behaviors, with ox1r producing a negative emotional state that 
leads to reward conditioning and response, and ox2r producing an antidepressant-like 
effect.76  When the ox1r is repeatedly antagonized, it can cause multiple effects on drug 
seeking, from attenuation during extinction, to enabling an acute ox1r antagonist dose to 
reduce cue-induced reinstatement.77  A low dose of an ox1r antagonist may also increase 
cue-induced reinstatement, likely from increasing surface ox1r expression due to 
inhibiting ox1r internalization.21,77  The ox1r is even responsible for drug tolerance, 
physical dependence, and physical signs of withdrawal.78  The ox1r is also responsible 
for causing the sympathetic responses to stress and moderate doses of methamphetamine 
use.79   
The Orexin-1 Receptor’s Role in Brain Activity and the Fight/Flight Response 
  The ox1r is also responsible for benzodiazepine- and caffeine-induced panic 
behaviors, as well as related anxiety and the panic network in the brain.80  Orexin is even 
responsible for many facets of the defense response, such as baroreflex suppression and 
stress-induced analgesia, leading to the “fight or flight” response.81  Furthermore, ox1r 
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activation increases cortical acetylcholine release82 and catecholamine production,83 
mediating panic responses via the autonomic system, as shown in Figure 6.84,85   
 
 
Figure 6. The Autonomic System.84,85   
 
Orexin can even assist reproduction in both sexes,1,86,87 as well as lead to 
synthesis of steroidal hormones such as testosterone.88  More specifically, orexin-A can 
even increase sexual arousal,89 yet it may lead to anxiety to initiate reproduction.90  
Furthermore, ox1r can even induce the release of arachidonic acid via PLA2 
(phospholipase A2).91  Orexin’s worth in the body is just as evident when it is absent as it 
is when present, as orexin loss is part of neurodegenerative diseases such as Parkinson’s 
disease.92,93  Alteration of orexin-A trafficking is a key part of Parkinson’s and 
Huntington’s diseases, dementia, depression, and narcolepsy.94  Change of ox1r 
expression may also be responsible for the alteration of brain function that transient 
ischemia-induced neuronal damage would have.95  Ischemia causes enhanced ox1r 
expression in the hippocampus and cortex, and the added ox1r may play a role in the 
ensuing ischemic insult.96  Ox1r expression increases in response to traumatic brain 
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injury, and it may play a role in response.97  The ox1r may also be responsible for causing 
the increased anxiety behind intense emotional arousal, such as fear conditioning, drug 
challenge, or hypercapnia, though antagonism does not lower baseline anxiety.98  In the 
cerebellum, the ox1r can assist with learning and timing of motor skills.99  The ox1r in 
the CA1 region of the hippocampus has a role in spatial learning/memory acquisition, 
consolidation, and retrieval,100 but in the dentate gyrus, the ox1r also has a role in spatial 
learning/memory acquisition and consolidation, but not retrieval.101  The ox1r and ox2r 
can be antagonized systemically without interfering with the hypothalamus-pituitary-
adrenal axis, showing that orexin plays a minor, yet important, role at basal orexin 
levels.83,102   
The Orexin-1 Receptor’s Role in Heart Activity 
  Furthermore, the ox1r assists the ox2r in directly exciting the neurons responsible 
for increasing heart rate and arterial pressure.103  The ox1r can even increase sympathetic 
outflow and its accompanying effects, including increased heart rate, arterial pressure, 
and phrenic nerve activity.104  This is also important, as the orexin system may be 
downregulated by the cytokine TNF-α.105  Orexin expression is also regulated by leptin 
administration.106  Both orexin receptors, as well as nitric oxide, are also responsible for 
the increased systolic blood pressure and heart rate that stress-induced hypertension 
entails.107  Ox1r and orexin-A expression at the choroid plexus may assist NO or 
serotonin transmission.94   
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The Orexin-1 Receptor’s Role in Ventilation 
  Among orexin’s many roles in triggering locomotion, analgesia, stress, and 
arousal, it also triggers the central chemoreceptive reflexes through which pCO2 and pH 
affect ventilation, in a circadian manner.108,109  During wakefulness, the ox1r is also 
responsible for the hyperventilation reflex to high pCO2.110   
The Orexin-1 Receptor’s Role in Pain 
  Ox1r can also protect cells from oxidative stress,111 and relieve pain112 without 
decreasing wakefulness.113  The ox1r is especially responsible for reducing the pain of 
mechanical allodynia,114 reducing neuropathic pain115—especially pain from diabetic 
neuropathy,116 reducing thermal pain via the pontine reticular formation,113 and can even 
be responsible for morphine analgesic tolerance.117  The ox1r can also be responsible for 
stress-induced antinociception.118  The ox1r in the ventral tegmental area (VTA) and the 
nucleus accumbens is responsible for the effects of lateral hypothalamus-stimulated 
antinociception.119   
The Orexin-1 Receptor’s Role in Possible Side Effects 
  However, side effects must be taken into account.  For instance, care must be 
taken, when designing a drug to act on the orexin system, to ensure that synergistic 
effects with other drugs do not occur, and almorexant is a dual orexin receptor antagonist 
that lacks such synergistic effects with alcohol (though the authors still advise against 
concurrent use of alcohol).60  Ox1r-specific antagonists could cause their intended effects 
without strongly promoting sleep,120,121 and without interfering with the cerebellar 
interpositus nucleus.122   
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The Definition of Ballesteros-Weinstein Numbering 
  The Ballesteros-Weinstein notation takes the most conserved residue in each helix 
across multiple GPCRs and assigns it the name X#.50, where X is the residue type, and # 
is the number of the transmembrane helix (1-7), or in the case of the EC2 loop, 45,39 and 
residues N- or C-terminal to that conserved residue have lesser or greater numbers in 
their Ballesteros-Weinstein name, as shown in Figure 7.123   
 
6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 
3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 
9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 
Rho I M V I A F L I C W V P Y A S V A F Y I F 
Rho 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276
D3 I V L G A F I V C W L P F F L T H V L N T 
D3 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353
D2L3 I V L G V F I I C W L P F F I T H I L N I 
D2L3 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399
D2S I V L G V F I I C W L P F F I T H I L N I 
D2S 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368
D2L I V L G V F I I C W L P F F I T H I L N I 
D2L 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397
D1 V I M G V F V C C W L P F F I L N C I L P 
D1 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296
S1P1 I V L S V F I A C W A P L F I L L L L D V 
S1P1 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280
CB1 L I L V V L I I C W G P L L A I M V Y D V 
CB1 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367
CB2 L V L A V L L I C W F P V L A L M A H S L 
CB2 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269
Orexin-1 V V L L V F A L C Y L P I S V L N V L K R 
Orexin-1 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322
 
Figure 7. Protein Alignment by Ballesteros-Weinstein Notation, Listed Above the 
Residues of Each Protein, With the Residues and Their Absolute Numbers Beneath.123   
 
The Definition of g+/g–/trans Conventions 
  The χ1 dihedral convention used measures the dihedral angle of N-Cα-Cβ-Cγ (or 
Oγ in the case of serine or threonine, or Sγ in the case of cysteine), by choosing the atom 
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(with the exception of the Cα atom) with the highest atomic number bound to the Cβ, 
e.g., threonine would use the atom Oγ1 to define χ1.  In case of a tie, such as in 
isoleucine, the Cγ1 carbon is an ethyl group, whereas Cγ2 is a methyl group, and that 
breaks the tie.  Serine, a residue that uses its hydroxyl oxygen as Oγ, is used as an 
example, as shown in Figure 8.124,125,126,127,128,129,130   
 
 
Figure 8. Left, the χ1 Measurement is 180°, Displaying a Trans Conformation.  Center, 
the χ1 measurement is –60°, displaying a g+ conformation.  Right, the χ1 measurement is 
+60°, displaying a g– conformation. 
 
However, Maestro (Schrödinger 2006) defines its valine χ1 differently, since both 
Cγ are methyl groups, as shown in Figure 9.   
 
 
Figure 9. Left, the χ1 Measurement of Valine is 180° Using the Green Cγ, Yet Its g+ 
Conformation is Defined by the Magenta Cγ.  Center, the χ1 Measurement of Valine is  
–60° Using the Green Cγ, Yet Its g– Conformation is Defined by the Magenta Cγ.   
Right, the χ1 Measurement of Valine is +60° Using the Green Cγ, yet its trans 
Conformation is Defined by the Magenta Cγ.   
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The Orexin-1 Receptor’s Importance and the Reason to Construct These Models 
  However, for all of the importance of the orexin-1 receptor, no crystal structure 
exists for it.3,24  As orexin-1 receptor agonists and antagonists are in their infancy,10 a 
model must be built of the ox1r, yet few models have been built, and only recently.3,24  
Previous attempts only involved using a crystal structure as the model’s basis by 
mutating it to the ox1r sequence, docking an antagonist within the R (inactive) structure, 
and minimizing it.3,24  Many other ways of receptor modeling have been used, including 
the use of receptor chimeras.6,131,132   
 The purpose of this experiment is to construct two in silico models of the ox1r.  
First, Conformational Memories133 is used to create low free energy conformations for 
the helices, docking the endogenous agonist4 in the R* (active) model, and improving on 
previous models’ docks.3,24  This approach also uses Modeller to connect the helices with 
loops, as well as to add N- and C-termini to the ends,134,135,136 as well as color-coding 
each part of the model.  Each ligand will be docked according to basic GPCR rules of 
activation,124 which hypothesize that orexin-A (an agonist)3,4,24 will allow Y6.48’s χ1 to 
be trans, and SB-674042 (an antagonist)3,24,137 will hold Y6.48’s χ1 in g+124 using the 
Ballesteros-Weinstein numbering system.123   
 The reason for Y6.48’s importance124 is that when the “toggle switch” found by 
Shi et al. in TMH6 has C6.47 in trans, W6.48 (Y6.48 in the ox1r) in g+, and F6.52 (S6.52 
in the ox1r) in g+, i.e. the R state, TMH6 is bent on the IC end toward 
TMH3.124,125,126,127,128,129,130  Additionally, Y5.58 is g+ in the R* state and trans in the R 
state.138  This bent position is locked in place when R3.50 forms a salt bridge (an “ionic 
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lock”) with E/D6.30.124,125,126,127,128,129,130  In the case of ox1r, the 6.30 residue is R6.30, 
so T6.33 is used as a salt bridge acceptor residue, as it is the only residue on TMH6 near 
R3.50 that can do so, as T6.34 does in the μ-opioid receptor, therefore this interaction is 
hereafter named an “ionic” lock, as only one of the partners has a charge.139,140,141  
However, the Cα-Cα distance is still measured from R3.50-R6.30, as this measurement is 
universal in GPCRs regardless of which residue X6.30 may be.142  Activation to the R* 
state changes the “toggle switch” so that C6.47 is g+, W6.48 (Y6.48 in the ox1r) is trans, 
and F6.52 (S6.52 in the ox1r) is trans.124,125,126,127,128,129,130  This straightens the CW/YXP 
hinge region, straightening TMH6,125,126,127,128,129,130 pulling its IC end away from R3.50, 
and breaking the ionic lock.143 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Ox1r Helices Construction 
  To begin ox1r model construction, the ox1r sequence was aligned with those of 
the β2-adrenergic receptor,144,145 the ox2r upon its release,7 the adenosine A2A receptor,146 
and rhodopsin,2 using the most highly conserved residues for each helix across Class A 
GPCRs:  N1.50, D2.50, R3.50, W4.50, P5.50, P6.50, and P7.50,2,144,145,146 as well as the 
conserved cysteine in the EC2 loop involved in a disulfide bond, C45.50.39  Further care 
was taken with the motifs TMH3 E/DRY (DRW for ox1r), TMH6 CWXP (CYXP for 
ox1r), and TMH7 NPXXY144,145 so that the chosen template would be correctly mutated.  
The β2-AR crystal structure144,145 and the adenosine A2A receptor crystal structure146 were 
mutated and renumbered to the ox1r sequence, as raw material for the Monte 
Carlo/simulated annealing program Conformational Memories (CM).133,147  This was 
necessary, as each of the ox1r helices had a helix-deforming residue (e.g., P, G, or 
T)148,149 that rendered the template unable to guarantee the proper helical 
conformation.3,24   
Ox1r Helices Assembly into Bundle 
  Helices 1 through 6 of the mutated β2-AR template,144,145 as well as a TMH3 
made “from scratch” to be used in place of the β2-AR-based TMH3 CM 
output,133,144,145,147 were varied via the Conformational Memories method, which explores 
each helix’s dihedrals and bond angles as follows.20,133,147,149  The φ dihedrals were set 
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at–50° to –70°, ψ at –40° to –60°, and ω at 180°, varying φ and ψ ±10°, χ limitlessly, and 
ω ±20°.20,133,147  The five-residue-long flexible areas in each helix ending in P (or T1.51 
in TMH1148) had φ and ψ varied at ±50°.20,149  The angles were varied ±8°, except for 
special cases such as methionine’s Cγ-Sδ-Cε, lysine’s Cε-Nζ-Hζ, and tyrosine’s Cζ-Oη-
Hη.  These special angles were varied ±15°.  To acquire the best structures, a region of 
best probability must be created with an exploratory phase.133,147  This was done by 
“heating” the helix to 3000 K, then letting it “cool down” in 18 stages to 310 K, with 
each stage consisting of 50000 Monte Carlo steps, each with two random dihedral 
changes and one random bond angle change per Monte Carlo step.133,147  Every one of 
these dihedral and bond angle changes use the Metropolis Criterion to ensure that more 
unfavorable moves would be less likely to be taken, and to give the helix access to more 
favorable energetic states.133,147  These “conformational memories” are used in the biased 
phase, which “heats” the helix to 749.4 K, “cools” it to 310 K in 7 stages, keeping the 
attempted moves within the “populated conformational space” and producing 105 
structures at 310 K.133,147  For ox1r helices 1-5, the CM output133,147 was superimposed 
onto the β2-AR alignment template using the Cαs on the IC end of each helix, excluding 
the five-residue-long flexible areas to permit the most variety of helical shape at the other 
end.2,20,124,144,145,146,149,150  This must be done this way as the intracellular portions of 
GPCRs look alike for TMH1 through TMH5.2,20,133,124,144,145,146,147,150  TMH6 must be 
superimposed with a different method because it must be free to move, though in the R 
state, the TMH6 CM output would line up with the template roughly the same way 
regardless of IC or EC superimposition.2,20,133,124,144,145,146,147,150  Ox1r’s helix 6 used the 
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EC end’s Cαs (6.51-6.61) for alignment, again excluding the five-residue-long flexible 
areas, as shown in Figure 10.2,20,124,144,145,146,149,150   
 
 
 
Figure 10. CM Output for TMH6 Superimposed on the β2-AR.2,20,124,144,145,146,149,150 
 
Ox1r’s helices 7 and 8 were taken directly from the adenosine A2A receptor since 
the ox1r and A2A elbow regions that connect helices 7 and 8 have 1 residue more than the 
β2-AR’s elbow does.3,144,145,146  The mutated TMH7/HX8 structure was then 
superimposed directly onto the β2-AR alignment template using the N, Cα, and C on 
P7.50.144,145   
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Ox1r Bundle Ligand Docking 
  Once the seven helices were superimposed, they were pulled apart as shown in 
Table 1 to ease ligand insertion.  The R* structure had orexin-A inserted manually in both 
the “forward” (C-terminus near TMH3-6) and “reverse” (C-terminus near TMH1, TMH2, 
and TMH7) directions, with the side chain dihedrals adjusted in both orexin-A and the 
ox1r R* structure for both docks to optimize interactions, with energy measurements 
taken, so that Y6.48 can be activated.3,22   
 
Table 1 
 
With TMH4 Perpendicular to the Screen, HX8 Parallel to the x-axis and the Bottom of 
the Screen, and the EC Side Facing out of the Screen, These Were the Distances (in Å) 
That the Helices Were Moved, with TMH3 Held Stationary 
 
TMH# 1 2 4 5 6 7 
x +1 +1 0 –1 –1 0 
y 0 +1 +1 0 –1 –1 
 
The R structure had SB-674042 inserted manually so that Y6.48 can be 
deactivated.3,137  Both R and R* structures also had water molecules inserted at similar 
positions to water molecules in the β2-AR,144,145 as long as the ligand did not interfere.  
These ligands were chosen as orexin-A is the endogenous agonist to ox1r,3,6 and SB-
674042 is an ox1r-specific antagonist.3,137  The above mentioned “toggle switch” 
residues, along with Y5.58, in each structure were adjusted to fit the respective state for 
each receptor,124,125,126,127,128,129,130,138 with R3.50 adjusted to interact with T6.33 in the R 
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state and to refrain from doing so in the R* state141,143 by adjusting these residues’ side 
chain dihedrals. 
 In order to properly dock each ligand, the SB-674042 dock mutation data had to 
be consulted to determine the proper ligand orientation within the R structure,3 and the 
global minimum structure of SB-674042 (and other local minima) had to be found with 
several conformational searches (as the aliphatic heterocycle in the middle had two ring 
pucker conformers) using ab initio Hartree-Fock calculations (6-31G*) in the modeling 
program Spartan (Wavefunction Inc., Irvine, CA).3  Table 2 reveals the effects of ox1r 
mutation on SB-674042 antagonism.3   
 
Table 2 
 
Effects of Mutation of Ox1r Residues on SB-674042 Antagonism.3   
 
SB-674042 Kd(Mutant) / Kd(WT) 
for Transmembrane Portion of Orexin-1 Receptor 
Q3.32 
→ A 
A3.33 
→ T 
V3.36 
→ A 
Y5.38 
→ A 
F5.42 
→ A 
Y5.47 
→ A 
Y6.48 
→ A 
H7.39 
→ A 
Y7.43 
→ A 
50.9**
* 
20.2** 2.1 N.D.B. N.D.B. 1.8 10.8** 22.7*** 9.3*** 
Note. *p < 0.05, **p < 0.01, ***p < 0.001, N.D.B. means no detectable binding  
because of high nonspecific binding.3 
 
The highest relative Kd in Table 2 was Q3.32’s 50.9, so SB-674042 must be 
docked in a way that gives it a strong energy of interaction.3  Since mutating the small 
A3.33 to T creates a large relative Kd, SB-674042 must be close enough to A3.33 for 
such a mutation to sterically crowd it.3  Furthermore, the ox2r has T3.33, which can cause 
TMH3 to bend.7,24,148,149  Because H7.39A and Y7.43A had high relative Kds, they must 
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be able to interact with one of SB-674042’s phenyl groups.3  A strong interaction with 
Y6.48 is necessary to hold the ox1r in the R state.3  However, V3.36 and Y5.47 do not 
have significant relative Kds, so they should not be involved significantly in SB-674042 
binding.3  For W45.54, Y5.38, and F5.42, the specific binding ability was destroyed by 
mutation to alanine (which may have caused protein misfolding), so no information of 
importance or lack thereof could be produced.3  This means that Q3.32 is the key residue 
to be used to interact with SB-674042, and since SB-674042 has no hydrogen bond 
donors, it must accept a key hydrogen bond from Q3.32.3  Using Spartan (Wavefunction 
Inc., Irvine, CA), electrostatic maps were created to find the most negative area of 
potential on SB-674042 and the most positive areas of potential on acetamide (chosen to 
approximate glutamine’s side chain).3,137  The former was created as Figures 11 and 12.   
 
      
Figure 11. Electrostatic Potential Maps of SB-674042, Where Redder Areas Correspond 
to the Most Negative Areas of the Molecule and Bluer Areas Correspond to More 
Positive Parts.  These Maps Correspond to the Sides with (Left) the Amide Oxygen and 
Oxadiazole Ring Nitrogens Facing out from the Page and (Right) the Methyl Pointing out 
from the Page.3,137   
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Figure 12. More Electrostatic Potential Maps of SB-674042.  These Maps Correspond to 
the Sides with (Left) the Proline-like Portion Pointing out from the Page and (Right) the 
Thiazole Ring Facing out from the Page.3,137 
 
The acetamide electrostatic potential maps were created as Figure 13.3  SB-674042 was 
then docked, and Q3.32’s χ1-3 dihedrals adjusted, so that the amide hydrogen on Q3.32 
donates a hydrogen bond to SB-674042’s amide oxygen. 
 
 
Figure 13. Electrostatic Potential Maps of Acetamide.  These Maps Correspond to (Far 
Left) Acetamide Flat in the Page’s Plane, and (Center-left) the Oxygen, (Center-right) the 
Methyl, and (Far Right) the Nitrogen Pointing out from the Page. 
 
Ox1r Bundle Minimization 
  For the R* structure, the ligand orexin-A was docked in the “forward” and 
“reverse” orientations to produce “forward” and “reverse” R* models.3,22  The R structure 
and both R* structures were minimized using an OPLS_2005 minimization force field, 
with no solvent, force field-defined charges, an extended cutoff, and a distance-dependent 
dielectric constant of 1.0, hereafter referred to as “dry” minimization conditions, to pull 
the helices together around the ligand to approximate their behavior in a lipid bilayer.  
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The minimization was done in steps, first constraining the ox1r and orexin-A backbone 
dihedrals strongly to maintain the helices’ shapes, and then successively constraining 
them less to hold the bundle’s shape as a whole.  Rough parameters were measured on 
SB-674042, so that the SB-674042 backbone dihedrals, as well as the Ooxadiazole-Coxadiazole-
Ctail phenyl bond angle were held at 3000 kJ mol–1 Å–2 to allow SB-674042 to keep its 
shape.  The R structure used the constant restraints at 3000 kJ mol–1 Å–2 throughout to 
hold R3.50 in a salt bridge to D3.49 and T6.33,124,125,126,127,128,129,130,141 hold the three 
toggle switch residues124,125,126,127,128,129,130 and Y5.58138 as they are, and hold K6.58 and 
R6.59 to keep TMH6 from collapsing on top.  The R* structures used the constant 
restraints at 3000 kJ mol–1 Å–2 throughout to hold the three toggle switch 
residues124,125,126,127,128,129,130 and Y5.58138 stationary, hold R3.50 straight, and hold R6.30 
and R6.31 clear of TMH5 to avoid snagging, so TMH6 can kick out naturally.  In all 
three structures, the R guanidinium systems and the Y χ6 (Cε-Cζ-Oη-Hη) dihedrals were 
held planar at 3000 kJ mol–1 Å–2 throughout to keep the π systems undisturbed during 
minimization.  The R structure’s “ionic” lock was constrained to 3.1 Å (T6.33 Oγ-closest 
guanidinium N on R3.50141) to keep it far enough apart to allow it to break when 
activated.  These minimized bundles had extracellular (EC1-3) and intracellular (IC1-3) 
loops added to them using Modeller.134,135,136  This program adds loops by varying one, 
two, or three raw loops at once, or even part of one, while keeping the remainder 
stationary.134,135,136   
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Ox1r Bundle Connection to Loops 
  First, in order to connect the bundle to the loops to form a single molecule, the N-
terminus was built from scratch and attached to TMH1, while the loops and C-terminus 
were constructed by extending each helix of each bundle, with dihedrals adjusted to 
attach the loops to the helices.  Afterward, the bundle was taken apart and reassembled to 
ensure that no part of the ox1r is out of order with the rest.  Afterward, each bundle’s 
loops and termini were minimized (with all else frozen) for 500 steps in a high dielectric 
(water), hereafter referred to as “wet” minimization conditions, since the loops and 
termini are in aqueous conditions that weaken electrostatic interactions.  These loops 
were further prepared by uncapping the termini so that the N- and C-termini have –NH3+ 
and –COO– groups on the backbone, respectively, as the actual ox1r would have.  This 
structure is the finished transmembrane bundle, and to further prepare it, the structure 
was simplified by removing all hydrogen atoms.   
Ox1r Loop Formation and Minimization 
  Each bundle was run through Modeller,134,135,136 which works as Fiser et al. 
described in 2000, by taking the PDB’s dihedral template library for each amino acid 
(with any and all possible conformations on hand), then varying one range (or several 
ranges) of residues to create the desired loop shape.134  These loops are given objective 
function rankings (lower is better) based on hydrophobicity, hydrogen bonding, and 
absence of steric clashing.  Of the 1080 total loop conformation sets for each bundle, the 
best 250 are given further inspection to see which set best interacts, according to the 
circumstances, with itself, the ligand, and the transmembrane bundle.  Each model had 
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the three EC loops varied so that the EC2 loop forms a disulfide bridge between C45.50 
and C3.25 (on the EC end of the TMH3).3  This bridge is also common to other GPCRs, 
such as A2A,146 β1-AR,150 β2-AR,144,145 CXCR4,151 and D3.152  The residues 45.51 to 45.54 
in the EC2b loop have the “up-down-up-down” arrangement that points D45.51 and 
R45.53 up, and E45.52 and W45.54 down.145  The EC2 loop not only forms the disulfide 
bridge, its D45.51 and W45.54 also hold the two halves of the EC2 loop out of the way to 
clear a path for orexin-A.3,24  Since P45.38 to R45.45 are similar to the β2-AR’s 
corresponding residues, that part of the EC2a loop is helical, and is kept from blocking 
the ligand binding cavity by D45.51’s interaction with R45.45.24,145  D45.51A may cause 
the entry gap to that binding cavity to shrink, but since SB-674042 is far narrower, it is 
not affected.3  Another residue is E45.52, which can keep the R state’s entry gap closed 
by interacting with R328 in the EC3 loop, or hold the R* state’s entry gap open for 
orexin-A by interacting with K3.26.  W45.54 can interact in an aromatic network that can 
hold the EC2b loop out of the way of any ligand.3  To allow sufficient working room to 
vary each loop, EC1 and EC3 were varied at the same time as EC2 to create rough loops 
for each structure.  EC1 was also refined based on the β2-AR.144,145  The IC loops were 
also varied as well, with IC3 varied so that TMH5 and TMH6 extend their helices into 
cytoplasm, in a similar manner to rhodopsin2 and P2Y12,141 and IC1 and IC2 out of the 
way of IC3.  Hydrogens were added, and the loops were reminimized, for 500 steps in 
“wet” minimization conditions.   
25 
 
 
Ox1r R* Dock Verification 
  Both R* structures had their respective docks’ energetic interaction measured on a 
residue-by-residue basis.  Table 3 details the effects of mutation of ox1r residues on the 
relative EC50s were collected3 and compared to the “reverse” and “forward” energies in 
“wet” and “dry” environments, especially.  These measurements used “wet” (80, 
constant) and “dry” (3, distance-dependent) dielectric constants to provide the 
environments for orexin-A to interact with the ox1r.  “Wet” refers to the dielectric 
constant of water, which is high, so that it weakens electrostatic interactions.  “Dry” 
refers to a low dielectric constant, which accentuates electrostatic interactions.   
 
Table 3 
 
Ox1r Residues and Mutation Effects on OxA-induced Ca2+ Internalization.3 
 
Reverse Energy  
Orexin-1 Receptor 
Forward Energy 
(kcal/mol) (kcal/mol) 
Wet Dry EC50(Mutant) / EC50(WT) Wet Dry 
–5.57 –6.29 Q3.32 → A 2.4-fold –3.68 –7.94 
–0.29 –0.36 A3.33 → T 1.8-fold –2.35 –2.60 
–3.15 –3.18 V3.36 → A 30.6-fold –1.42 –1.86 
–3.30 –3.51 Y5.47 → A 84.4-fold n/a (not close enough) 
–3.18 –3.31 Y6.48 → A 163.9-fold –3.97 –6.13 
–5.81 –5.97 H7.39 → A 241.1-fold –6.07 –13.52 
–2.05 –2.30 Y7.43 → A 8.7-fold –2.58 –2.62 
 
The data in Table 3 reveal that H7.39 has an important role in binding to orexin-
A, since it has a strong interaction energy that is stronger in the “forward” dock.3  Since it 
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is stronger in the “forward” dock’s “dry” measurement than its “wet” measurement, and 
the interaction is very far from extracellular solution, this shows that H7.39 interacts via 
multiple hydrogen bonds.  A3.33 has a small role, as A3.33T may not impact the van der 
Waals interactions.3  However, despite the small energetic role, V3.36A could lessen 
hydrophobic surface area, allowing water to enter that part and decrease the favorability 
of the dock significantly.3  The high “reverse” energy in both “wet” and “dry” 
measurements for Q3.32 is inconsistent with its minor role in binding orexin-A.3  
However, its minor role can be donating a single hydrogen bond in the “forward” dock, 
as the “dry” measurement is more favorable than the “wet” one.3  The binding role of the 
vitally important residue of Y6.482,127,153,154 is supported by the stronger energy of 
interaction in the “forward” dock.3  Y5.47 was close enough to interact with orexin-A in 
the reverse dock only, but its role is to π-stack with Y6.48.3  Regardless of the direction 
of the dock, Y7.43’s minor role is consistent with the low interaction energy.3  Table 4 
details how mutating the orexin-A’s residues affect the pEC50 of that mutant when it 
binds to the ox1r.22,155  In Table 4, orexin-A was truncated to residues 15-33 to ease 
synthesis, and Heifetz et al. rated the mutation effects by arrows (up for significant 
increase, equal sign for no significant change, and down for significant decrease, and 
more arrows for more significant change) for easier use.22,155   
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Table 4 
 
Residues of the Peptide, Orexin-A, and Mutation Effects on OxA-induced Ca2+ 
Internalization.22,155   
 
Reverse Energy 
Orexin-A (15-33) 
Forward Energy 
(kcal/mol) (kcal/mol) 
Wet Dry WT (pEC50 6.45 ± 0.06, =) Wet Dry 
–4.56 –4.37 R15 (→A 6.46 ± 0.03, =) –2.58 –7.66 
–3.27 –3.47 
L16 (→A 71% of  
10 μM oxA, ↓) 
–4.21 –4.70 
+2.01 –8.29 Y17 (→A 6.11 ± 0.03, =) –2.61 –3.96 
–3.11 –3.98 E18 (→A 6.71 ± 0.04, =) +3.01 –24.28 
–0.73 –0.77 
L19 (→A 60% of  
10 μM oxA, ↓↓) 
–7.50 –7.42 
n/a (not close enough) 
L20 (→A 37% of  
10 μM oxA, ↓↓) 
–1.64 –1.66 
–5.17 –6.49 H21 (→A 5.89 ± 0.02, =) –4.86 –5.71 
n/a (not close enough) G22 (→A 6.19 ± 0.09, =) –3.97 –5.27 
–0.34 –0.38 G24 (→A 6.08 ± 0.03, =) n/a (not close enough) 
–4.54 –4.90 N25 (→A 6.00 ± 0.09, =) –2.69 –4.49 
–12.21 –13.70 
H26 (→A 61% of  
10 μM oxA, ↓↓) 
–8.49 –15.20 
–2.25 –2.14 
G29 (→A 15% of  
10 μM oxA, ↓↓↓) 
–0.97 –2.39 
–8.68 –9.34 
I30 (→A inactive at  
10 μM, ↓↓↓) 
–8.06 –9.16 
–5.83 –6.28 
L31 (→A 12% of 10  
μM oxA, ↓↓↓) 
–11.40 –12.01 
–2.38 –2.77 
T32 (→A 39% of 10 μM  
oxA, ↓↓↓) (→D-T inactive  
at 10 μM oxA, n/a) 
–3.57 –5.13 
–10.15 –10.92 
L33 (→A 15% of 10 μM  
oxA, ↓↓↓) (→D-L 18%  
of 10 μM oxA, n/a) 
–9.08 –10.72 
–1.07 –2.29 Amide34 –0.73 –1.04 
–119.05 –175.09 Totals (for WT oxA) –132.59 –221.86 
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Table 4’s data show that R15, with “wet” measurements has a less favorable 
energy of interaction in the “forward” dock than in the “reverse” dock, consistent with its 
insignificant binding role, since R15 is surrounded with loop residues in water.22  L16’s 
important role in orexin-A binding is reflected here, however, as its binding energies in 
the “forward” dock are more favorable than those in the “reverse” dock.22  Y17 has a 
minor role, supported by favorable energies in the “forward” dock, yet the “reverse” 
dock’s energies for Y17 are unfavorable (in “wet”) or too favorable (in “dry”).22  E18’s 
presence inhibited activity, as shown by unfavorable “wet” energies in the “forward” 
dock (since it interacts with loop residues), yet the “reverse” dock’s energies were 
favorable.22  Regardless of the conditions, the favorability of L19’s energies in the 
“forward” dock were ~10× those of the “reverse” dock.22  L20’s importance, though low 
in energy, may be to keep orexin-A shaped the way it is.22  H21’s “forward” dock 
energies were more consistent with its minor role than its reverse dock energies are.22  
The roles of G22, G24, and G29 (especially G29) are for flexibility, and N25’s forward 
energies are also consistent with its minor role.22  H26 has a strong energy in the 
“forward” dock’s “dry” measurements that is consistent with its major role, and since its 
“dry” energy was more favorable than its “wet” energy, that suggests an electrostatic 
interaction between the ox1r and H26.22  I30 and L33 have interactions that are consistent 
with their major roles regardless of the direction of the dock or the conditions used.22  
L31’s stronger energy in the “forward” dock (about ~2× as strong) is also consistent with 
its major binding role.22  T32 has a role as a helix stabilizer, which is consistent with a 
mildly favorable binding energy compared to other major residues.22  The C-terminal 
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amide is small, with little role accordingly.22  The above data suggest strongly that the 
“forward” dock of the orexin-A peptide in the ox1r is correct mainly due to L19’s greater 
energetic role in orexin-A’s “forward” dock than its “reverse” dock, as well as H7.39’s 
more powerful interactions in the “forward” dock, and the “forward” dock’s more 
favorable overall energy.  The interaction energies and binding data in Tables 3 and 4 led 
to the creation of the R* bundle of the ox1r and orexin-A.3,22   
Ox1r Termini Formation, Palmitoylation, and Minimization 
  Once the correct direction of ligand docking was chosen, the R structure with 
docked SB-674042 and the R* structure with orexin-A docked in the “forward” direction 
both had the N- and C-termini varied 17 residues at a time simultaneously from the 
bundle to the ends,134,135,136 all while ensuring the ox1r model’s residues are in the correct 
order at every step, then hydrogens were re-added as before and the termini minimized 
“wet” for 500 steps.  The models had C375 adjusted so that it can point into the lipid 
bilayer, and a palmitoyl group was added to both models’ C375 residue to point into that 
bilayer.3,156  Afterward, both models were minimized 500 steps “dry,” and the loops and 
termini 500 steps “wet.”  Both models were then aligned with the β2-AR144,145 from the 
OPM (Orientations of Proteins in Membranes) database (http://opm.phar.umich.edu/) so 
that they can be properly used in later experiments.157  This is because MD simulations 
use the OPM database’s models as a reference.157   
Ox1r Helices Assembly into Bundle Based on Ox2r Crystal Structure 
  With the release of the ox2r crystal structure (4s0v), a new pair of ox1r homology 
models must be built.7  The ox2r crystal structure was mutated to the ox1r sequence and 
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renumbered according to the CM output residue numbers.133,144,145,147  This was necessary 
for ease of superimposition of the CM output,133,144,145,147 and the template helices were 
pulled apart as shown in Table 5 to ease superposition further.   
 
Table 5 
 
With TMH4 Perpendicular to the Screen, HX8 Parallel to the x-axis and the Bottom of 
the Screen, and the EC Side Facing out of the Screen, These Were the Distances (in Å) 
That the Helices Were Moved, with TMH3 Held Stationary, and One Template Made for 
Each Value of z, from 0 to 10 Inclusive.  The Structure Chosen for Superposition was  
z = 4, so That the Helices were Pulled Apart 2.0 Å. 
 
TMH# 1 2 4 5 6 7 
x +0.5z +0.5z 0 –0.5z –0.5z 0 
y 0 +0.5z +0.5z 0 –0.5z –0.5z 
 
As the Conformational Memories method bases its output on favorable moves 
taken due to the residue sequence of the input,20,133,147,149 the previous CM output based 
on Helices 1 through 6 of the mutated β2-AR template144,145 was usable here.  For ox1r 
helices 1-5 and the ox1r R structure’s helix 6, the CM output133,144,145,147 was 
superimposed onto the ox2r alignment template (pulled apart 2.0 Å) using the Cαs on the 
IC end of each helix, excluding the five-residue-long flexible areas to permit the most 
variety of helical shape at the other end.2,7,20,124,149,150  The ox1r R* structure’s helix 6 
used the EC end’s Cαs (6.51-6.61) for alignment, again excluding the five-residue-long 
flexible areas, as shown in Figure 14.2,7,20,124,133,147,149,150 
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Figure 14. CM Output for TMH6 Superimposed on the Ox2r.2,7,20,124,133,147,149,150   
 
This must be done this way as the intracellular portions of GPCRs look alike for 
TMH1 through TMH5, yet TMH6 must be free to move, though in the R state, the TMH6 
CM output would line up with the template roughly the same way regardless of IC or EC 
superimposition.2,7,20,124,133,147,149,150  Ox1r’s helices 7 and 8 taken directly from the ox2r 
since the ox1r and ox2r elbow regions that connect helices 7 and 8 have the same number 
of residues.3,7  The mutated TMH7/HX8 structure (with C375 attached) was then 
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superimposed directly onto the ox2r alignment template using the N, Cα, and C on 
P7.50.7   
Ox1r Bundle Ligand Docking Based on Ox2r Crystal Structure 
  Using the ox1r R and R* models based on the β2-AR144,145 as examples, the R* 
structure had orexin-A inserted manually in the “forward” (C-terminus near TMH3-6) 
direction, and the orexin-A and ox1r side chain dihedrals adjusted to optimize 
interactions, so that Y6.48 can be activated,3,22 and the R structure had SB-674042 
inserted manually, and Q3.32’s side chain dihedrals adjusted to optimize interactions, so 
that Q3.32 donates a hydrogen bond to SB-674042’s amide oxygen, and that Y6.48 can 
be deactivated.3  The abovementioned “toggle switch” residues in each structure were 
adjusted to fit the respective state for each receptor,124,125,126,127,128,129,130 with R3.50 
adjusted to interact with T6.33 in the R state and to refrain from doing so in the R* 
state,141,143 by adjusting these residues’ side chain dihedrals.  Both R and R* structures 
had water molecules inserted at similar positions to the water molecules in the ox2r,7 as 
long as the ligands did not interfere.   
Ox1r Bundle Minimization Based on Ox2r Crystal Structure 
  After docking, the R and R* structures were minimized using “dry” minimization 
conditions to pull the helices together around the ligand to approximate their behavior in 
a lipid bilayer.  This minimization was done in steps as before, first constraining the ox1r 
(and orexin-A in the R* structure) backbone dihedrals strongly to maintain the helices’ 
shapes, and successively constraining them less strongly, down to 0 kJ mol–1 Å–2, to hold 
the bundle’s shape as a whole.  As the previous model’s attempt to minimize the R model 
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with SB-674042 docked resulted in SB-674042’s dihedrals becoming distorted, a more 
drastic technique was required, resulting in SB-674042 being frozen in place for the 
minimization.  The R structure used its constant restraints at 3000 kJ mol–1 Å–2 to hold 
R3.50 in a salt bridge to D3.49 and T6.33,124,125,126,127,128,129,130,141 hold the three toggle 
switch residues124,125,126,127,128,129,130 and Y5.58138 as they are, and hold the “ionic” lock at 
3.1738 Å (T6.33 Oγ-closest guanidinium N on R3.50141) to keep it far enough apart to 
allow it to break when activated.124,125,126,127,128,129,130  The R* structure used its constant 
restraints at 3000 kJ mol–1 Å–2 to hold the three toggle switch 
residues124,125,126,127,128,129,130 and Y5.58138 as they are, as well as hold R3.50 
straight.124,125,126,127,128,129,130  The restraints of R6.30 and R6.31 in the R* structure and of 
K6.58 and R6.59 in the R structure as used in the previous model were unnecessary due 
to the ox2r crystal structure having greater homology than the β2-AR does with the 
ox1r.7,24,144,145  In both structures, the R guanidinium systems and the Y χ6 (Cε-Cζ-Oη-
Hη) dihedrals were held planar at 3000 kJ mol–1 Å–2 throughout to keep the π systems 
undisturbed during minimization.  These minimized bundles had loops added by basing 
the EC1 loop on the ox2r crystal structure’s EC1 loop,7 and the extracellular (EC2 and 
EC3) and intracellular (IC1-3) loops added to them using Modeller.134,135,136   
Ox1r Bundle Based on Ox2r Crystal Structure Connection to Loops 
  First, in order to connect the bundle to the loops to form a single molecule, the 
results from the previous model’s loops were connected in order to ensure that no part of 
the ox1r is out of order with the next.  During connection, the termini were kept straight 
as they were so that they would not obstruct loop formation by Modeller,134,135,136 and the 
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dihedrals were adjusted so that the EC1 loop resembles that of ox2r,7 and all loops were 
attached to their bundle anchors (e.g., EC2 to TMH4 and TMH5) as a rough structure.  
Afterward, each bundle’s loops and termini were minimized (with all else frozen) for 500 
steps in “wet” minimization conditions, since the loops and termini are in aqueous 
conditions that weaken electrostatic interactions.  The termini having already been 
uncapped as before, this structure is the finished transmembrane bundle, further prepared 
for the next step of adding loops using Modeller134,135,136 by having all hydrogen atoms 
removed from it.   
Ox1r Based on Ox2r Crystal Structure Loop Formation and Minimization 
  Each bundle was run through Modeller134,135,136 to form 1080 loop conformation 
sets for each bundle, with the best 250 of those 1080 given further inspection to see 
which set best interacts, according to the circumstances, with itself, the ligand, and the 
transmembrane bundle.  Each model had EC2 and EC3, and all three IC loops, varied so 
that IC3 would become an extension of TMH5 and TMH6 as before,2,141 IC1 and IC2 
stay out of IC3’s way, and that the EC2 loop form a disulfide bridge between C3.25 and 
C45.50 as before.3  The “up-down-up-down” arrangement that points D45.51 and R45.53 
up, and E45.52 and W45.54 down, is retained.145  The EC2 loop’s D45.51 and W45.54 
retained their duties of holding the two halves of the EC2 loop out of the way to clear a 
path for orexin-A,3,24 with P45.38-R45.45’s helicity from before and the R45.45-D45.51 
interaction retained as well to keep the ligand binding cavity open.24,145  E45.52 was also 
chosen to interact with R328 in the EC3 loop to keep the R state’s entry gap closed, as 
well as to hold the R* state’s entry gap open for orexin-A by interacting with K3.26, just 
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as before.  W45.54’s role in an aromatic network to keep the EC2b loop out of the way of 
any ligand was retained,3 with EC3 varied at the same time to keep it out of the way of 
EC2.  All five aforementioned loops were varied simultaneously in order to save 
computational time.  The necessary C3.25-C45.50 disulfide bond was formed,3 
hydrogens were added, and the loops were reminimized for 500 steps in “wet” 
minimization conditions.   
Ox1r Based on Ox2r Crystal Structure Termini Formation, Palmitoylation, and 
Minimization 
  Afterward, the placeholding termini were replaced with the completed termini 
from the previous models,134,135,136 so that the new R model has the previous R model’s 
termini and the new R* model has the previous R* model’s termini.  This saved 
computational time, as the termini only needed one anchor for each, as opposed to two 
anchors for each loop, and were relatively distant from the bundle.134,135,136  Since C375 
for each model was already attached to the bundle and pointed correctly toward the lipid 
bilayer, no further adjustment was required to allow for proper orientation, and a 
palmitoyl group was added to both models’ C375 residue to point into that bilayer.3,7,156  
Afterward, both models were minimized 500 steps “dry,” and the loops and termini 500 
steps “wet.”  Both models were then aligned with the ox2r7 from the OPM database so 
that they can be properly used in later experiments.157   
Parametrization Equation and Necessity 
  With the completion of the R and R* models, the next step is to equilibrate these 
models, each with bound ligands, in a molecular dynamics (MD) simulation of a 
palmitoyl-oleoyl-phosphatidylcholine (POPC) lipid bilayer, aligned based on the OPM 
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alignment of GPCR crystal structures.157,158,159,160  This is done using the CHARMM 
force field, which uses a potential energy function that penalizes deviations from 
equilibrium values of bond lengths, bond angles, improper dihedral angles, Urey-Bradley 
distances, dihedral torsion angles, and distances based on Lennard-Jones van der Waals 
and electrostatic interactions between nonbonded atoms, as shown in Equation 1.158,159,160   
 
	 	
	
	
	
	
	 	
	
1 cos
, , 	
	
 
Equation 1. The CHARMM Potential Energy Function, Where the Potential Energy (E) is 
a Sum of Deviations from Equilibrium Values for all Bond Lengths, All Bond Angles, 
All Urey-Bradley Terms, All Dihedral Angles, and All Improper Dihedrals, Each with Its 
Own Force Constant, and All Nonbonded Terms (a Sum of Lennard-Jones van der Waals 
and Electrostatic Interactions). 
 
However, such simulation cannot be performed without determining proper force 
field parameters for SB-674042 (in the R structure) and the pyroglutamic acid residue 
that begins orexin-A (in the R* structure).3,4,137  Therefore, such parameters must be 
constructed and validated as follows, by using QM data (Hartree-Fock 6-31G*) as a basis 
for developing these new parameters.159,160  The first step is to use the modeling program 
Spartan (Wavefunction Inc., Irvine, CA) and run a conformational search to determine a 
true global minimum for each molecule to be entered into the CHARMM General Force 
Field (CGenFF, https://cgenff.paramchem.org/) as a starting point in the search for new 
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parameters, as CGenFF includes organic compounds that the CHARMM topology and 
parameter files lack.161,162,163,164  Doing so was necessary to find (and make new Lennard-
Jones van der Waals parameters for) new atom types, retrieve the whole molecules’ bond 
length, bond angle, dihedral angle, and improper torsion parameters, produce the 
CHARMM topology for each molecule, and determine each molecule’s 
charges.161,162,163,164   
Construction of Model Compounds 
  Each molecule that needed new parameters (both SB-674042 and pyroglutamate, 
the latter NMA-capped on the C-terminus) was broken into several model compounds for 
determining charges (the charge model compounds), as well as bonds, angles, and 
torsions (the bond length-bond angle-dihedral torsion (BAT) model compounds) for SB-
674042 and its model compounds, with each model compound categorized by their 
corresponding number, with Charge Model Compounds 1-6 and BAT Model Compounds 
1-4 used for SB-674042, and Charge Model Compounds 1, 2, 4, and 7 used for BAT 
Model Compound 5, which was used solely to repair the CO1-C51-C51-C61 dihedral 
torsion parameter absent from BAT Model Compounds 1-4.137,159,160,161,162,163,164  SB-
674042 and the charge model compounds are shown in Figures 15 and 
16.137,159,160,161,162,163,164 SB-674042’s BAT compounds are shown in Figures 17 and 
18.137,159,160,161,162,163,164   
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Figure 15. Whole Molecule of SB-674042, With Rings Identified With Letters, and Parts 
Numbered and Circled.137,159,160,161,162,163,164   
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Figure 16. Charge Model Compounds of SB-674042, Labeled by 
Number.137,159,160,161,162,163,164   
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Figure 17. BAT Model Compounds 1-3 of SB-674042.137,159,160,161,162,163,164   
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Figure 18. BAT Model Compounds 4-5 of SB-674042.137,159,160,161,162,163,164   
 
As pyroglutamate-NMA was already a small molecule, it served as its own BAT model 
compound, as shown in Figure 19.4,159,160,161,162,163,164   
4 5 
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Figure 19. Whole Molecule of Pyroglutamate-NMA.4,159,160,161,162,163,164   
 
The charge model compounds were based on the lactam model compound and on the 
backbone carbonyl groups and NMA C-terminus cap in the CHARMM topology file, as 
shown in Figure 20.4,159,160,161,162,163,164   
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Figure 20. Charge Model Compounds of Pyroglutamate-NMA. The One on the Right was 
Not Needed, as the Backbone Carbonyl Charges and NMA C-terminus Cap Charges from 
the CHARMM Topology Files are Used Instead.4,159,160,161,162,163,164   
 
Each model compound had a conformational search performed on it as before, and was 
entered into CGenFF161,162,163,164 to find (and make new Lennard-Jones van der Waals 
parameters for) new atom types, retrieve the model compound’s bond length, bond angle, 
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dihedral angle, and improper torsion parameters, produce the CHARMM topology for 
each molecule, and determine each molecule’s charges.  New atom types were assigned 
based on CHARMM’s four-character equivalents to the CGenFF six-character atom 
types, with new types introduced so that repetition of atom types for differently placed 
atoms, bond lengths, bond angles, and dihedral angles would not 
happen.159,160,161,162,163,164  This involves reproducing the masses and Lennard-Jones van 
der Waals parameters of these atom types from the CGenFF topology and parameter files 
to use in the four-character CHARMM topology and parameter files.159,160,161,162,163,164  If 
the penalty for the charges did not exceed 10, the charges were usable.161,162,163,164  If the 
penalty exceeded 10, but was less than 50, the charges could be improved by 
validation.161,162,163,164  If the penalty exceeded 50, the charges had to be validated as 
follows.161,162,163,164  The only model compound that failed such a charge test was 1,3,4-
oxadiazole, whose charges were validated as follows.   
Charge Validation 
  Using Jaguar, energy calculations at the Hartree-Fock 6-31G* level were 
performed on water and 1,3,4-oxadiazole separately, and on a complex of water and 
1,3,4-oxadiazole in which they interact by pointing a hydrogen atom on 1,3,4-oxadiazole 
toward the oxygen atom on water, or by pointing a hydrogen atom on water toward an 
oxygen atom or nitrogen atom on 1,3,4-oxadiazole, with the difference (and the 
hydrogen-oxygen/nitrogen distance) being calculated as the QM interaction energy and 
distance for each complex of water and 1,3,4-oxadiazole, used as the basis for the MM 
calculations, as shown in Figure 21.158   
42 
 
 
 
 
Figure 21. Interactions Between 1,3,4-oxadiazole and Water.158   
 
These data were entered into a spreadsheet that calculated the QM interaction energies (in 
kcal/mol) based on the energy results of the Jaguar energy calculations.158  Additionally, 
this spreadsheet also had an inventory of 1,3,4-oxadiazole’s charges for each MM 
calculation, complete with the sums of these charges.158  A verification formula was 
added that divides 1 by the sum of the charges, such that a #DIV/0! error message is 
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returned if the charges are (correctly) neutral, and a non-error-message number returned 
if the charges are not neutral, as shown in Figure 22.   
 
Atom 
Name Positive Neutral 
C1 0.630 0.630 
N2 -0.490 -0.490 
N3 -0.490 -0.490 
C4 0.630 0.630 
O5 0.560 -0.440 
H6 0.080 0.080 
H7 0.080 0.080 
Sum 1.000 0.000 
Check 1.000000 #DIV/0! 
 
Figure 22. Effect of the Charges of 1,3,4-oxadiazole on the Verification Formula 
Beneath, With the Left Set of Numbers Showing the Effects of a +1 Charge (Supplied by 
O5’s Charge Changed from –0.44 to +0.56), and the Right Showing the Effects of a 
Neutral Charge. 
 
  For the MM calculations, a similar complex is generated for each QM 1,3,4-
oxadiazole and water complex and the charges in the topology of 1,3,4-oxadiazole are 
adjusted as follows.158  The charges of the ring oxygen, the ring nitrogen, and the 
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hydrogen used in these interactions were adjusted, while keeping the charges symmetrical 
and neutral across the molecule as shown in Figure 23.158   
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Figure 23. Charge Adjustments in 1,3,4-oxadiazole, in Which the Main Charges  
to Be Changed are Circled, the Boxed Carbon is Adjusted to Maintain Neutrality,  
and the Triangled Atoms are Kept Equal to Their Counterparts at All Times.   
 
These adjustments continued until the CHARMM interaction energy was as close 
to within 0.25 kcal/mol of the QM interaction energy, and the CHARMM interaction 
distance as close to within 0.1 Å of the QM interaction distance, as possible.158   
Bond Length, Bond Angle, and Dihedral Angle Measurement of Model Compounds 
  With the charges for each charge model compound calculated, the BAT model 
compounds were formed by removing the charges of the extra hydrogen atoms from each 
heavy atom, adding the charges from these hydrogen atoms to their adjacent heavy 
atoms, and then connecting these heavy atoms to form the charges for the BAT model 
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compounds so the bond lengths, bond angles, and dihedral angles can be optimized for 
each.165,166,167  This is shown in Figure 24.165,166,167   
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Figure 24. BAT Model Compounds for SB-674042, with the Charge Model Compounds 
for Each Circled.   
 
  The QM structures for these model compounds each had all of its bond lengths, 
bond angles, and dihedral angles measured and listed in a spreadsheet that also compared 
its bond lengths, bond angles, and dihedral torsions to the MM measurements, with the 
difference sent to a pass/fail test that works as follows.  A script was created that 
measured the MM bond lengths, bond angles, and dihedral torsions to be listed in this 
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spreadsheet for each of those QM measurements, and simultaneously produced the MM-
minimized conformation for comparison to the QM global minimum for that compound.  
The QM-MM difference is listed and the absolute value thereof taken.  The bottom of 
each list also contains the maximum and root-mean-square of these absolute values for 
that list for ease of quick verification of that compound.  Each value in that list, as well as 
the maximum, is run through a verification formula that determines whether or not the 
MM is within 0.03 Å of length,165,166,167 3° of bond angle,158 or 8° of dihedral angle158 of 
the QM compound, as shown in Equation 2.   
 
	 	
1
, 	
	 100000 
Equation 2. Verification Formula to Determine if the MM Measurement is Within the 
Margin of Error of QM, Where x is the Absolute Difference Between a Measurement in 
QM and the Same in MM, y is 0.03 Å in Length, 3° of Bond Angle, or 8° of Dihedral 
Angle, and 100000 is Added for Ease of Verification.   
 
An error message #DIV/0! is returned if the measurement falls within the margin 
of error, but a large number (~100000) is returned if it does not, and the cell is set to five 
decimal places for the sole reason of increasing the visibility of any failing bond length, 
bond angle, or dihedral angle immensely to the point of easy distinction, as the error 
message is significantly shorter than the large number.   
  A generator script is used to produce a table of internal coordinates to be modified 
according to the model compound’s QM measurements of bonds, angles, and dihedrals, 
and these modified internal coordinates are added to the topology file for that model 
compound.  This is crucial for the following steps.   
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  For every bond length, bond angle, and dihedral angle that falls outside of the 
margin of error, energy surfaces had to be produced by varying the problem bond length, 
bond angle, or dihedral angle in Spartan (Wavefunction Inc., Irvine, CA) using a Hartree-
Fock 6-31G* basis set over a certain range of bond length, bond angle, or dihedral angle 
and at equal intervals to produce 37 separate conformers of the compound.168  For 
example, a freely-rotating dihedral would be varied over a 360° range at 10° increments 
to produce 37 conformers (36 different conformers with the first and last identical).168  
Each of those conformers had an MP2/HF-6-31G* energy calculation performed on it, 
then each energy measurement was converted to kcal/mol and entered into a QM-MM 
potential energy surface comparison spreadsheet to produce the QM energy profile 
reference graph.158   
Bond Length and Bond Angle Optimization of Model Compounds 
  The procedure is to repair the bond lengths and bond angles together, then to 
repair the dihedrals.165,166,167,168  To create the corresponding MM potential energy 
surface, the problem bond length or bond angle is frozen in place using the internal 
coordinate file at the values corresponding to the 37 conformers produced by the 
corresponding QM energy surface experiment, with the rest of that conformer minimized 
and an energy measured for that conformer.165,166,167,168  Using this MM potential energy 
surface script, lists of measurements and energies were produced in a spreadsheet-
friendly format and entered into the QM-MM potential energy surface comparison 
spreadsheet, which produced energy profile graphs that visualize the difference between 
the QM and MM energy surfaces.165,166,167,168  The bond length and bond angle force 
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constants (Kb and Kθ values) and idealized bond lengths and bond angles (b0 and θ0 
values) were varied manually until the MM energy surfaces closely matched the QM 
energy surfaces for all problem bond length and bond angle parameters, and that all bond 
length and bond angle measurements fall within the margin of error.158,165,166,167   
Dihedral Angle Optimization of Model Compounds 
  With the bond lengths and bond angles repaired, the dihedrals 
followed.165,166,167,168  A similar script to (and the basis of) the bond length/bond angle 
potential energy surface script was used to create the CHARMM potential 
energies.165,166,167,168  It did not modify the internal coordinate file, but it instead 
constrained the problem dihedral with an immobilizing non-sinusoidal force restraint to 
the values corresponding to the 37 conformers produced by the corresponding QM 
energy surface experiment, with the conformer minimized and an energy measured for 
that conformer.165,166,167,168  Like the previous script, this script also produces 
spreadsheet-friendly lists of measurements to be entered into yet another QM-MM 
potential energy surface comparison spreadsheet.165,166,167,168  The torsional force 
constants (Kφ, listed as Kχ in the parameter file), periodicity values (n), and offset values 
(δ) were varied manually, with multiple dihedral parameters layered in as necessary in 
such a way as to not repeat periodicity values, have periodicity values of anything other 
than 1-4 or 6, or have the offset value be anything other than 0° or 180°, until the MM 
energy surfaces closely matched the QM energy surfaces for all problem dihedral 
parameters, and that all dihedral angle measurements fall within the margin of 
error.158,165,166,167  In some difficult cases, all force constants for the problem dihedral 
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would be zeroed, the MM potential energy surface taken and entered into a spreadsheet, 
and simulated dihedral parameters added to the graph to precisely and accurately choose 
new dihedral parameters immediately.  With the dihedrals repaired, the bond lengths and 
angles are to be verified to be within the margin of error, and the previous two steps 
(bond lengths/bond angles and dihedral torsions) repeated iteratively on all BAT model 
compounds until all bond lengths, bond angles, and dihedral angles fall within the margin 
of error for all BAT model compounds using the same topology and parameter files for 
each BAT model compound.158,165,166,167   
Construction of SB-674042 and Pyroglutamate, and Their Intermodel Connections 
  In order to parametrize the entire molecule, the charges and atom types were 
assembled for the complete SB-674042 compound just as the charges for the BAT model 
compounds were calculated, and an internal coordinate file was created just as those for 
each BAT model compound was created.158,159,160,161,162,163,164,165,166,167  The measurement 
script for SB-674042 was created just as those for the BAT model compounds were, with 
measurements taken with the old parameters and with the new BAT-based 
parameters.158,165,166,167  If any measurements fell outside the margin of error, new QM 
energy surfaces were created just as they had been for problem bond lengths, bond 
angles, and dihedral angles for (and using, in the first two cases) the BAT model 
compounds, with MM energy surface scripts created to match, so that the MM energy 
surface for the problem parameter can be made to match the QM energy surface by 
parameter modification in similar fashion to those of the BAT model 
compounds.158,165,166,167,168  This is repeated until all bond length, bond angle, and 
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dihedral angle measurements fall within the margin of error.158,165,166,167,168  Furthermore, 
the QM structures for the global minimum and two local minima were minimized using 
the old and new MM parameters to display the difference between the old and new 
parameters.158,165,166,167,168  This produced MM models that resembled the QM output 
more than the old parameters’ MM models did.158,165,166,167,168   
  For pyroglutamate, the remaining steps involve generation of pyroglutamate-
proline-NH2 (PyroEP) to ensure the proper way of connecting pyroglutamate as an N-
terminal protein residue and a primary amide cap as a C-terminal residue patch in 
CHARMM.161,162,163,164,165,166,167,168  This was followed up with minimization with the 
CHARMM parameters, then determining if there are any missing parameters and missing 
internal coordinates pertaining to amino acid connection that needed to be 
present.161,162,163,164,165,166,167,168  If there are any, then similar parameters to those 
connecting one amino acid to another were substituted in with atom names changed to 
match, so that pyroglutamate can be used as an N-terminal amino acid cap regardless of 
whether the next residue is a proline or not.161,162,163,164,165,166,167,168 
Construction of the Simulated Lipid Bilayer Cell to House the Ox1r R and R* 
Models 
  The ox1r model, in the inactive state and docked with the antagonist SB-674042 
as described above,3,7,24,137 was truncated at Y41 (N-terminus) and acetylated there.  In 
addition, the receptor was capped at C375 with methylamide.  The complex was aligned 
with the S1P1 structure169 from the OPM database.157  In order to ensure that the 
hydrophobic residues on the amphipathic helix 8 protrude into the hydrophobic region of 
the initial POPC(1-palmitoyl-2-oleoyl-phosphatidylcholine) lipid bilayer, this structure 
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was shifted 3 Å along the membrane normal in the +z direction (away from cytoplasm).  
This results in the transmembrane region of orexin being approximately centered at the 
middle of the lipid bilayer with Hx8 orientated parallel to the plane of the membrane at 
the lipid/water interface.  The model membrane simulation cell was constructed using the 
method described in Grossfield et. al170 with the addition of constraints on the cis-double 
bond of POPC (force constant = 250 kcal mol–1 radian–2).  This resulted in a simulation 
cell of initial size 86.14 Å x 86.14 Å x 136.0 Å with 176 molecules of POPC and 22188 
molecules of H2O.  Periodic boundary conditions were employed in the molecular 
dynamics, thus a buffer of at least 12 Å was provided in each dimension to avoid having 
ox1r interact with its images.  The CHARMM 22 protein force field156 and the 
CHARMM 36 lipid force field171 were used in this study.  Moreover, C375 was 
palmitoylated using parameters from earlier CB2 simulation experiments,172 and missing 
parameters for SB-674042137 and for orexin-A’s pyroglutamate residue4 were developed 
and discussed above.  Charge neutrality was enforced with addition of chloride counter 
ions, and an overall ionic strength of 0.15M was obtained by adding NaCl. The final 
system contained 95754 atoms.   
  The simulation cell for the active orexin receptor docked with the orexin-A 
peptide3,4,7,22,24 was constructed in a similar fashion as that described above for the 
inactive state.  Similar to the inactive state, the receptor was truncated, capped with 
methylamide, and palmitoylated at C375.  However, the N-terminus was acetylated at 
L32 rather than Y41, as several of these residues contact the bound peptide agonist, such 
as L32, L35, W36, L40, Y41, and P42.3,4,7,22,24  The active receptor has a slightly 
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different shape than the R state and this leads to a slightly modified initial cell of 
dimension 91.11 Å x 91.11 Å x 128.0 Å.  In addition to the protein and ions, the final 
system contained 206 POPC molecules and 23385 water molecules, for a total of 104034 
atoms.   
  The simulation cell construction procedure was repeated for a total of 4 
independent simulations for the inactive ox1r-SB-674042 complex3,7,24,137 and 6 
independent simulations for the activated ox1r-orexin-A complex.3,4,7,22,24  Once 
constructed, minimization and molecular dynamics were performed for each independent 
system as described below.   
Initial Minimization of the Ox1r R and R* Models in a Simulated Lipid Bilayer 
  As described in Grossfield et al.170 to relieve poor initial contacts, 2000 steps of 
steepest descent minimization were performed using CHARMM,173 with all heavy atoms 
of the protein, ligands, and internal waters fixed.  This was followed by a series of 
warming/minimization steps using NAMD.174  Each step included 500 steps of conjugate 
gradient minimization followed by 500 steps of MD at a 5 K higher temperature.  
Throughout this phase restraints were applied to the protein/ligand and internal water 
molecules (force constant = 5 kcal mol–1 Å–2).  This was performed until the target 
temperature of 310 K was reached.  Finally, these restraints were released in a series of 
minimizations wherein the force constant was gradually reduced from 5.0 to 2.5, then to 
1.0, to 0.5, to 0.25, to 0.1, and lastly to 0.05 kcal mol–1 Å–2, with 500 steps of 
minimization at each step. Finally, 2000 steps of restraint free minimization were 
executed.  MD simulations were then performed on the fully minimized systems.   
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Details of Molecular Dynamics Simulations of the Ox1r R and R* Models 
  Prior to unrestrained molecular dynamics on these systems, 2 ns of position 
restrained (force constant = 5.0 kcal mol–1 Å–2) molecular dynamics was performed using 
the AMBER12 package.175,176,177  For all production runs the GPU accelerated PME 
(Particle Mesh Ewald) pmemd.cuda was utilized.  Long range electrostatics were 
included using PME with the recommended 8 Å cutoff175,176 and default values for the 
charge grid spacing, which were chosen to be approximately 1 Å and B-spline (cubic).  
The NPT ensemble was used to maintain temperature (T = 310 K, Langevin dynamics 
with a collision frequency of 5 ps–1) and pressure (P = 1.0 bar, using the weak coupling 
Berendsen pressure control with pressure relaxation time of 8 ps).178  High frequency 
bonds to hydrogen were restrained using the shake method allowing the use of a 2 fs 
integration time step.  The 2 ns of restrained MD allows the simulation cell to adjust and 
produce a reasonable density, without perturbing the receptor docked structure.3,4,7,22,24,137  
This was followed by 50 ns of unrestrained MD.   
  Once the MD runs were finished, the finished MD trajectories and structure files 
were loaded into the program VMD179 and monitored to determine the quality of the 
bundle.  This is done so that if the bundle successfully maintained fundamental 
interactions such as ligand-receptor interaction site distances,3,4,22 and qualities such as 
Y6.48 χ1 dihedrals and R3.50-R6.30 distances,124,125,126,127,128,129,130,141,142,143 as 
hypothesized, it would be declared successful.  If it did not, then the problems would be 
diagnosed and corrected, and MD experiments repeated, until the MD experiment would 
be declared successful.175,176   
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Repair of Ox1r R and R* Models Based on Molecular Dynamics Experiments 
 After performing preliminary MD runs, the R and R* structures’ IC1 loops were 
replaced with an IC1 loop structurally based on that from the ox2r crystal structure so 
that M77 in both the R and R* structures tucks into a hydrophobic pocket and away from 
cytoplasm.7,175,176  Further changes ensued for each bundle.  When minimizing, the more 
modern OPLS3 force field was used in place of OPLS_2005 when available.   
  The R model had SB-674042 redocked so that it can interact with H7.393 (via 
hydrogen bond to the amide oxygen and π-stack with the fluorophenyl group) and with 
N6.557 (via hydrogen bond to the 1,3,4-oxadiazole nitrogen) as well as with Q3.32.3  The 
R structure also had its R3.50-T6.33 “ionic” lock reconfigured as is present in the ox2r 
crystal structure7 so that the “ionic” lock would be less likely to break as long as the 
receptor remains in the R state.124,125,126,127,128,129,130,141  Furthermore, the R structure had 
its EC2b and EC3 loops replaced with EC2b and EC3 loops that are structurally based on 
those from the ox2r crystal structure, with the top end of TMH6 replaced with that from 
ox2r to allow K6.58 and R6.59 to donate hydrogen bonds to D45.51, for H5.39 to donate 
a hydrogen bond to E45.52, and for the EC3 loop to be out of the way of these 
interactions.7  This was repeated until a successful R bundle was made, which had SB-
674042 move to one place, while maintaining its interaction with Q3.32,3 and had it 
remain there for the remainder of the simulation.3,7,24,137,175,176   
  The R* structure had small adjustments to improve stability, and as the R* 
structure has no hydrogen bond partner for R6.59, it would be allowed to interact with 
phospholipid groups.  It was further repaired by repositioning the orexin-A ligand to keep 
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its N-terminus high enough to clear TMH1, while maintaining its interaction with 
H7.39.3,22  The conformational space of the C-terminus (residues 15-33) of orexin-A22 
was then explored, as shown in Figure 25.133,147   
 
 
 
Figure 25. CM Output of Orexin-A (15-33), Superimposed on the Cαs of L31, T32, and 
L33, With the Chosen C-terminus Displayed in Blue, as the C-terminal End of It Fits Into 
the Ox1r Binding Pocket Better Than the Other C-termini Do.4,22,133,147   
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The conformational space of the C-terminus of orexin-A had to be explored 
because it became apparent that the entire ligand was not meant to fit within the ox1r, 
similar to other peptide-bound crystal structures,146,180,181,182,183,184,185,186,187 which meant 
that only a small part of orexin-A would be needed to activate the ox1r.3,4  It was done by 
running CM on a protein sequence that matches those residues, using full ±180° ranges 
for the φ and ψ dihedrals, running 150000 Monte Carlo steps per temperature stage, and 
producing 112 output peptides in order to be extra thorough.4,22,133,147  The EC3 loop and 
top turn of TMH6 was replaced with that from the ox2r crystal structure, and the ox2r-
template-based7 ox1r bundle after the CM helices were superimposed,133,144,145,147 after 
crystallographic waters were added,7 but before orexin-A was docked,3,4,22 was 
minimized together so that the bundle would be stable prior to orexin-A docking.  The 
remaining loops and termini from the previous R* structure were reused to save 
computational time.134,135,136   
 The CM output of orexin-A (15-33)4,22,133,147 was docked so that its C-terminus 
could reach into the binding pocket as a random coil, consistent with peptide-bound 
crystal structures,146,180,181,182,183,184,185,186,187 as opposed to conventional means of 
modeling that preserved the α-helical structure for the orexin-A C-terminus.9,155,188  This 
produced a dock that permitted H7.39 to accept a hydrogen bond from the amide cap of 
orexin-A3,161,162,163,164 and permitted D45.51 to accept a hydrogen bond from orexin-A’s 
H26,3,22 the latter interaction not simultaneously possible with the former by docking the 
whole orexin-A molecule,9,155,188 and produce numerous hydrophobic contacts 
within.3,9,22,155,188  Modeller134,135,136 was used to create the N-terminus, but as no 
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conformation produced was able to assemble both disulfide bonds while retaining the 
helical conformation in the orexin-A N-terminus,134,135,136 the residues 1-14 were taken 
directly from the orexin-A NMR structure and the backbone dihedrals adjusted to allow it 
to keep clear of the extracellular loops.4  This structure had MD experiments performed 
on it, and they revealed that more repairs would be necessary.3,4,7,22,24,175,176   
Ox1r Based on Direct Mutation of Ox2r Crystal Structure Termini Formation, 
Palmitoylation, and Minimization 
  This experiment showed the shortcomings of pull-apart-and-minimize homology 
modeling as higher-identity crystal structures became available.7,188  Therefore, new R 
and R* structures were made by direct mutation and renumbering using Maestro 
(Schrödinger 2006), such that the only residues that need to be added are the ic3 loop and 
termini, which can be reused from other models to save computational time,134,135,136 and 
that Conformational Memories need only be used for helices with differing proline 
locations and for TMH6 of active GPCR models.124,125,126,127,128,129,130,133,143,144,145,147,148,149   
  First, the R structure was created by adding hydrogen atoms to the ox2r crystal 
structure,7 removing the Pyrococcus abysii glycogen synthase and anything else that is 
neither ox2r crystal structure nor crystallographic water molecules from it,7 directly 
mutating it to the ox1r sequence and numbering,3 and filling in the short gaps in the 
sequence, all using Maestro’s (Schrödinger 2006) homology modeling program, with 
minor side chain dihedral changes following afterward, especially those of C, S, and T.  
Any histidine whose interactions would be more consistent as a histidine with its 
hydrogen on Nε2, but not on Nδ1, was then mutated accordingly (H75, H76, and H5.39).  
Minimization of all nonpolar hydrogen atoms and changed side chains within the 
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structure “dry,” then those in the loop regions “wet,” to ease contacts within the structure 
followed.   
  The ligand SB-674042 was docked within the new R structure using the same 
pose as the final pose from the successful R bundle’s MD experiment, with Q3.32’s side 
chain oriented to donate a hydrogen bond to SB-674042’s amide oxygen,3 and the ligand 
and Q3.32’s side chain were minimized “dry,” then “wet,” within to allow the ligand to 
relax within the binding pocket, to retain its interaction with Q3.32, and to relieve 
contacts between SB-674042 and the ox1r structure.3,7,24,137,175,176  The IC3 loop from the 
previous R bundle was retained, while reusing the remaining part of the crystal structure 
that would connect to the IC3 loop in order to maintain fidelity with the crystal structure, 
and the N- and C-termini were also reused in a similar manner, with the new IC3 loop 
minimized “wet,” as shown in Figure 26.7,134,135,136   
 
 
 
Figure 26. The New IC3 Loop for the R State.7,134,135,136   
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  The new R* structure was made by using the newest R structure and aligning the 
best CM-produced TMH6 that kicked out124,125,126,127,128,129,130,143 along the Cαs of 
residues 6.51-6.56 (as opposed to 6.51-6.61),7,133,144,145,147 as shown in Figure 27. That 
TMH6 was aligned along the Cαs of residues 6.51-6.56, and not those of 6.51-6.61, for 
the same reason the top turn of TMH6 was replaced:  the ox2r crystal structure’s top turn 
was not wound as tightly as that of the CM helix used.7,133,144,145,147  This is shown in 
Figure 28.7,133,144,145,147   
This meant that removing residues 6.57-6.61 from the superimposition was 
necessary to improve how the helix superimposed onto the crystal structure’s 
TMH6.7,133,144,145,147  The residues on TMH6 and its intracellular extension were replaced 
below I6.51 (so that the C-terminus of the replaced part was P6.50) with the CM output, 
R3.50 was straightened out, and both R3.50124,125,126,127,128,129,130,143 and the CM-based 
half of TMH67,133,144,145,147 were minimized “dry” so that no gaps occurred between 
TMH6 and the rest of the crystal structure, that Y6.48 would be in 
trans124,125,126,127,128,129,130 and donating a hydrogen bond to T5.46, and that the R3.50-
R6.30 distance would be ~17 Å.124,125,126,127,128,129,130,142,143  Y5.58 was already in g+ in the 
ox2r crystal structure,7,138 so no changes were necessary.  The IC3 loop from the previous 
R* bundle was reused, and the crystal structure residues 5.67-5.68 retained to maintain 
fidelity with the crystal structure at TMH5, then the new IC3 loop was minimized “wet,” 
as shown in Figure 29.7,134,135,136   
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Figure 27. Best CM Helix for TMH6 (in Light Green) Superimposed on the Newest Ox1r 
R Structure Based on Direct Mutation of the Ox2r in Such a Way as to Permit the New 
TMH6 to Kick Out with Respect to the Template TMH6 (in Light Blue) and Have a 
Closer RMSD Match and Better Interhelical Contacts Than It Had in Figure 
14.7,133,144,145,147   
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Figure 28. The Best CM Helix for TMH6 Superimposed is Wound Tighter on the EC 
Side Than the Newest Ox1r R Structure Based on Direct Mutation of the 
Ox2r.7,133,144,145,147 
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Figure 29. The New IC3 Loop for the R* State.7,134,135,136   
 
  Orexin-A (15-33)’s CM output4,22,133,147 was then docked so the C-terminus can 
reach into the pocket as a random coil as before.146,180,181,182,183,184,185,186,187  Due to 
increased knowledge about technique and structure, it was docked so that H7.39’s 
hydrogen bond donor counterpart was instead T32’s hydroxyl side chain, as it has a 
larger positive charge than the amide cap’s polar hydrogens, and H7.39 can accept a 
hydrogen bond from T32 via its Nε2 while its Nδ1 hydrogen donates a hydrogen bond to 
D2.65.3,7,22,161,162,163,164  This is similar to Karhu et al. which has T32 interact with H7.39 
via its Nδ1.9  However, unlike Karhu et al.,9 H26 remained a hydrogen bond donor to 
D45.51.3,22  Furthermore, I30, L31, and L33 all had important hydrophobic roles,22 
including L33’s van der Waals contacts with F5.429 and Y6.48,3,22 with N6.55 moved to 
trans, letting it donate a hydrogen bond to H5.39’s side chain, to permit orexin-A the 
room to interact with the ox1r.  Orexin-A’s NMR structure4 was then placed on the EC2a 
β-sheet structure with L16, L19, and L20 set up to create van der Waals contacts with that 
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EC2a loop structure.7,22  This structure is common to peptide-binding receptors and may 
permit the peptide ligand to “discharge” itself into the binding 
pocket.3,4,7,22,24,140,146,180,181,182,183,184,185,186,187   
  The first 24 residues of the NMR structure of orexin-A4 were then attached to 
residues 25-33 of the CM output of orexin-A (15-33)4,22,133,147 and that connection, then 
the entire orexin-A structure, was minimized “wet” to permit orexin-A to settle in and 
pursue these good interactions.3,4,7,22,24  It was then further optimized using the program 
Schrödinger Prime, holding the transmembrane Cαs at 5000 kJ/mol, to improve these 
interactions even more.3,4,7,22,24   
  When tested in MD experiments,157,158,159,160 further repairs for both the R and R* 
models’ ligand docking became necessary.3,4,7,22,24   
The Procedure of Glide Ligand Docking 
 The ligand docking program Glide works by simulating the ligand binding site of 
the receptor with different energetic fields, and also by analyzing the ligand orientation 
and conformation.189,190,191  All of the available ligand conformations are tested to fit the 
receptor grid created by those fields so that only the good poses are tested, then the ligand 
is minimized in the receptor grid with the OPLS-AA force field to lower the energy of 
poses that fit the grid, then the docks are scored.189,190,191  There are two ways to score 
Glide ligand docks, SP and XP.189,190,191  The initial parts of Glide ligand docks use the 
SP function, which totals the free energy changes from bond rotation, Coulombic and van 
der Waals energies, and polar and nonpolar mismatches.189,190,191  The XP function goes 
even further by additionally rewarding water displacement into bulk solution and 
64 
 
 
rewarding more attractive polar/ionic interactions, as it also punishes restriction of 
motion.189,190,191   
Ox1r Based on Direct Mutation of Ox2r Crystal Structure Ligand Dock Repair 
  The R bundle had SB-674042 docked using the Glide docking program as 
follows.3,7,24,189,190,191  First, the R bundle was used as a Glide grid, with Q3.32 and N6.55 
listed as hydrogen bond donors, then SB-674042 was docked using the Glide XP (Extra 
Precision, the most robust Glide docking technique at hand) ligand docking 
program.3,7,24,189,190,191  The new dock replaced the hydrogen bond from Q3.32’s amide 
hydrogens to SB-674042’s amide oxygen (namely O13) with another hydrogen bond 
from Q3.32’s amide hydrogens to the slightly less negatively charged, but far easier to 
access, oxadiazole ring nitrogens (namely N40), and allowed for three new π-π 
interactions to form.3,7,24,189,190,191   
  The R* bundle had the N-terminus reconfigured to add additional contacts 
between orexin-A’s N-terminus and the ox1r’s extracellular TMH1-2-7 area and displace 
additional waters from in between those areas.3,4,7,22,24  Furthermore, the residues 
connecting orexin-A’s central helix4,22 to its hydrophobic C-terminus4,22,133,147 were 
refined with Modeller,134,135,136 which cleaned up the conformation so that it would be far 
more stable, and allowed H26 to donate a hydrogen bond to D45.51 and accept two from 
R45.53.3,4,7,22,24   
  Further repairs for the ox1r R* structure were necessary, so the last 4 residues of 
orexin-A were capped N-terminally with an acetyl group and docked with Glide XP, with 
the R* bundle used as a Glide grid and its H7.39 Nε2 listed as a hydrogen bond 
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acceptor.3,4,7,22,24,189,190,191  Afterward, the residues connecting orexin-A’s central helix4,22 
to its hydrophobic C-terminus4,22,133,147 were refined with Modeller,134,135,136 such that I30 
in orexin-A would be remodeled with Modeller after L31 is placed with Glide XP in 
I30’s presence,4,22,134,135,136,189,190,191 allowing H26 and the orexin-A backbone to donate 
hydrogen bonds to D45.51, while R45.53 and K6.58 donate several hydrogen bonds to 
the orexin-A backbone.3,4,7,22,24   
  Still further repairs were needed, as the orexin-A N-terminus bound too well to 
the ox1r’s extracellular TMH1-2-7 area, so the orexin-A N-terminus was reconfigured to 
bind instead to the ox1r EC2 loop.3,4,7,22,24  As the previous round of minimizations of 
ox1r with orexin-A bound had completely optimized the orexin-A C-terminal dock, but 
since the round of minimizations that reoptimized the N-terminus and middle Helix 1 of 
orexin-A moved the other end of that connector,3,4,7,22,24,133,134,135,136,147,189,190,191 the 
residues connecting orexin-A’s central helix4,22 to its hydrophobic C-
terminus4,22,133,134,135,136,147 were again refined with Modeller,134,135,136 allowing H26 and 
the orexin-A backbone to donate hydrogen bonds to D45.51, while R45.53 and K6.58 
donate several hydrogen bonds to the orexin-A backbone.3,4,7,22,24   
  The results of that R* structure’s MD run, as it had all of the hallmarks of a good 
R* bundle with the exception of involving H7.39 in an interaction with orexin-
A,3,4,7,22,24,124,125,126,127,128,129,130,139,141,143,175,176 were used for the newest R* structure, but 
H7.39 was mutated so that its polar hydrogen was on Nε2 so it could donate a hydrogen 
bond to the orexin-A backbone and T32’s hydrogen bond to the side chain of E45.52 was 
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retained, along with H26’s side chain donating a hydrogen bond to D45.51’s side 
chain.3,4,7,22,24   
  After this point, both the R and R* structures were finished3,4,7,22,24 and, once 
converted to CHARMM, they were ready to use in MD experiments 
again.157,158,159,160,175,176   
Summary of the Number of Programs Required to Dock Orexin-A in the Ox1r 
 In all, six programs were used to dock orexin-A in the ox1r3,4,7,22,24:  
Conformational Memories to create the rough orexin-A C-terminus,4,22,133,147 Maestro 
(Schrödinger 2006) to hand-dock the orexin-A NMR structure and the Conformational 
Memories output and assemble them together as a complete molecule of orexin-A, while 
repairing orexin-A’s N-terminus,3,4,7,22,24,133,140,147,146,180,181,182,183,184,185,186,187 Schrödinger 
Prime to optimize that dock,3,4,7,22,24 Glide to refine the dock of orexin-A’s last four 
residues,3,4,7,22,24,189,190,191 Modeller to connect the last three residues of orexin-A (as I30 
would have to be refined again) to the central helix optimized by Schrödinger Prime in a 
low-free-energy fashion,3,4,7,22,24,134,135,136 and lastly, MD to optimize the orexin-A dock 
once more.3,4,7,22,24,175,176   
Calculations of Energies of Interaction and MD Trajectory Data Graphs 
  With the R and R* structures’ successful MD experiments, two further 
experiments were carried out.3,4,7,22,24,175,176  The ox1r R and R* models were extracted 
along with their ligands from the first and last frames of their respective trajectories using 
VMD179 and the energies of interaction were calculated for each ligand before and after 
the MD experiment was allowed to run.3,4,7,22,24,157,158,159,160,175,176  Furthermore, VMD179 
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was used to create graphs of the backbone and transmembrane Cα RMSD, Y6.48 χ1 
dihedral measurements, and various distance measurements.3,4,7,22,24,157,158,159,160,175,176   
Ox1r Based on Direct Mutation of Ox2r Crystal Structure Comparisons with 
Orexin-B Docks and with New Ox1r Crystal Structures 
  Two further experiments were carried out in addition to calculations of interaction 
energies and VMD graphing.179  One was comparing the ox1r R* structure with orexin-A 
docked within it as extracted from the final frame of its MD experiment with a dock of 
orexin-B into the vacant ox1r R* structure that was extracted from that same 
frame.3,4,7,22,24,131,132,157,158,159,160,175,176  Another was comparing the recently released 
orexin-1 receptor crystal structures (4zj8 and 4zjc)192 with the orexin-1 receptor models 
before and after the MD simulations3,4,7,22,24,157,158,159,160 to see the various structural 
similarities and differences between them.3,4,7,22,24,192   
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CHAPTER III 
 
RESULTS 
 
Primary Sequence of the Orexin-1 Receptor and Comparisons with Other GPCR 
Sequences 
  The orexin-1 receptor3,24 has many common features, as well as differing features, 
with other GPCRs, such as the μ-opioid receptor,140 the β2-AR,144,145 and the ox2r,7 as 
shown in Figure 30.152,169   
 
1 Human Sequences  
See Key on last page With Absolute Sequence Numbers Below  
1 
Orexin-1 M E
Orexin-1 1 2 
Orexin-2 M S G T K L E D S P 
Orexin-2 1 2 3 4 5 6 7 8 9 10
Beta-2 
Beta-2 
MOR M D S S A A P T N A S N C T D A L A Y S S C S P A P 
MOR 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
N-Ter→ 
x 
x 
x 
x 
2 x 
Orexin-1 P S A T P G A Q M G V P P G S R E P S P V P P D Y E
Orexin-1 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Orexin-2 P C R N W S S A S E L N E T Q E P F L N P T D Y D D
Orexin-2 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
Beta-2 M G Q P G N G S A F L L A P N
Beta-2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
MOR S P G S W V N L S H L D G N L S D P C G P N R T D L
MOR 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52
X 
X 
x 
 
Figure 30. Sequence Alignment152,169 of the Ox1r,3,24 Ox2r,7 β2-AR,144,145 and the μ-
opioid Receptor.140 
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 x  1 1 1 1 1 1 1 1 1 1 1 
x  2 3 3 3 3 3 3 3 3 3 3 
3 x  9 0 1 2 3 4 5 6 7 8 9 
Orexin-1 D E F  L R Y L W R D Y L Y P K Q Y E W V L I A A Y 
Orexin-1 29 30 31  32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53
Orexin-2 E E F  L R Y L W R E Y L H P K E Y E W V L I A G Y 
Orexin-2 37 38 39  40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61
Beta-2 R S H  A P D H D V T Q Q R D E V W V V G M G I V M
Beta-2 16 17 18  19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
MOR G G R  D S L C P P T G S P S M I T A I T I M A L Y 
MOR 53 54 55  56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77
x  TMH1→ 
x  
x  
1 1 1  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
3 4 4  4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 6 
4 0 1 2  3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 
Orexin-1 V A V  F V V A L V G N T L V C L A V W R N H H M
Orexin-1 54 55 56  57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77
Orexin-2 I I V  F V V A L I G N V L V C V A V W K N H H M
Orexin-2 62 63 64  65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85
Beta-2 S L I  V L A I V F G N V L V I T A I A K F E R L 
Beta-2 41 42 43  44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
MOR S I V  C V V G L F G N F L V M Y V I V R Y T K M
MOR 78 79 80  81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101
x  IC1 Loop→
x  
x  
x 2  2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
x 3  3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 
5 x 8  9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 
Orexin-1 R T V  T N Y F I V N L S L A D V L V T A I C L P A S 
Orexin-1 78 79 80  81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103
Orexin-2 R T V  T N Y F I V N L S L A D V L V T I T C L P A T 
Orexin-2 86 87 88  89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111
Beta-2 Q T V  T N Y F I T S L A C A D L V M G L A V V P F G
Beta-2 65 66 67  68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
MOR K T A  T N I Y I F N L A L A D A L A T S T L P F Q S 
MOR 102 103 104  105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127
x  TMH2→ 
x  
x  
 
Figure 30. Cont.
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 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
6 6 6 6 6 6 2 2 2 2 2 2 2 2 3 3 3 3 3 3 
6 2 3 4 5 6 7             2 3 4 5 6 7 8 9 0 1 2 3 4 5 
Orexin-1 L L V D I T E S W L F G H A L C K V I P Y L Q A V S 
Orexin-1 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129
Orexin-2 L V V D I T E T W F F G Q S L C K V I P Y L Q T V S 
Orexin-2 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137
Beta-2 A A H I L M K M W T F G N F W C E F W T S I D V L C 
Beta-2 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116
MOR V N Y L M G T W P F G   T I L C K I V I S I D Y Y N 
MOR 128 129 130 131 132 133 134 135 136 137 138   139 140 141 142 143 144 145 146 147 148 149 150 151 152
x EC1 Loop→ TMH3→ 
x 
x 
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 
7 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 
Orexin-1 V S V A V L T L S F I A L D R W Y A I C H P L L F K
Orexin-1 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155
Orexin-2 V S V S V L T L S C I A L D R W Y A I C H P L M F K
Orexin-2 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163
Beta-2 V T A S I E T L C V I A V D R Y F A I T S P F K Y Q
Beta-2 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142
MOR M F T S I F T L C T M S V D R Y I A V C H P V K A L 
MOR 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178
x D/ERY/F/W Motif IC2 Loop→ 
x 
x 
x 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 
x 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 
8 x 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 
Orexin-1 S T A R R A R G S I L G I W A V S L A I M V P Q
Orexin-1 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179
Orexin-2 S T A K R A R N S I V I I W I V S C I I M I P Q
Orexin-2 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187
Beta-2 S L L T K N K A R V I I L M V W I V S G L T S F L P 
Beta-2 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168
MOR D F R T P R N A K I I N V C N W I L S S A I G L P V 
MOR 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204
x TMH4→ 
x 
x 
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4 4 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45 45
6 6 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 
9 1 2 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 
Orexin-1 A A V M E C S S V L P E L A N R T R L F S V C D E R 
Orexin-1 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205
Orexin-2 A I V M E C S T V F P G L A N K T T L F T V C D E R 
Orexin-2 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213
Beta-2 I Q M H W Y R A T H Q E A I N C Y A N E T C C D F F 
Beta-2 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194
MOR M F M A T T K Y R Q G S I D C T L T 
MOR 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222
x EC2 Loop→  Internal loop  C3.25 
x  disulfide  disulfide 
x  bridge  bridge 
45 45 45 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 
5 5 5 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 
10 4 5 6 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 
Orexin-1 W A D D L Y P K I Y H S C F F I V T Y L A P L G
Orexin-1 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229
Orexin-2 W G G E I Y P K M Y H I C F F L V T Y M A P L C 
Orexin-2 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237
Beta-2 T N Q A Y A I A S S I V S F Y V P L V 
Beta-2 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213
MOR F S H P T W Y W E N L L K I C V F I F A F I M P V L 
MOR 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248
x TMH5→ 
x 
x 
5 5 5 5 5 5 5 5 5 5 5 5 5 5 
5 5 5 5 5 5 5 6 6 6 6 6 6 6 
11 3 4 5 6 7 8 9 0 1 2 3 4 5 6 
Orexin-1 L M A M A Y F Q I F R K L W G R Q I P G T T S A L V 
Orexin-1 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255
Orexin-2 L M V L A Y L Q I F R K L W C R Q I P G T S S V V Q
Orexin-2 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263
Beta-2 I M V F V Y S R V F Q E A K R Q L Q K I D K S E G R 
Beta-2 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239
MOR I I T V C Y G L M I L R L K S V R M L S G S 
MOR 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 
x IC3 Loop→ 
x 
x 
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x 
x 
12 x 
Orexin-1 R N W K R P S D Q L G D L E Q G L S G E P Q P R A R 
Orexin-1 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281
Orexin-2 R K W K P L Q P V S Q P R G P G Q P T K S R M S A V 
Orexin-2 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289
Beta-2 F H V Q N L S Q V E Q D G R T G H G L R R S 
Beta-2 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 
MOR 
MOR 
x 
x 
x 
x 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 
x 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 
13 x 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 
Orexin-1 A F L A E V K Q M R A R R K T A K M L M V V L L V F 
Orexin-1 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307
Orexin-2 A A E I K Q I R A R R K T A R M L M I V L L V F 
Orexin-2 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313
Beta-2 S K F C L K E H K A L K T L G I I M G T F 
Beta-2 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282
MOR K E K D R N L R R I T R M V L V V V A V F 
MOR 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291
x TMH6→ 
x 
x 
6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 
4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 6 6 
14 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 
Orexin-1 A L C Y L P I S V L N V L K R V F G M F R Q A S D R 
Orexin-1 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333
Orexin-2 A I C Y L P I S I L N V L K R V F G M F A H T E D R 
Orexin-2 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339
Beta-2 T L C W L P F F I V N I V H V I Q D N L I R 
Beta-2 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 
MOR I V C W T P I H I Y V I I K A L V T I P E T 
MOR 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 
x CWXP Motif EC3 Loop→ 
x 
x 
 
Figure 30. Cont.
73 
 
 
7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 
2 3 3 3 3 3 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 5 5 5 5 5 
15 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 
Orexin-1 E A V Y A C F T F S H W L V Y A N S A A N P I I Y N 
Orexin-1 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359
Orexin-2 E T V Y A W F T F S H W L V Y A N S A A N P I I Y N 
Orexin-2 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365
Beta-2 K E V Y I L L N W I G Y V N S G F N P L I Y C 
Beta-2 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327
MOR T F Q T V S W H F C I A L G Y T N S C L N P V L Y A 
MOR 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339
TMH7→ NPXXY 
x Motif 
x 
7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 
5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 
16 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 
Orexin-1 F L S G K F R E Q F K A A F S C C L P G L G P C G S 
Orexin-1 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385
Orexin-2 F L S G K F R E E F K A A F S C C C L G V H H R Q E 
Orexin-2 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391
Beta-2 R S P D F R I A F Q E L L C L R R S S L K A Y G N 
Beta-2 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352
MOR F L D E N F K R C F R E F C I P T S S N I E Q Q N S 
MOR 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365
X Elbow HX8→ C-Ter→ 
X 
X 
X 
X 
17 x 
Orexin-1 L K A P S P R S S A S H K S L S L Q S R C S I S K I 
Orexin-1 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411
Orexin-2 D R L T R G R T S T E S R K S L T T Q I S N F D N I 
Orexin-2 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417
Beta-2 G Y S S N G N T G E Q S G Y H V E Q E K E N K L L C 
Beta-2 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378
MOR T R I R Q N T R D H P S T A N T V D R T N H Q L E N 
MOR 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391
X 
X 
X 
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X 
X 
18 x 
Orexin-1 S E H V V L T S V T T V L P 
Orexin-1 412 413 414 415 416 417 418 419 420 421 422 423 424 425
Orexin-2 S K L S E Q V V L T S I S T L P A A N G A G P L Q N 
Orexin-2 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443
Beta-2 E D L P G T E D F V G H Q G T V P S D N I D S Q G R 
Beta-2 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404
MOR L E A E T A P L P 
MOR 392 393 394 395 396 397 398 399 400
x 
x 
x 
X 
X Sequence total 
19 x residues 
Orexin-1 425 Orexin-1 
Orexin-1 425 Orexin-1 
Orexin-2 W 444 Orexin-2 
Orexin-2 444 444 Orexin-2 
Beta-2 N C S T N D S L L 413 Beta-2 
Beta-2 405 406 407 408 409 410 411 412 413 413 Beta-2 
MOR 400 MOR 
MOR 400 MOR 
X 
X 
x 
x Key 
x 
20 Sequence Uniprot ID 
Orexin-1 O43613 
Orexin-2 O43614 
MOR P35372 
Beta-2 P07550 
Notes: Nterm and the boxed residues (TMH1) are missing from the D3 crystal structure. 
If the gray TMH regions extend or don't seem to match up with the ends of other sequences 
it is because we can see in a crystal structure the change and we don't know for sure where the 
phospholipid bilayer headgroups would lie or the natural tilt of the TMH7 bundle. 
X 
X 
X 
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x Key 
x 
20 Sequence Uniprot ID 
Orexin-1 O43613 
Orexin-2 O43614 
MOR P35372 
Beta-2 P07550 
Notes: Nterm and the boxed residues (TMH1) are missing from the D3 crystal structure. 
If the gray TMH regions extend or don't seem to match up with the ends of other sequences 
it is because we can see in a crystal structure the change and we don't know for sure where the 
phospholipid bilayer headgroups would lie or the natural tilt of the TMH7 bundle. 
X 
X 
X 
X 
X 
21 x Color Key 
Prolines 
Highly conserved 
Reasonably conserved  
Loop gap warning (only used in TMH7 to HX8 elbow)  
TMH and helical regions: modified for crystal structures   
Assorted Motifs: N-ter glycosylation sites, GG motif, and GW motif   
C In a disulfide bridge 
C C3.25 disulfide bridge from EC2 Loop  
C Internal within the same loop or termini disulfide bridge   
X Loop w/helical secondary structure  
X Loop w/beta-sheet secondary structure  
S Known phosphorylation site  
D Alternate Beta-Arrestin site instead of phosphorylated S or T 
T Possible phosphorylation motif  
C Possible Palmitoylation site  
K Show sequence conflict.  
May have alternate listed nearby on the table as with S1PR1 KSL vs NV  
x     
Glycosylation Motif is NXS or NXT, and X can't be a Proline 
L Underlined font=IC1 hydrophobic residue commonly pointing 
towards extracellular and not towards intracellular 
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Absent from both the μ-opioid receptor140 and the β2-AR,144,145 yet present in both orexin 
receptors,3,7,24 is a proline at position 3.29, as this allows for a kink to occur in Helix 3 in 
both orexin receptors,3,7,24 yet in neither the μ-opioid receptor140 nor the β2-AR.144,145  
Unlike the μ-opioid receptor (F1.51)140 and the β2-AR and the ox2r (V1.51),7,144,145 the 
ox1r has T1.513,24 to allow for increased ability to kink the TMH1.148  Both orexin 
receptors possess W3.51-Y5.32,3,7,24 whereas the μ-opioid receptor and the β2-AR both 
possess Y3.51-I3.52(μ)/F3.52(β2).140,144,145  In helices 2 and 4, among both orexin 
receptors,3,7,24 the μ-opioid receptor,140 and the β2-AR,144,145 one of these receptors has the 
proline in a different position than the other three.  For instance, the μ-opioid receptor has 
the helix 2 proline at P2.58,140 whereas the others have that proline at P2.59.3,7,24,144,145  
Another instance is the helix 4 proline, in which the β2-AR has its own at P4.60,144,145 
whereas the others have it at P4.59.3,7,24,140   
However, of the 4 GPCRs, only the β2-AR has the conserved E6.30 for the R3.50-
E6.30 salt bridge,124,125,126,127,128,129,130,144,145 so the μ-opioid receptor must use T6.34 as a 
hydrogen bond acceptor,124,125,126,127,128,129,130,140,141 with T6.33 performing a similar role, 
in addition to an arginine-arginine T-stack between R3.50 and R6.30, in both orexin 
receptors.3,7,24,124,125,126,127,128,129,130,139,141  Within the TMH6 toggle switch, all 4 receptors 
have a phenylalanine at F6.44 and a cysteine at C6.47,3,7,24,140,144,145 but the orexin 
receptors possess a tyrosine at Y6.483,7,24 instead of the conserved tryptophan at W6.48 in 
the other two,140,144,145 and all three differ with respect to X6.52: the orexin receptors have 
S6.52,3,7,24 the μ-opioid receptor has H6.52,140 and the β2-AR has F6.52.144,145  In TMH7, 
the μ-opioid receptor has A7.40,140 whereas the others have W7.40.3,7,24,144,145  However, 
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the β2-AR skips 7.56, and has a proline at P7.58 (-SP),144,145 a feature that both orexin 
receptors (LSG) and the μ-opioid receptor lack (LDE).3,7,24,140   
General Topology, Structure, and Interactions of the Orexin-1 Receptor 
  Following the above steps produced two orexin-1 receptor models: one R model 
and one R* model.  The R model with SB-674042 bound is shown in Figure 31.3,7,24  The 
R* model with orexin-A bound is shown in Figure 32.3,4,7,22,24 
 
 
 
Figure 31. The Finished Ox1r R Model.3,7,24 
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Figure 32. The Finished Ox1r R* Model.3,4,7,22,24   
 
Each consists of seven transmembrane α-helices arranged in a bundle, 
counterclockwise from the EC side.  The transmembrane helices I (red), III (yellow), V 
(light blue), and VII (blue-purple) have their N-terminal ends of these helices on the EC 
side and the C-terminal ends of these helices on the IC side.3,7,24  The transmembrane 
helices II (orange), IV (green), and VI (royal blue) have their N-terminal ends of these 
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helices on the IC side and the C-terminal ends of these helices on the EC side.3,7,24  At the 
C-terminal end of transmembrane helix VII, there is a 1-residue elbow (medium blue) 
that connects it to a helix parallel to the lipid bilayer.3,7,24  This helix is horizontal helix 
VIII (purple).3,7,24  These helices (I, II, III, IV, V, VI, and the VII-VIII complex) are 
connected with loops, as IC loops connect helices I and II (IC1, orange), III and IV (IC2, 
yellow), and V and VI (IC3, light green), and EC loops connect helices II and III (EC1, 
yellow orange), IV and V (EC2, yellow green), and VI and VII (EC3, sky blue).3,7,24  The 
improved coloration is necessary to ease navigation of different GPCRs, as they differ in 
length yet have common motifs, leading to Maestro’s (Schrödinger 2006) residue 
position color scheme changing from one GPCR to another.3,7,24,144,145,146  The color 
codes are listed in Table 6.   
 
Table 6 
 
RGB Color Codes of the Carbons of Each TM Helix, Helix 8, the Ligand, and the 
Palmitoyl Group, with the Minimum at 0 and the Maximum at 255.  All Other Carbons 
are Colored by Ox1r Residue Position, and All Other Elements are Colored by 
Element.3,7,24 
 
RGB Color Codes for Ox1r Carbons and Ligand Carbons 
Part Residues or Chain Red Green Blue 
TMH1 Residues 43-74 255 0 0 
TMH2 Residues 80-109 255 170 0 
TMH3 Residues 116-150 255 255 0 
TMH4 Residues 157-181 0 255 0 
TMH5 Residues 209-243 0 255 255 
TMH6 Residues 293-324 0 0 255 
TMH7 Residues 334-361 85 0 255 
HX8 Residues 363-374 170 0 255 
Palmitoyl Residue 426 170 255 0 
Ligand Chain B 255 0 255 
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In a way similar to the β2-AR144,145 and the ox2r,7 the EC1 loop is arranged so that 
W112 is pointed into lipid, holding the EC1 loop rigid.  In the first working R bundle, 
also similar to the β2-AR,144,145 the EC2 loop is arranged so that the half N-terminal to 
C45.50 (202), the EC2a loop, forms an α-helix.  In the working R* bundle and in the 
second working R bundle, the EC2a loop instead forms a pair of β-strands that form a β-
sheet, as is common to many peptide-binding receptors.3,7,140,146,180,181,182,183,184,185,186,187  
Furthermore, as the ox2r7 and β2-AR144,145 have, the part C-terminal to C45.50 (202), the 
EC2b loop, has D45.51 (203) pointed upward with a salt bridge interaction with R6.59 
(322), E45.52 (204) pointed downward and accepting a hydrogen bond from H5.39, 
R45.53 (205) pointed upward, and W45.54 (206) pointed downward in an aromatic stack 
in the R model as shown in Figure 33.3,7,24   
 
 
 
Figure 33. The EC2b Loop of the R Structure.3,7,24 
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The EC2b loop is shown for the R* model in a similar way in Figure 34.3,7,24  This 
keeps the EC2b loop out of the binding pocket.3,24  IC1 and IC2 are short connections that 
interact freely with cytosol, and IC3 extends in the form of α-helical extensions of 
transmembrane helices V and VI, similar to rhodopsin2 and the P2Y12 receptor.141  The 
N-terminus is kept away from the top of each bundle, as is prevalent in the β2-AR,144,145 
but unlike rhodopsin,2 as orexin-A is a positively-charged (+1) signaling peptide that 
enters from the extracellular side.3,4,22,24  The C-terminus is kept away from the bottom of 
the bundle so that a G protein12 or β-arrestin15 can bind, and both termini are kept away 
from the lipid bilayer2,144,145,157 and in an aqueous environment.2,144,145  In each model, 
there is a palmitoyl group bound to a thioester linkage to C375, helping anchor the ox1r 
in the lipid membrane regardless of activation state.3,7,156 
 
 
 
Figure 34. The EC2b Loop of the R* Structure.3,7,24   
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 The helices of the ox1r interact with one another in numerous ways.  Both the R 
and R* models have these interactions, beginning with N1.50 donating a hydrogen bond 
to S7.46’s backbone oxygen, as shown in Figure 35 for the R structure.3,7,24   
 
 
 
Figure 35. N1.50 Donates a Hydrogen Bond to S7.46’s Backbone Oxygen in the R 
Model.3,7,24 
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 The helices of the ox1r interact with one another in numerous ways.  Both the R 
and R* models have these interactions, beginning with N1.50 donating a hydrogen bond 
to S7.46’s backbone oxygen, as shown in Figure 36 for the R* structure.3,7,24  The R 
model’s TMH2, TMH3, and TMH4 also interact as well by N2.45 donating a hydrogen 
bond to T3.42 and additionally accepting one from W4.50, as shown in Figure 37.3,7,24 
 
 
 
Figure 36. N1.50 Donates a Hydrogen Bond to S7.46’s Backbone Oxygen in the R* 
Model.3,7,24   
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Figure 37. N2.45 Donates a Hydrogen Bond to T3.42 and Accepts One from W4.50, in 
the R Model.3,7,24 
 
The R* model’s TMH2, TMH3, and TMH4 also interact as well by N2.45 
donating a hydrogen bond to T3.42 and additionally accepting one from W4.50, as shown 
in Figure 38.3,7,24   
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Figure 38. N2.45 Donates a Hydrogen Bond to T3.42 and Accepts One from W4.50, in 
the R* Model.3,7,24   
 
D2.50 accepts a hydrogen bond from N7.49 in the ox1r R structure, as shown in Figure 
39.3,7,24   
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Figure 39. D2.50 Accepts a Hydrogen Bond from N7.49 in the R Model.3,7,24   
 
D2.50 accepts a hydrogen bond from N7.49 in the ox1r R* structure, as shown in Figure 
40.3,7,24   
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Figure 40. D2.50 Accepts a Hydrogen Bond from N7.49 in the R* Model.3,7,24   
 
R6.59 has its role in keeping the EC2 loop and TMH6 together, as it donates salt bridge 
hydrogen bonds to E45.52, as shown in Figures 41 and 42.3,7,24   
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Figure 41. R6.59 Donates Salt Bridge Hydrogen Bonds to E45.52 in the R Model.3,7,24   
 
 
 
Figure 42. R6.59 Donates Salt Bridge Hydrogen Bonds to E45.52 in the R* Model.3,7,24   
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There are also cation-π and π-stack interactions common to both the R and R* models, 
with one being F114 donating a π-π T-stack to W112 in the EC1 loop, as shown in Figure 
43 for the R bundle.3,7,24   
 
 
 
Figure 43. F114 Donates a π-π T-stack Interaction to W112 in the R Model.3,7,24   
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F114 donates a π-π T-stack to W112 in the EC1 loop in a similar way as it does for the 
ox1r R bundle’s EC1 loop, and both in a similar way to the ox2r crystal structure, as is 
shown in Figure 44 for the R* bundle.3,7,24   
 
 
 
Figure 44. F114 Donates a π-π T-stack Interaction to W112 in the R* Model.3,7,24   
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Yet another common interaction is H3.56 donating a π-π T-stack to W3.51 in TMH3, 
which in turn donates another to Y3.52, as shown in Figure 45 for the R structure.3,7,24   
 
 
 
Figure 45. H3.56 Donates a π-π T-stack Interaction to W3.51, Which in Turn Donates 
Another to Y3.52, in the R Model.3,7,24   
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The interaction of H3.56 donating a π-π T-stack to W3.51 in TMH3, which in turn 
donates another to Y3.52, is also shown in Figure 46 for the R* structure.3,7,24   
 
 
 
Figure 46. H3.56 Donates a π-π T-stack Interaction to W3.51, Which in Turn Donates 
Another to Y3.52, in the R* Model.3,7,24   
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  The R model has some interactions that are absent from the R* model, as shown 
here.  R3.50 donates salt bridge hydrogen bonds to D3.49124,125,126,127,128,129,130 and 
donates an arginine-arginine T-stack139 to R6.30,3,7,24 as shown in Figure 47.   
 
 
 
Figure 47. R3.50 Donates Salt Bridge Hydrogen Bonds to D3.49,124,125,126,127,128,129,130 and 
an Arginine-Arginine T-stack139 to R6.30,3,7,24 in the R Model.   
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A cluster of interactions occurs in the IC1 region, as N2.40 and Y2.41 interact with M77, 
R78, and T79, as shown in Figure 48 for the R structure.3,7,24   
 
 
 
Figure 48. N2.40 Uses its Amide Side Chain to Donate a Hydrogen Bond to M77’s 
Backbone Oxygen, and its Backbone Amide to Donate One to T79, While Y2.41 Accepts 
a Hydrogen Bond from R78, in the R Model.3,7,24  
95 
 
 
D2.65 in TMH2 is shown to accept two hydrogen bonds from Y7.32 and H7.39 in 
TMH7, as shown in Figure 49.3,7,24   
 
 
 
Figure 49. D2.65 Uses its Backbone Oxygen to Accept a Hydrogen Bond from Y7.32, 
and its Side Chain to Accept One from H7.39, in the R Model.3,7,24   
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Another interaction similar to one in the ox2r is the pair of hydrogen bonds that R6.31 
donates to L5.65’s backbone, as shown in Figure 50.3,7,24   
 
 
 
Figure 50. R6.31 Donates Two Hydrogen Bonds to L5.65’s Backbone in the R 
Model.3,7,24   
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Q4.60 has its role in keeping the EC2 loop, TMH4, and TMH5 together in the R 
structure, as it donates a hydrogen bond to E45.52 and accepts one from Y5.38, as shown 
in Figure 51.3,7,24   
 
 
 
Figure 51. Q4.60 Donates a Hydrogen Bond to E45.52 and Accepts One from Y5.38 in 
the R Model.3,7,24   
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As originally present in the ox2r crystal structure, H5.39 donates a hydrogen bond to 
E45.52, as shown in Figure 52.3,7,24   
 
 
 
Figure 52. H5.39 Donates a Hydrogen Bond to E45.52 in the R Model.3,7,24   
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Another such interaction is R4.43 donating a cation-π interaction to Y2.41, as shown in 
Figure 53.3,7,24   
 
 
 
Figure 53. R4.43 Donates a cation-π Interaction to Y2.41 in the R Model.3,7,24   
100 
 
 
Another such interaction is Y5.38 donating a π-π T-stack to H5.39, with W45.54 nearby, 
as part of the aromatic cluster between the EC2b loop and TMH5, as shown in Figure 54 
in the R structure.3,7,24   
 
 
 
Figure 54. Y5.38 Donates a π-π T-stack Interaction to H5.39 in the R Model.3,7,24   
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 The R* bundle has its own hydrogen bond interactions, as well.  Y6.48 donates a 
hydrogen bond to T5.46’s backbone oxygen, helping stabilize the R* 
state,124,125,126,127,128,129,130 as shown in Figure 55.3,7,24   
 
 
 
Figure 55. Y6.48 Donates a Hydrogen Bond to T5.46’s Backbone Oxygen in the R* 
Model.3,7,24,124,125,126,127,128,129,130   
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Another set of interactions in the R* bundle involve Y39 in the ox1r N-terminus donating 
a hydrogen bond to E110 in the EC1 loop, as shown in Figure 56.3,7,24   
 
 
 
Figure 56. Y39 Donates a Hydrogen Bond to E110 in the EC1 Loop in the R* Model.3,7,24 
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Another set of interactions in the R* bundle involve Y41 in the ox1r N-terminus donating 
a hydrogen bond to the backbone oxygen of D332 in the EC3 loop, as shown in Figure 
57.3,7,24   
 
 
 
Figure 57. Y41 Donates a Hydrogen Bond to the Backbone Oxygen of D332 in the EC3 
Loop in the R* Model.3,7,24   
104 
 
 
A cluster of interactions in the R* structure occurs in the IC1 region, as V1.57, W1.58, 
and N2.40 interact with M77 and R78, as shown in Figure 58.3,7,24   
 
 
 
Figure 58. N2.40 Uses its Amide Side Chain to Donate a Hydrogen Bond to M77’s 
Backbone Oxygen, While V1.57 and W1.58 Use Their Backbone Oxygens to Accept 
Two Hydrogen Bonds from R78, in the R* Model.3,7,24   
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D2.65 in the R* model’s TMH2 is shown to accept two hydrogen bonds from K1.29 and 
one more from Y1.39, as Y1.39 accepts a hydrogen bond from S2.61, as shown in Figure 
59.3,7,24   
 
 
 
Figure 59. D2.65 Uses Its Backbone Oxygen and Side Chain to Accept Two Hydrogen 
Bonds from K1.29, and Also Uses its Side Chain to Accept Another Hydrogen Bond 
from Y1.39, While Y1.39 Accepts a Hydrogen Bond from S2.61, in the R* Model.3,7,24   
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Q4.60 and Y5.38 have their roles in keeping the EC2 loop, TMH4, and TMH5 together in 
the R* structure as Q4.60 accepts a hydrogen bond from W45.54, while Y5.38 donates a 
hydrogen bond to I4.56’s backbone oxygen, as shown in Figure 60.3,7,24   
 
 
 
Figure 60. Q4.60 Accepts a Hydrogen Bond from W45.54, as Y5.38 Donates a Hydrogen 
Bond to I4.56’s Backbone Oxygen, in the R* Model.3,7,24   
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In the R* model, H5.39 accepts a hydrogen bond from N6.55, which in turn accepts one 
from R6.59, as shown in Figure 61.3,7,24   
 
 
 
Figure 61. H5.39 Accepts a Hydrogen Bond from N6.55, as N6.55 Accepts Another 
Hydrogen Bond from R6.59, in the R* Model.3,7,24   
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Yet another set of interactions in the R* bundle involves R6.30, which donates a 
hydrogen bond each to Q6.26’s backbone oxygen and side chain, while donating another 
to L5.65’s backbone oxygen, as shown in Figure 62.3,7,24   
 
 
 
Figure 62. R6.30 Donates a Hydrogen Bond Each to Q6.26’s Backbone Oxygen and Side 
Chain, While Donating Another to L5.65’s Backbone Oxygen, in the R* Model.3,7,24   
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Yet another set of interactions in the R* bundle also involves K7.59 donating a hydrogen 
bond each to H76 and to E7.62, while N1.60 donates another hydrogen bond to Q7.63, as 
shown in Figure 63.3,7,24   
 
 
 
Figure 63. K7.59 Donates a Hydrogen Bond Each to H76 and to E7.62, While N1.60 
Donates Another Hydrogen Bond to Q7.63, in the R* Model.3,7,24   
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Another hydrogen bond formed is K6.32 donating a hydrogen bond to F7.55’s backbone 
oxygen, while R7.61 donates another hydrogen bond to N7.54’s backbone oxygen, as 
shown in Figure 64.3,7,24   
 
 
 
Figure 64. K6.32 Donates a Hydrogen Bond to F7.55’s Backbone Oxygen, While R7.61 
Donates Another Hydrogen Bond to N7.54’s Backbone Oxygen, in the R* Model.3,7,24   
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Another new interaction formed in the R* structure is K6.32 donating a cation-π 
interaction to F7.55 in TMH7, as shown in Figure 65.3,7,24   
 
 
 
Figure 65. K6.32 Donates a Cation-π Interaction to F7.55 in the R* Model.3,7,24   
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Another such interaction in the R* structure is Y5.38 donating a π-π T-stack to H5.39, 
while the latter donates another to W45.54, as part of the aromatic cluster between the 
EC2b loop and TMH5, as shown in Figure 66.3,7,24   
 
 
 
Figure 66. Y5.38 Donates a π-π T-stack Interaction to H5.39, as H5.39 Donates Another 
to W45.54, in the R* Model.3,7,24   
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Another new interaction formed in the R* structure is R45.45 in the EC2 loop donating a 
cation-π interaction to F45.47, as shown in Figure 67.3,7,24   
 
 
 
Figure 67. R45.45 in the EC2 Loop Donates a Cation-π Interaction to F45.47 in the R* 
Model.3,7,24   
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Another new interaction formed in the R* structure is K6.25 in the IC3 loop donating a 
cation-π interaction to F6.20, as shown in Figure 68.3,7,24   
 
 
 
Figure 68. K6.25 in the IC3 Loop Donates a Cation-π Interaction to F6.20 in the R* 
Model.3,7,24   
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Interactions of the Orexin-1 Receptor R Structure with SB-674042 
  In the R bundle, SB-674042 chiefly interacts with the residue Q3.32 by using its 
N40 oxadiazole nitrogen to accept a hydrogen bond,3,7,24 as shown in Figures 69 and 70.   
 
 
Figure 69. Overall Dock of SB-674042 in the R Model.3,7,24   
 
 
Figure 70. Main Interaction of SB-674042 Accepting a Hydrogen Bond from Q3.32 in 
the R Model.3,7,24   
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Part 1 of SB-674042 (the A-ring) interacts with the ox1r by means of light van der Waals 
contacts with V3.36 and Y5.47 and a wide range of heavy van der Waals contacts with 
F5.42, F5.43, T5.46, I6.51, S6.52, and N6.55, as shown in Figure 71, and accepts a π-π T-
stack from F5.42, as shown in Figure 72.3,7,24   
 
 
Figure 71. Part 1 of SB-674042 Interacts with V3.36, F5.42, F5.43, T5.46, Y5.47, I6.51, 
S6.52, and N6.55 by van der Waals in the R Model.3,7,24   
 
 
Figure 72. Part 1 of SB-674042 Interacts with F5.42 by Accepting a π-π T-stack in the R 
Model.3,7,24   
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Part 2 of SB-674042 (including the B ring) interacts with the ox1r by means of multiple 
heavy van der Waals contacts with Q3.32, V3.36, F5.42, Y6.48, I6.51, and V7.42, as 
shown in Figure 73, and by accepting a π-π T-stack from F5.42 in Figure 74.3,7,24,124   
 
 
Figure 73. Part 2 of SB-674042 Interacts with Q3.32, V3.36, F5.42, Y6.48, I6.51, and 
V7.42 by van der Waals in the R Model.3,7,24,124   
 
 
Figure 74. Part 2 of SB-674042 Interacts with F5.42 by Accepting a π-π T-stack in the R 
Model.3,7,24   
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Part 3 of SB-674042 (the C-ring) interacts with the ox1r by means of many heavy van der 
Waals contacts with I6.51, N6.55, F7.35 and H7.39, as shown in Figure 75.3,7,24   
 
 
Figure 75. Part 3 of SB-674042 Interacts with I6.51, N6.55, F7.35, and H7.39 By van der 
Waals in the R Model.3,7,24   
 
Part 4 of SB-674042 (the methylene bridge) was not close enough to interact with the 
ox1r by means of van der Waals contacts, as it was a small part of SB-674042, as shown 
in Figure 76.3,7,24   
 
 
Figure 76. Part 4 of SB-674042 is Not Close Enough to Interact By van der Waals in the 
R Model.3,7,24   
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Part 5 of SB-674042 (the D-ring) interacts with the ox1r by means of light van der Waals 
contacts with H7.39 and heavy van der Waals contacts with Q3.32, as shown in Figure 
77, and donates a π-π T-stack to H7.39, as shown in Figure 78.3,7,24   
 
 
Figure 77. Part 5 of SB-674042 Interacts with Q3.32 and H7.39 By van der Waals in the 
R Model.3,7,24   
 
 
Figure 78. Part 5 of SB-674042 Interacts with H7.39 By Donating a π-π T-stack in the R 
Model.3,7,24   
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Part 6 of SB-674042 (the E ring) interacts with the ox1r by means of light van der Waals 
contacts with C2.57 and Y7.43, and numerous heavy van der Waals contacts with S2.61, 
W112 (EC1), I3.28, P3.29, and Q3.32, as shown in Figure 79.3,7,24   
 
 
Figure 79. Part 6 of SB-674042 Interacts with C2.57, S2.61, W112 (EC1), I3.28, P3.29, 
Q3.32, and Y7.43 By van der Waals in the R Model.3,7,24   
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 In the ox1r, a reason why D45.51A may not be an effective mutation is that 
D45.51 is a negatively charged residue, whereas SB-674042 has no hydrogen bond 
donors that can interact with the carboxylic acid side chain it has.3,7,24  Furthermore, the 
reason that Q3.32A had as much effect as it did was that mutation to an alanine costs the 
ox1r the hydrogen bond and much of the contacts Q3.32 would cause.3,7,24  The reason 
that A3.33T would have its effect is that it could cause TMH3 to bend and change the 
structure of the binding pocket.3,7,24,148,149  W45.54A has its effect of abolishing binding 
because W45.54 is situated between TMH4 and TMH5 and stabilizes them, interacting 
very heavily with its surrounding residues, and mutation to an alanine would cause a 
large gap between TMH4 and TMH5 that would cause the ox1r to partially collapse on 
that side.3,7,24  Y5.38A has its strong effect because Y5.38 helps hold TMH4 and TMH5 
together, especially by donating a hydrogen bond to Q4.60 as found by Heifetz et al. and 
Yin et al., and donating a π-π T-stack to H5.39 as found by Yin et al., and a mutation to 
alanine would abolish all of those, possibly causing another partial collapse.3,7,24  F5.42A 
was effective because it would cause a partial collapse of the ox1r there, while costing the 
ox1r the van der Waals contacts and flat π-π stack F5.42 would cause.3,7,24  Y6.48A, 
H7.39A, and Y7.43A were all effective mutations because each of those mutations would 
cost the ox1r much of the contacts that Y6.48, H7.39, and Y7.43 would cause 
respectively.3,7,24   
Interactions of the Orexin-1 Receptor R* Structure with Orexin-A 
  The R* structure admits orexin-A through a small opening in the extracellular 
side of the ox1r, similar to the structure of the ox2r.3,4,7,22,24  The structure of orexin-A is 
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an α-helix comprised of its residues R15 to A23, with an N-terminal structure consisting 
of a short α-helix of its residues C6 to Q9 with two disulfide bonds (C6-C12 and C7-
C14), keeping it close to that middle helix, while the C-terminal end of orexin-A, 
originally an α-helix from its N25 to its C-terminus, becomes a random coil that extends 
into the ox1r binding pocket to activate the ox1r.3,4,7,22,24  The R* bundle featured many 
interactions with the ox1r, from the middle helix of orexin-A, especially L16, L19, and 
L20, interacting with the ox1r EC2 loop’s β-sheets, to the C-terminus of orexin-A 
interacting with the ox1r transmembrane core, as shown in Figure 80.3,4,7,22,24   
 
 
 
Figure 80. Overall Dock of Orexin-A in the R* Model.3,4,7,22,24   
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A closer view of orexin-A’s interactions with the ox1r (showing the orexin-A N-terminus 
and hydrophilic region) is shown in Figures 81 and 82.3,4,7,22,24   
 
 
 
Figure 81. Dock of Orexin-A in the R* Model, as Seen from Orexin-A Residues 1-5 and 
the Ox1r N-terminus and Its EC2 Loop.3,4,7,22,24   
 
 
 
Figure 82. Dock of Orexin-A in the R* Model, as Seen from Orexin-A Residues 6-14 and 
the Ox1r N-terminus and EC1 and EC2 Loops.3,4,7,22,24 
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A closer view of orexin-A’s interactions with the ox1r (showing the orexin-A central 
helix and first half of the orexin-A C-terminus) is shown in Figures 83 and 84.3,4,7,22,24   
 
 
 
Figure 83. Dock of Orexin-A in the R* Model, as Seen from Orexin-A Residues 15-23 
and the Ox1r EC2 Loop.3,4,7,22,24 
 
 
 
Figure 84. Dock of Orexin-A in the R* Model, as Seen from Orexin-A Residues 24-28 
and the Ox1r Transmembrane Region Opening.3,4,7,22,24   
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A closer view of orexin-A’s interactions with the ox1r (showing the second half of the 
orexin-A C-terminus, which is where the most important interactions with the ox1r would 
be) is shown in Figure 85.3,4,7,22,24   
 
 
 
Figure 85. Dock of Orexin-A in the R* Model, as Seen from Orexin-A Residues 29-33 
and the Ox1r Transmembrane Region.3,4,7,22,24 
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The first of these interactions between orexin-A and the ox1r is a small sampling of 
interactions between the N-termini of both orexin-A and the ox1r, with orexin-A’s Y17 
interacting by a π-π flat stack with ox1r’s Y39 and donating a hydrogen bond to ox1r’s 
E110 in the EC1 loop, while orexin-A’s S13 donates a hydrogen bond to ox1r’s Y39 and 
orexin-A’s H21 donates another hydrogen bond to ox1r’s E110’s backbone oxygen, as 
shown in Figure 86.3,4,7,22,24   
 
 
 
Figure 86. Orexin-A’s Y17 Interacts by Means of a π-π Flat Stack with Ox1r’s Y39 and 
Donating a Hydrogen Bond to E110 in the Ox1r’s EC1 Loop, While Orexin-A’s S13 
Donates a Hydrogen Bond to Ox1r’s Y39 and Orexin-A’s H21 Donates Another 
Hydrogen Bond to Ox1r’s E110’s Backbone Oxygen.3,4,7,22,24   
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Another sampling is orexin-A’s D5 interacting with the ox1r N-terminus by accepting a 
hydrogen bond from R33, as shown in Figure 87.3,4,7,22,24   
 
 
 
Figure 87. Orexin-A’s D5 Interacts By Accepting a Hydrogen Bond from R33 of the 
Ox1r R* Model.3,4,7,22,24   
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Another sampling is orexin-A’s R15 interacting with the ox1r EC2 loop by donating a 
hydrogen bond to E45.39’s backbone oxygen, as shown in Figure 88.3,4,7,22,24   
 
 
 
Figure 88. Orexin-A’s R15 Interacts By Donating a Hydrogen Bond to E45.39’s 
Backbone Oxygen of the Ox1r R* Model.3,4,7,22,24   
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Orexin-A’s L16 interacts with the ox1r EC1 and EC2 loops by heavy van der Waals 
contacts with S111 in the EC1 loop, V45.36, P45.38, and F45.47, as shown in Figure 
89.3,4,7,22,24   
 
 
 
Figure 89. Orexin-A’s L16 Interacts By van der Waals Contacts with S111 (EC1), 
V45.36, P45.38, and F45.47 of the Ox1r R* Model.3,4,7,22,24   
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Next is orexin-A’s L19 interacting with the ox1r EC2 loop by light van der Waals 
contacts with P45.38, and by heavy van der Waals contacts with V45.36 and L45.37, as 
shown in Figure 90.3,4,7,22,24   
 
 
 
Figure 90. Orexin-A’s L19 Interacts By van der Waals Contacts with V45.36, L45.37, 
and P45.38 of the Ox1r R* Model.3,4,7,22,24   
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Afterward is orexin-A’s L20 interacting with the ox1r EC1 and EC2 loops by light van 
der Waals contacts with W112 in the EC1 loop, and by heavy van der Waals contacts 
with S111 in the EC1 loop, V45.36, and V45.49, as shown in Figure 91.3,4,7,22,24   
 
 
 
Figure 91. Orexin-A’s L20 Interacts By van der Waals Contacts with S111 (EC1), W112 
(EC1), V45.36, and V45.49 of the Ox1r R* Model.3,4,7,22,24   
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One major interaction is orexin-A’s H26, which interacts with the ox1r EC2 and EC3 
loops by donating a hydrogen bond to D45.51, as well as using its backbone to accept 
another from Q329 in the EC3 loop, as shown in Figure 92.3,4,7,22,24   
 
 
 
Figure 92. Orexin-A’s H26 Interacts By Donating a Hydrogen Bond to D45.51, and 
Using Its Backbone to Accept Another from Q329 (EC3), of the Ox1r R* Model.3,4,7,22,24   
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Orexin-A’s H26 also interacts with the ox1r EC2 and EC3 loops by light van der Waals 
contacts with V45.36, C45.50, and Q329 in the EC3 loop, and by heavy van der Waals 
contacts with V45.49 and D45.51, as shown in Figure 93.3,4,7,22,24   
 
 
 
Figure 93. Orexin-A’s H26 Interacts By van der Waals Contacts with V45.36, V45.49, 
C45.50, D45.51, and Q329 (EC3) of the Ox1r R* Model.3,4,7,22,24   
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Following H26 is orexin-A’s A27, which interacts with the ox1r EC2 loop by using its 
backbone amide to donate a hydrogen bond to D45.51, as shown in Figure 94.3,4,7,22,24   
 
 
 
Figure 94. Orexin-A’s A27 Interacts By Using Its Backbone Amide to Donate a 
Hydrogen Bond to D45.51 of the Ox1r R* Model.3,4,7,22,24   
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Following H26 is orexin-A’s A27, which interacts with the ox1r EC2 loop by light van 
der Waals contacts with C45.50, and by heavy van der Waals contacts with D45.51 and 
E45.52, as shown in Figure 95.3,4,7,22,24   
 
 
 
Figure 95. Orexin-A’s A27 Interacts By van der Waals Contacts with C45.50, D45.51, 
and E45.52 of the Ox1r R* Model.3,4,7,22,24   
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Subsequent is orexin-A’s A28 interacting with the ox1r EC1 and EC2 loops by light van 
der Waals contacts with W112 in the EC1 loop, V45.49, and C45.50, as shown in Figure 
96.3,4,7,22,24   
 
 
 
Figure 96. Orexin-A’s A28 Interacts By van der Waals Contacts with W112 (EC1), 
V45.49, and C45.50 of the Ox1r R* Model.3,4,7,22,24   
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Subsequent is orexin-A’s G29 interacting with the ox1r TMH7 by using its backbone to 
accept a hydrogen bond from Y7.32, as shown in Figure 97.3,4,7,22,24   
 
 
 
Figure 97. Orexin-A’s G29 Interacts By Using Its Backbone to Accept a Hydrogen Bond 
from Y7.32 of the Ox1r R* Model.3,4,7,22,24   
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Afterward is orexin-A’s G29 interacting with the ox1r TM region by light van der Waals 
contacts with V2.64 and D2.65, and by heavy van der Waals contacts with Y7.32, as 
shown in Figure 98.3,4,7,22,24   
 
 
 
Figure 98. Orexin-A’s G29 Interacts By van der Waals Contacts with V2.64, D2.65, and 
Y7.32 of the Ox1r R* Model.3,4,7,22,24   
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Next is orexin-A’s I30 interacting with the ox1r TM region and EC3 loop by light van der 
Waals contacts with D2.65, and by heavy van der Waals contacts with V2.64, A330 of 
the EC3 loop, Y7.32, and T7.36, as shown in Figure 99.3,4,7,22,24   
 
 
 
Figure 99. Orexin-A’s I30 Interacts By van der Waals Contacts with V2.64, D2.65, A330 
(EC3), Y7.32, and T7.36 of the Ox1r R* Model.3,4,7,22,24  
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Afterward is orexin-A’s L31 interacting with the ox1r EC1 loop and transmembrane 
region by light van der Waals contacts with C2.57, V2.64, W112 of the EC1 loop, P3.29, 
and Y7.43, and by heavy van der Waals contacts with S2.61, I3.28, and H7.39, as shown 
in Figure 100.3,4,7,22,24   
 
 
 
Figure 100. Orexin-A’s L31 Interacts By van der Waals Contacts with C2.57, S2.61, 
V2.64, W112 (EC1), I3.28, P3.29, H7.39, and Y7.43 of the Ox1r R* Model.3,4,7,22,24   
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Following L31 is orexin-A’s T32, which interacts with the ox1r transmembrane region by 
donating a hydrogen bond to E45.52, and using its backbone to accept another hydrogen 
bond from H7.39, as shown in Figure 101.3,4,7,9,22,24   
 
 
 
Figure 101. Orexin-A’s T32 Interacts By Donating a Hydrogen Bond to E45.52, While 
Using Its Backbone Oxygen to Accept Another from H7.39, of the Ox1r R* 
Model.3,4,7,9,22,24   
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Orexin-A’s T32 also interacts with the ox1r EC2 loop and TM region by light van der 
Waals contacts with E45.52 and H7.39, and by heavy van der Waals contacts with P3.29, 
M45.31, and R6.59, as shown in Figure 102.3,4,7,9,22,24   
 
 
 
Figure 102. Orexin-A’s T32 Interacts By van der Waals Contacts with P3.29, M45.31, 
E45.52, R6.59, and H7.39 of the Ox1r R* Model.3,4,7,9,22,24   
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Lastly is orexin-A’s L33 and its amide cap, which interact with the ox1r transmembrane 
region by using its backbone oxygen to accept a hydrogen bond from Q4.60, while the 
amide cap donates a hydrogen bond each to the backbone oxygen of P3.29 and to 
Q3.32’s side chain, as shown in Figure 103.3,4,7,22,24   
 
 
 
Figure 103. Orexin-A’s L33 Interacts By Using Its Backbone Oxygen to Accept a 
Hydrogen Bond from Q4.60, While Using Its Amide Cap to Donate a Hydrogen Bond 
Each to the Backbone of P3.29 and to Q3.32’s Side Chain of the Ox1r R* Model.3,4,7,22,24 
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Lastly is orexin-A’s L33 and its amide cap, which interact with the ox1r EC2 loop and 
transmembrane region by light van der Waals contacts with M45.31, and by heavy van 
der Waals contacts with P3.29, Q3.32, A3.33, Q4.60, F5.42, I6.51, N6.55, and R6.59, as 
shown in Figure 104.3,4,7,22,24,124   
 
 
 
Figure 104. Orexin-A’s L33 Interacts By van der Waals Contacts with P3.29, Q3.32, 
A3.33, Q4.60, M45.31, F5.42, I6.51, N6.55, and R6.59 of the Ox1r R* Model.3,4,7,22,24,124   
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  The orexin-A mutation R15A was not effective because R15 was pointing into the 
extracellular fluid, and its interactions would easily be replaced by those of water.3,4,7,22,24  
L16A was effective because it would cost orexin-A many of the contacts L16 would 
cause, and less water would be displaced between orexin-A and the EC2 loop.3,4,7,22,24  
Y17A was not effective because it would cause the N-terminus of orexin-A to close the 
gap the mutation would cause, as Y17 contacts both the central helix and N-terminus of 
orexin-A, yet though its side chain has heavy van der Waals contacts with Y39, E110, 
and S111, and a hydrogen bond to E110, those interactions can be replaced with those 
from the orexin-A N-terminus and water.3,4,7,22,24  E18A was not an effective mutation as 
it points into extracellular fluid, and its interactions would easily be replaced with those 
of water.3,4,7,22,24  L19A and L20A were both effective because each would cost orexin-A 
many of the contacts that L19 and L20 would cause, respectively, and less water would 
be displaced between orexin-A and the EC2 loop for each of those two mutations.3,4,7,22,24  
H21A was not an effective mutation, as it could cause Y17 to switch to trans to replace 
the contacts lost, and in turn cause the N-terminus to close the gap caused by that 
mutation just as it would for Y17A, again with no significant loss of contact.3,4,7,22,24  
G22A and G24A were not effective mutations because they would not sterically crowd 
any nearby residue significantly, and they contribute little to no contact with the 
ox1r.3,4,7,22,24  N25A was not an effective mutation because it points into extracellular 
fluid, and its interactions would easily be replaced with those of water.3,4,7,22,24  H26A 
was a very effective mutation as it costs orexin-A much of the contacts H26 would cause, 
as well as the one hydrogen bond its side chain would donate and the cation-π interaction 
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it would accept.3,4,7,22,24  A27G and A28G were effective mutations as they each cost 
orexin-A much of the contacts A27 and A28 would cause, respectively.3,4,7,22,24,155  G29A 
was effective because it would lose conformational flexibility.3,4,7,22,24,148,149  I30A and 
L31A were effective as they each cost orexin-A much of the contacts that I30 and L31 
would cause, respectively, with less water displaced from the ox1r binding pocket for 
each.3,4,7,22,24  T32A was effective because it would not only cost orexin-A much of the 
contacts T32 would cause, it would also lose the hydrogen bond T32 donates to E45.52 
and the internal one it accepts from L33’s backbone amide hydrogen.3,4,7,9,22,24  
Furthermore, chiral inversion of T32 would sterically crowd I30, likely cost T32 the 
hydrogen bond it would donate to E45.52, and likely force L33 to crowd the ox1r binding 
pocket to retain the hydrogen bond to L33, as shown in Figure 105.3,4,7,9,22,24   
 
 
 
Figure 105. Chiral Inversion of Orexin-A’s T32 and Its Effects.3,4,7,9,22,24   
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L33A was effective as it costs orexin-A much of the contacts that L33 would cause, and 
displace less water from the ox1r binding pocket as well.3,4,7,22,24  Furthermore, chiral 
inversion of L33 would cost orexin-A some contacts and a hydrogen bond between L33’s 
backbone oxygen and Q4.60, and another hydrogen bond between the C-terminal amide 
and P3.29’s backbone oxygen, while the hydrogen bond donated to Q3.32 is substituted 
for one accepted from Q3.32 along with steric strain, as shown in Figure 106.3,4,7,22,24   
 
 
 
Figure 106. Chiral Inversion of Orexin-A’s L33 and Its Effects.3,4,7,22,24   
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  In the ox1r, a reason why Q3.32A may not be an effective mutation is that Q3.32 
is a polar residue, which could have water molecules replace the contribution it has, since 
alanine would be small enough to admit them nearby.3,4,7,22,24  Furthermore, the reason 
that A3.33T had no significant effect was that it would reduce the surface area of the ox1r 
binding pocket’s hydrophobic patch, as threonine is partially hydrophobic.3,4,7,22,24  The 
reason that V3.36A would have its effect is that it would also reduce the hydrophobic 
patch’s surface area.3,4,7,22,24  D45.51A has its effect because it would cost ox1r a residue 
that stabilizes the EC2b loop, as an alanine would be hydrophobic and change the EC2 
loop’s shape, and also cost it the van der Waals contacts and hydrogen bonds D45.51 
would cause.3,4,7,22,24  W45.54A has its effect of abolishing binding because W45.54 is 
situated between TMH4 and TMH5 and stabilizes them, interacting very heavily with its 
surrounding residues, and mutation to an alanine would cause a large gap between TMH4 
and TMH5 that would cause the ox1r to partially collapse on that side, as well as costing 
the ox1r the contacts W45.54 would cause.3,4,7,22,24  Y5.38A has its strong effect because 
Y5.38 helps hold TMH4 and TMH5 together, especially by donating a hydrogen bond to 
TMH4, whether to Q4.60 as found by Heifetz et al. and Yin et al. or to I4.56’s backbone 
oxygen, and donating a π-π T-stack to H5.39 as found by Yin et al., and a mutation to 
alanine would abolish all of those, possibly causing another partial collapse.3,4,7,22,24  
F5.42A was effective because it would cause a partial collapse of the ox1r there, while 
costing the ox1r the van der Waals contacts F5.42 would cause.3,4,7,22,24  Y5.47A has its 
effect because it would cost the ox1r the contacts with Y6.48 that Y5.47 would 
cause.3,4,7,22,24  Y6.48A is an effective mutation because Y6.48’s χ1 conformational 
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change would be necessary for activation,124,125,126,127,128,129,130 and that mutation would 
also cost the ox1r the prospective contacts, and the hydrogen bond to T5.46, that Y6.48 
would cause.3,4,7,22,24  H7.39A was an effective mutation because it would cost the ox1r 
the contacts and the hydrogen bond that H7.39 would cause.3,4,7,22,24  However, Y7.43A 
was not an effective mutation because it was not close enough to orexin-A to contact it 
very well.3,4,7,22,24   
  This showed a greater understanding of how SB-674042 and orexin-A interact 
with the ox1r.3,4,7,22,24   
CHARMM Atom Types 
  New atom types were created for the optimization of the CHARMM parameters, 
with unique atom types made for each respective set of atoms depending on which part of 
the molecules they may occupy, and their subsequent use in MD simulation, and 
Lennard-Jones van der Waals nonbonded parameters were created for each, using the 
CGenFF database, as is shown in Tables 7, 8, and 9.4,137,158,159,160,161,162,163,164   
 
Table 7 
 
CHARMM Atom Types Required for SB-674042 and Pyroglutamate, Their Masses, and 
Their Corresponding Elements, with the “Present” Set of Atoms Already Present as 
CHARMM Atoms in the Atom Type List, and the “Added” Set of Atoms Added to the 
Atom Type List, as They Were Not Present.4,137,158,159,160,161,162,163,164 
 
CHARMM Atomic Mass Table 
Present Mass Numbers CHARMM Atom Types Element Atomic Mass 
1 H H 1.00800 
20 C C 12.01100 
22 CT1 C 12.01100 
29 CP1 C 12.01100 
31 CP3 C 12.01100 
150 
 
 
Table 7 
Cont. 
CHARMM Atomic Mass Table 
Present Mass Numbers CHARMM Atom Types Element Atomic Mass 
50 N N 14.00700 
54 NH1 N 14.00700 
70 O O 15.99900 
Added Mass Numbers CHARMM Atom Types Element Atomic Mass 
122 C61 C 12.01100 
123 H61 H 1.00800 
124 C51 C 12.01100 
125 C53 C 12.01100 
126 N50 N 14.00700 
127 O50 O 15.99900 
128 C11 C 12.01100 
129 C21 C 12.01100 
130 C31 C 12.01100 
131 HG1 H 1.00800 
132 HG2 H 1.00800 
133 HG3 H 1.00800 
134 HP1 H 1.00800 
135 N11 N 14.00700 
136 HG52 H 1.00800 
137 N50X N 14.00700 
138 O50X O 15.99900 
139 NG0 N 14.00700 
140 CO1 C 12.01100 
141 OD1 O 15.99940 
142 C215 C 12.01100 
143 S50 S 32.06000 
144 S50Y S 32.06000 
145 N50Y N 14.00700 
146 FR1 F 18.99800 
147 C66 C 12.01100 
148 H62 H 1.00800 
149 HAY H 1.00800 
150 HBY H 1.00800 
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Table 7 
Cont. 
CHARMM Atomic Mass Table 
Added Mass Numbers CHARMM Atom Types Element Atomic Mass 
151 CTY1 C 12.01100 
152 CTY2 C 12.01100 
153 CTY3 C 12.01100 
154 H5 H 1.00800 
155 CCY C 12.01100 
156 NG2 N 14.00700 
 
 
Table 8 
 
CHARMM Atom Types Required for SB-674042 and Pyroglutamate, and the 
Instructions for Use of Each, with the Words Sourced from the Original CGenFF 
Topology File Spelled Verbatim (e.g., “Flourine,” “Uera,” etc.).4,137,158,159,160,161,162,163,164 
 
CHARMM Atom Type Information 
CHARMM Atom Types Notes (spelling is as present in topology file) 
H polar H 
C carbonyl C, peptide backbone 
CT1 aliphatic sp3 C for CH 
CP1 tetrahedral C (proline CA) 
CP3 tetrahedral C (proline CD) 
N proline N 
NH1 peptide nitrogen 
O carbonyl oxygen 
C61 aromatic C 
H61 aromatic H 
C51 his CG and CD2 carbons 
C53 his CE1 carbon 
N50 neutral his unprotonated ring nitrogen 
O50 furan oxygen 
C11 aliphatic sp3 C for CH 
C21 aliphatic sp3 C for CH2 
C31 aliphatic sp3 C for CH3 
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Table 8 
Cont. 
CHARMM Atom Type Information 
CHARMM Atom Types Notes (spelling is as present in topology file) 
HG1 alkane, CH, new LJ params 
(see toppar_all22_prot_aliphatic_c27.str) 
HG2 alkane, CH2, new LJ params 
(see toppar_all22_prot_aliphatic_c27.str) 
HG3 alkane, CH3, new LJ params 
(see toppar_all22_prot_aliphatic_c27.str) 
HP1 polar H 
N11 primary amine nitrogen 
HG52 oxadiazole aromatic H and formamide H (RCOH) 
N50X neutral his unprotonated ring nitrogen 
for 1,3,4-oxadiazole 
O50X furan oxygen for 1,3,4-oxadiazole 
NG0 N,N-disubstituted amide, proline N (CO=NRR') 
CO1 carbonyl C: amides 
OD1 carbonyl O: amides, esters, 
[neutral] carboxylic acids, aldehydes, uera 
C215 aliphatic sp3 C for CH2 for cyclopentane 
S50 THIP, thiophene 
S50Y THIP, thiophene 
N50Y neutral his unprotonated ring nitrogen 
for 1,3-thiazole 
FR1 aromatic flourine 
C66 6-mem aromatic carbon bound to F 
H62 nonpolar H, neutral 6-mem planar ring C 
adjacent to heteroatom 
HAY nonpolar H for pyroglutamate ring 
HBY backbone H for pyroglutamate ring 
CTY1 aliphatic sp3 C for CH for pyroglutamate ring 
CTY2 aliphatic sp3 C for CH2 for pyroglutamate ring 
CTY3 aliphatic sp3 C for CH3 for pyroglutamate ring 
H5 polar H 
CCY carbonyl C, asn,asp,gln,glu,cter,ct2,pca 
NG2 amide nitrogen 
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Table 9 
 
CHARMM Atom Types Required for SB-674042 and Pyroglutamate, and Their Lennard-
Jones van der Waals Parameters.4,137,158,159,160,161,162,163,164 
 
CHARMM Lennard-Jones Nonbonded Parameters 
CHARMM Atom Types Epsilon Rmin/2 Epsilon, 1-4 Rmin/2, 1-4 
H -0.046000 0.224500 x x 
C -0.110000 2.000000 x x 
CT1 -0.020000 2.275000 -0.010000 1.900000 
CP1 -0.020000 2.275000 -0.010000 1.900000 
CP3 -0.055000 2.175000 -0.010000 1.900000 
N -0.200000 1.850000 -0.000100 1.850000 
NH1 -0.200000 1.850000 -0.200000 1.550000 
O -0.120000 1.700000 -0.120000 1.400000 
C61 -0.070000 1.992400 x x 
H61 -0.022000 1.320000 x x 
C51 -0.050000 1.800000 x x 
C53 -0.050000 1.800000 x x 
N50 -0.200000 1.850000 x x 
O50 -0.152100 1.770000 x x 
C11 -0.020000 2.275000 -0.010000 1.900000 
C21 -0.055000 2.175000 -0.010000 1.900000 
C31 -0.080000 2.060000 -0.010000 1.900000 
HG1 -0.022000 1.320000 x x 
HG2 -0.028000 1.340000 x x 
HG3 -0.024000 1.340000 x x 
HP1 -0.046000 0.224500 x x 
N11 -0.200000 1.850000 x x 
HG52 -0.046000 0.900000 x x 
N50X -0.200000 1.850000 x x 
O50X -0.152100 1.770000 x x 
NG0 -0.200000 1.850000 -0.000100 1.850000 
CO1 -0.110000 2.000000 x x 
OD1 -0.120000 1.700000 -0.120000 1.400000 
C215 -0.055000 2.175000 -0.010000 1.900000 
S50 -0.450000 2.000000 x x 
S50Y -0.450000 2.000000 x x 
N50Y -0.200000 1.850000 x x 
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Table 9 
Cont. 
CHARMM Lennard-Jones Nonbonded Parameters 
CHARMM Atom Types Epsilon Rmin/2 Epsilon, 1-4 Rmin/2, 1-4 
FR1 -0.120000 1.700000 x x 
C66 -0.070000 1.900000 x x 
H62 -0.046000 1.100000 x x 
HAY -0.022000 1.320000 x x 
HBY -0.022000 1.320000 x x 
CTY1 -0.020000 2.275000 -0.010000 1.900000 
CTY2 -0.055000 2.175000 -0.010000 1.900000 
CTY3 -0.080000 2.060000 -0.010000 1.900000 
H5 -0.046000 0.224500 x x 
CCY -0.070000 2.000000 x x 
NG2 -0.200000 1.850000 x x 
 
These atom types, masses, usage instructions, and Lennard-Jones van der Waals 
nonbonded parameters were acquired, leading to the next step:  obtaining charge 
parameters and building compound topologies.4,137,158,159,160,161,162,163,164,165,166,167 
CHARMM Charge Parameters and Compound Topologies 
  The structure, atom names, atom types, and charges for the model compound 
1,3,4-oxadiazole were determined, and shown in Table 10 and Figure 
107.137,158,159,160,161,162,163,164,165,166,167   
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Table 10 
 
Atom Names, Atom Types, and Charges of 1,3,4-
oxadiazole.137,158,159,160,161,162,163,164,165,166,167   
 
1,3,4-Oxadiazole Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
C1 C53 0.335 0.630 
N2 N50 -0.355 -0.490 
N3 N50 -0.355 -0.490 
C4 C53 0.335 0.630 
O5 O50 -0.320 -0.440 
H6 HG52 0.180 0.080 
H7 HG52 0.180 0.080 
 
 
 
Figure 107. Structure and Atom Names of 1,3,4-
oxadiazole.137,158,159,160,161,162,163,164,165,166,167   
 
It was included among the remaining charge model compounds for both SB-674042 and 
pyroglutamate-NMA, all of which had their charges taken directly from CGenFF, then 
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assembled as previously stated to determine the charges of the BAT model compounds 
and the charges of SB-674042 and pyroglutamate-NMA, the first of which is SB-674042 
BAT Model Compound 1 (made to connect rings D and E of SB-674042), whose 
structure, atom names, atom types, and charges are shown in Table 11 and Figure 
108.137,158,159,160,161,162,163,164,165,166,167   
 
Table 11 
 
Atom Names, Atom Types, and Charges of SB-674042 BAT Model Compound 
1.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 BAT Model Compound 1 Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
C1 C61 0.169 0.000 
C2 C61 -0.116 -0.115 
C3 C61 -0.115 -0.115 
C4 C61 -0.115 -0.115 
C5 C61 -0.115 -0.115 
C6 C61 -0.116 -0.115 
H7 H61 0.115 0.115 
H8 H61 0.115 0.115 
H9 H61 0.115 0.115 
H10 H61 0.115 0.115 
H11 H61 0.115 0.115 
C12 C53 0.453 0.710 
N13 N50X -0.458 -0.490 
N14 N50X -0.361 -0.490 
C15 C53 0.344 0.630 
O16 O50X -0.325 -0.440 
H17 HG52 0.180 0.080 
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The structure and atom names of SB-674042 BAT Model Compound 1 are shown in 
Figure 108.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 108. Structure and Atom Names of SB-674042 BAT Model Compound 
1.137,158,159,160,161,162,163,164,165,166,167   
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Next is SB-674042 BAT Model Compound 2, whose structure, atom names, atom types, 
and charges are shown in Figure 109 and Table 12.137,158,159,160,161,162,163,164,165,166,167   
 
 
Figure 109. Structure and Atom Names of SB-674042 BAT Model Compound 
2.137,158,159,160,161,162,163,164,165,166,167   
 
Table 12 
 
Atom Names, Atom Types, and Charges of SB-674042 BAT Model Compound 
2.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 BAT Model Compound 2 Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
C1 C53 0.344 0.630 
N2 N50X -0.361 -0.490 
N3 N50X -0.410 -0.490 
C4 C53 0.408 0.710 
O5 O50X -0.283 -0.440 
H6 HG52 0.180 0.080 
C7 C21 -0.060 -0.180 
H8 HG2 0.090 0.090 
H9 HG2 0.090 0.090 
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Table 12 
Cont. 
SB-674042 BAT Model Compound 2 Charges 
Atom Name Atom Type Old Charges New Charges 
C10 C11 0.014 0.084 
C11 C215 -0.183 -0.180 
C12 C215 -0.178 -0.180 
C13 C215 -0.006 -0.006 
N14 NG0 -0.291 -0.332 
H15 HG1 0.090 0.090 
H16 HG2 0.090 0.090 
H17 HG2 0.090 0.090 
H18 HG2 0.090 0.090 
H19 HG2 0.090 0.090 
H20 HG2 0.090 0.090 
H21 HG2 0.090 0.090 
C22 CO1 0.441 0.427 
O23 OD1 -0.501 -0.519 
H24 HG52 0.076 0.076 
 
Afterward is SB-674042 BAT Model Compound 3, whose structure, atom names, atom 
types, and charges are shown in Table 13 and Figure 110.137,158,159,160,161,162,163,164,165,166,167   
 
Table 13 
 
Atom Names, Atom Types, and Charges of SB-674042 BAT Model Compound 
3.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 BAT Model Compound 3 Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
C1 C53 0.303 0.360 
N2 N50Y -0.676 -0.610 
C3 C51 0.268 0.331 
C4 C51 -0.311 -0.301 
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Table 13 
Cont. 
SB-674042 BAT Model Compound 3 Charges 
Atom Name Atom Type Old Charges New Charges 
S5 S50Y 0.017 0.010 
H6 HG52 0.210 0.210 
C7 C31 -0.145 -0.270 
H8 HG3 0.090 0.090 
H9 HG3 0.090 0.090 
H10 HG3 0.090 0.090 
C11 CO1 0.522 0.503 
O12 OD1 -0.453 -0.519 
C13 C11 0.031 0.084 
C14 C215 -0.184 -0.180 
C15 C215 -0.180 -0.180 
C16 C215 0.018 -0.006 
H17 HG1 0.090 0.090 
H18 HG2 0.090 0.090 
H19 HG2 0.090 0.090 
H20 HG2 0.090 0.090 
H21 HG2 0.090 0.090 
H22 HG2 0.090 0.090 
H23 HG2 0.090 0.090 
N24 NG0 -0.328 -0.332 
C25 C31 -0.262 -0.270 
H26 HG3 0.090 0.090 
H27 HG3 0.090 0.090 
H28 HG3 0.090 0.090 
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Figure 110. Structure and Atom Names of SB-674042 BAT Model Compound 
3.137,158,159,160,161,162,163,164,165,166,167   
 
Following SB-674042 BAT Model Compound 3 is SB-674042 BAT Model Compound 
4, whose structure, atom names, atom types, and charges are shown in Figure 111 and 
Table 14.137,158,159,160,161,162,163,164,165,166,167   
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Figure 111. Structure and Atom Names of SB-674042 BAT Model Compound 
4.137,158,159,160,161,162,163,164,165,166,167   
 
Table 14 
 
Atom Names, Atom Types, and Charges of SB-674042 BAT Model Compound 
4.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 BAT Model Compound 4 Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
C1 C53 0.301 0.360 
N2 N50Y -0.669 -0.610 
C3 C51 0.150 0.201 
C4 C51 -0.239 -0.091 
S5 S50Y 0.011 0.010 
H6 HG52 0.173 0.130 
C7 C31 -0.145 -0.270 
H8 HG3 0.090 0.090 
H9 HG3 0.090 0.090 
H10 HG3 0.090 0.090 
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Table 14 
Cont. 
SB-674042 BAT Model Compound 4 Charges 
Atom Name Atom Type Old Charges New Charges 
C11 C61 -0.175 -0.175 
C12 C61 -0.050 -0.095 
C13 C66 0.029 0.118 
C14 C61 0.307 0.099 
C15 C61 -0.179 -0.175 
C16 C61 -0.104 -0.107 
H17 H61 0.115 0.115 
H18 H62 0.194 0.194 
F19 FR1 -0.219 -0.204 
H20 H61 0.115 0.115 
H21 H61 0.115 0.115 
 
Subsequent is SB-674042 BAT Model Compound 5, whose structure, atom names, atom 
types, and charges are shown in Table 15 and Figure 112.137,158,159,160,161,162,163,164,165,166,167   
 
Table 15 
 
Atom Names, Atom Types, and Charges of SB-674042 BAT Model Compound 
5.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 BAT Model Compound 5 Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
C1 C61 0.325 0.099 
C2 C66 0.029 0.118 
C3 C61 -0.050 -0.095 
C4 C61 -0.175 -0.175 
C5 C61 -0.104 -0.107 
C6 C61 -0.179 -0.175 
F7 FR1 -0.219 -0.204 
H8 H62 0.194 0.194 
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Table 15 
Cont. 
SB-674042 BAT Model Compound 5 Charges 
Atom Name Atom Type Old Charges New Charges 
H9 H61 0.115 0.115 
H10 H61 0.115 0.115 
H11 H61 0.115 0.115 
C12 C51 -0.260 -0.091 
C13 C51 0.293 0.331 
N14 N50Y -0.675 -0.610 
C15 C53 0.303 0.360 
S16 S50Y 0.017 0.010 
C17 C31 -0.145 -0.270 
H18 HG3 0.090 0.090 
H19 HG3 0.090 0.090 
H20 HG3 0.090 0.090 
C21 CO1 0.704 0.548 
O22 OD1 -0.482 -0.544 
H23 HP1 0.374 0.309 
N24 NG2 -0.939 -0.622 
H25 HP1 0.374 0.309 
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Figure 112. Structure and Atom Names of SB-674042 BAT Model Compound 
5.137,158,159,160,161,162,163,164,165,166,167   
 
Subsequent is the whole molecule of SB-674042, whose structure, atom names, atom 
types, and charges are shown in Figure 113 and Table 16.137,158,159,160,161,162,163,164,165,166,167   
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Figure 113.  Structure and Atom Names of the Whole Molecule of SB-
674042.137,158,159,160,161,162,163,164,165,166,167   
 
Table 16 
 
Atom Names, Atom Types, and Charges of the Whole Molecule of SB-
674042.137,158,159,160,161,162,163,164,165,166,167   
 
Whole Molecule of SB-674042 Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
C1 C61 -0.175 -0.175 
C2 C61 -0.104 -0.107 
C3 C61 -0.179 -0.175 
C4 C61 0.325 0.099 
C5 C66 0.029 0.118 
C6 C61 -0.050 -0.095 
F7 FR1 -0.219 -0.204 
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Table 16 
Cont. 
Whole Molecule of SB-674042 Charges 
Atom Name Atom Type Old Charges New Charges 
H8 H61 0.115 0.115 
H9 H61 0.115 0.115 
H10 H61 0.115 0.115 
H11 H62 0.194 0.194 
Group 
C12 CO1 0.522 0.503 
O13 OD1 -0.453 -0.519 
C14 C51 0.260 0.331 
N15 N50Y -0.675 -0.610 
C16 C53 0.303 0.360 
S17 S50Y 0.017 0.010 
C18 C51 -0.260 -0.091 
C19 C31 -0.145 -0.270 
H20 HG3 0.090 0.090 
H21 HG3 0.090 0.090 
H22 HG3 0.090 0.090 
C23 C11 0.038 0.084 
C24 C215 -0.183 -0.180 
C25 C215 -0.178 -0.180 
C26 C215 0.018 -0.006 
N27 NG0 -0.328 -0.332 
H28 HG1 0.090 0.090 
H29 HG2 0.090 0.090 
H30 HG2 0.090 0.090 
H31 HG2 0.090 0.090 
H32 HG2 0.090 0.090 
H33 HG2 0.090 0.090 
H34 HG2 0.090 0.090 
Group 
C35 C21 -0.060 -0.180 
H36 HG2 0.090 0.090 
H37 HG2 0.090 0.090 
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Table 16 
Cont. 
Whole Molecule of SB-674042 Charges 
Atom Name Atom Type Old Charges New Charges 
Group 
C38 C53 0.417 0.710 
N39 N50X -0.416 -0.490 
N40 N50X -0.464 -0.490 
C41 C53 0.462 0.710 
O42 O50X -0.288 -0.440 
Group 
C43 C61 -0.115 -0.115 
C44 C61 -0.115 -0.115 
C45 C61 -0.116 -0.115 
C46 C61 0.169 0.000 
C47 C61 -0.116 -0.115 
C48 C61 -0.115 -0.115 
H49 H61 0.115 0.115 
H50 H61 0.115 0.115 
H51 H61 0.115 0.115 
H52 H61 0.115 0.115 
H53 H61 0.115 0.115 
 
Subsequent is the pyroglutamate-NMA, whose structure, atom names, atom types, and 
charges are shown in Figure 114 and Table 17.4,158,159,160,161,162,163,164,165,166,167   
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Figure 114. Structure and Atom Names of Pyroglutamate-
NMA.4,158,159,160,161,162,163,164,165,166,167   
 
 
Table 17 
 
Atom Names, Atom Types, and Charges of Pyroglutamate-
NMA.4,158,159,160,161,162,163,164,165,166,167   
 
Pyroglutamate-NMA Charges 
Atom Name Atom Type Old Charges New Charges 
Group Group 
N NH1 -0.596 -0.580 
HN H 0.371 0.360 
CA CTY1 0.163 0.160 
HA HBY 0.090 0.090 
CB CTY2 -0.192 -0.190 
HB2 HAY 0.090 0.090 
HB1 HAY 0.090 0.090 
CG CTY2 -0.011 -0.010 
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Table 17 
Cont. 
Pyroglutamate-NMA Charges 
Atom Name Atom Type Old Charges New Charges 
HG3 HAY 0.090 0.090 
HG2 HAY 0.090 0.090 
CD CCY 0.299 0.300 
OE O -0.490 -0.490 
Group 
C C 0.508 0.510 
O O -0.500 -0.510 
Group 
N8 NH1 -0.472 -0.470 
H16 H5 0.310 0.310 
C9 CTY3 -0.110 -0.110 
H17 HG3 0.090 0.090 
H18 HG3 0.090 0.090 
H19 HG3 0.090 0.090 
 
These charge parameters allowed the bond length, bond angle, and dihedral torsion 
parameters to be determined.4,137,158,159,160,161,162,163,164,165,166,167   
CHARMM Bond Length, Bond Angle, Urey-Bradley, Dihedral, and Improper 
Dihedral Parameters 
  The bond length, bond angle, Urey-Bradley, dihedral torsion, and improper 
torsion parameters were initially taken from the CGenFF force field and were the starting 
point for the purposes of recursively optimizing the bond length and bond angle 
parameters, with measurement comparisons for the bond lengths as done for SB-674042 
before and after recursively optimizing bonds and angles together, then dihedrals, and 
listing the bond lengths outside the margin of error as highlighted olive, boxed, and 
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italicized, with the SB-674042 bond lengths before this optimization compiled in Table 
18.137,158,159,160,161,162,163,164,165,166,167   
 
Table 18 
 
SB-674042 Bond Lengths Prior to Optimization137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 Length Test Before CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
C1 -H8 1.0744 1.0808 0.0064 0.0000 #DIV/0! 
C1 -C2 1.3856 1.3999 0.0143 0.0002 #DIV/0! 
C2 -H9 1.0745 1.0815 0.0070 0.0000 #DIV/0! 
C2 -C3 1.3834 1.4001 0.0167 0.0003 #DIV/0! 
C3 -H10 1.0747 1.0798 0.0051 0.0000 #DIV/0! 
C3 -C4 1.3922 1.4042 0.0120 0.0001 #DIV/0! 
C1 -C6 1.3838 1.4019 0.0181 0.0003 #DIV/0! 
C6 -H11 1.0738 1.0790 0.0052 0.0000 #DIV/0! 
C6 -C5 1.3762 1.3922 0.0159 0.0003 #DIV/0! 
C5 -F7 1.3317 1.3608 0.0291 0.0008 #DIV/0! 
C5 -C4 1.3855 1.4018 0.0163 0.0003 #DIV/0! 
C4 -C18 1.4784 1.4847 0.0063 0.0000 #DIV/0! 
C18-S17 1.7409 1.7136 -0.0273 0.0007 #DIV/0! 
C16-S17 1.7371 1.6978 -0.0394 0.0015 100106.95187 
C18-C14 1.3470 1.3829 0.0359 0.0013 100168.91892 
N15-C14 1.3783 1.4231 0.0448 0.0020 100067.61325 
N15-C16 1.2757 1.3171 0.0414 0.0017 100088.02817 
C16-C19 1.4993 1.4942 -0.0051 0.0000 #DIV/0! 
C19-H20 1.0809 1.1114 0.0305 0.0009 102222.22222 
C19-H21 1.0843 1.1095 0.0252 0.0006 #DIV/0! 
C19-H22 1.0838 1.1095 0.0257 0.0007 #DIV/0! 
C14-C12 1.5029 1.5106 0.0077 0.0001 #DIV/0! 
C12-O13 1.2045 1.2341 0.0296 0.0009 #DIV/0! 
C12-N27 1.3477 1.3665 0.0188 0.0004 #DIV/0! 
C23-N27 1.4655 1.4402 -0.0253 0.0006 #DIV/0! 
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Table 18 
Cont. 
SB-674042 Length Test Before CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
C26-N27 1.4646 1.4628 -0.0018 0.0000 #DIV/0! 
C26-H33 1.0797 1.1019 0.0222 0.0005 #DIV/0! 
C26-H34 1.0837 1.1033 0.0196 0.0004 #DIV/0! 
C26-C25 1.5275 1.5230 -0.0045 0.0000 #DIV/0! 
C25-C24 1.5289 1.5363 0.0074 0.0001 #DIV/0! 
C25-H31 1.0834 1.0981 0.0147 0.0002 #DIV/0! 
C25-H32 1.0859 1.1023 0.0164 0.0003 #DIV/0! 
C24-H29 1.0828 1.0975 0.0147 0.0002 #DIV/0! 
C24-H30 1.0835 1.1023 0.0188 0.0004 #DIV/0! 
C24-C23 1.5357 1.5329 -0.0028 0.0000 #DIV/0! 
C23-H28 1.0838 1.1067 0.0229 0.0005 #DIV/0! 
C23-C35 1.5397 1.5360 -0.0037 0.0000 #DIV/0! 
C35-H36 1.0806 1.1099 0.0293 0.0009 #DIV/0! 
C35-H37 1.0837 1.1086 0.0249 0.0006 #DIV/0! 
C35-C38 1.4913 1.4968 0.0054 0.0000 #DIV/0! 
C38-O42 1.3421 1.3581 0.0160 0.0003 #DIV/0! 
C38-N39 1.2679 1.3206 0.0527 0.0028 100044.05286 
N39-N40 1.3794 1.3036 -0.0758 0.0057 100021.82453 
N40-C41 1.2704 1.3366 0.0661 0.0044 100027.66252 
C41-O42 1.3391 1.3669 0.0278 0.0008 #DIV/0! 
C41-C46 1.4665 1.5040 0.0375 0.0014 100133.15579 
C46-C45 1.3889 1.4124 0.0235 0.0006 #DIV/0! 
C46-C47 1.3918 1.4127 0.0209 0.0004 #DIV/0! 
C45-H51 1.0732 1.0813 0.0081 0.0001 #DIV/0! 
C47-H52 1.0735 1.0816 0.0081 0.0001 #DIV/0! 
C45-C44 1.3857 1.3993 0.0136 0.0002 #DIV/0! 
C47-C48 1.3825 1.3993 0.0168 0.0003 #DIV/0! 
C44-H50 1.0756 1.0807 0.0051 0.0000 #DIV/0! 
C48-H53 1.0746 1.0808 0.0062 0.0000 #DIV/0! 
C43-C44 1.3848 1.3993 0.0145 0.0002 #DIV/0! 
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Table 18 
Cont. 
SB-674042 Length Test Before CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
C43-C48 1.3873 1.3993 0.0120 0.0001 #DIV/0! 
C43-H49 1.0756 1.0807 0.0051 0.0000 #DIV/0! 
Largest absolute error 0.0758 0.0057 100021.82453 
RMS error 0.0249 #DIV/0! 
 
The SB-674042 bond lengths after this optimization, with MM bond lengths that more 
closely mirror the QM bond lengths, were compiled in Table 
19.137,158,159,160,161,162,163,164,165,166,167   
 
Table 19 
 
SB-674042 Bond Lengths After Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 Length Test After CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
C1 -H8 1.0744 1.0809 0.0065 0.0000 #DIV/0! 
C1 -C2 1.3856 1.3983 0.0127 0.0002 #DIV/0! 
C2 -H9 1.0745 1.0816 0.0071 0.0001 #DIV/0! 
C2 -C3 1.3834 1.3991 0.0156 0.0002 #DIV/0! 
C3 -H10 1.0747 1.0801 0.0054 0.0000 #DIV/0! 
C3 -C4 1.3922 1.4070 0.0148 0.0002 #DIV/0! 
C1 -C6 1.3838 1.4005 0.0167 0.0003 #DIV/0! 
C6 -H11 1.0738 1.0791 0.0053 0.0000 #DIV/0! 
C6 -C5 1.3762 1.3915 0.0153 0.0002 #DIV/0! 
C5 -F7 1.3317 1.3336 0.0019 0.0000 #DIV/0! 
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Table 19 
Cont. 
SB-674042 Length Test After CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
C5 -C4 1.3855 1.4062 0.0207 0.0004 #DIV/0! 
C4 -C18 1.4784 1.4753 -0.0031 0.0000 #DIV/0! 
C18-S17 1.7409 1.7228 -0.0181 0.0003 #DIV/0! 
C16-S17 1.7371 1.7310 -0.0061 0.0000 #DIV/0! 
C18-C14 1.3470 1.3571 0.0101 0.0001 #DIV/0! 
N15-C14 1.3783 1.3888 0.0105 0.0001 #DIV/0! 
N15-C16 1.2757 1.2732 -0.0025 0.0000 #DIV/0! 
C16-C19 1.4993 1.4971 -0.0022 0.0000 #DIV/0! 
C19-H20 1.0809 1.0827 0.0018 0.0000 #DIV/0! 
C19-H21 1.0843 1.0807 -0.0036 0.0000 #DIV/0! 
C19-H22 1.0838 1.0807 -0.0031 0.0000 #DIV/0! 
C14-C12 1.5029 1.4920 -0.0109 0.0001 #DIV/0! 
C12-O13 1.2045 1.2115 0.0070 0.0000 #DIV/0! 
C12-N27 1.3477 1.3677 0.0200 0.0004 #DIV/0! 
C23-N27 1.4655 1.4729 0.0074 0.0001 #DIV/0! 
C26-N27 1.4646 1.4644 -0.0002 0.0000 #DIV/0! 
C26-H33 1.0797 1.1019 0.0222 0.0005 #DIV/0! 
C26-H34 1.0837 1.1022 0.0185 0.0003 #DIV/0! 
C26-C25 1.5275 1.5300 0.0025 0.0000 #DIV/0! 
C25-C24 1.5289 1.5374 0.0085 0.0001 #DIV/0! 
C25-H31 1.0834 1.0978 0.0144 0.0002 #DIV/0! 
C25-H32 1.0859 1.1021 0.0162 0.0003 #DIV/0! 
C24-H29 1.0828 1.0977 0.0149 0.0002 #DIV/0! 
C24-H30 1.0835 1.1023 0.0188 0.0004 #DIV/0! 
C24-C23 1.5357 1.5252 -0.0105 0.0001 #DIV/0! 
C23-H28 1.0838 1.1068 0.0230 0.0005 #DIV/0! 
C23-C35 1.5397 1.5370 -0.0027 0.0000 #DIV/0! 
C35-H36 1.0806 1.1094 0.0288 0.0008 #DIV/0! 
C35-H37 1.0837 1.1094 0.0257 0.0007 #DIV/0! 
C35-C38 1.4913 1.4916 0.0003 0.0000 #DIV/0! 
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Table 19 
Cont. 
SB-674042 Length Test After CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
C38-O42 1.3421 1.3274 -0.0147 0.0002 #DIV/0! 
C38-N39 1.2679 1.2640 -0.0039 0.0000 #DIV/0! 
N39-N40 1.3794 1.3857 0.0063 0.0000 #DIV/0! 
N40-C41 1.2704 1.2704 0.0000 0.0000 #DIV/0! 
C41-O42 1.3391 1.3333 -0.0058 0.0000 #DIV/0! 
C41-C46 1.4665 1.4631 -0.0034 0.0000 #DIV/0! 
C46-C45 1.3889 1.4127 0.0237 0.0006 #DIV/0! 
C46-C47 1.3918 1.4108 0.0190 0.0004 #DIV/0! 
C45-H51 1.0732 1.0808 0.0076 0.0001 #DIV/0! 
C47-H52 1.0735 1.0811 0.0076 0.0001 #DIV/0! 
C45-C44 1.3857 1.4003 0.0146 0.0002 #DIV/0! 
C47-C48 1.3825 1.4005 0.0180 0.0003 #DIV/0! 
C44-H50 1.0756 1.0806 0.0050 0.0000 #DIV/0! 
C48-H53 1.0746 1.0808 0.0062 0.0000 #DIV/0! 
C43-C44 1.3848 1.4011 0.0162 0.0003 #DIV/0! 
C43-C48 1.3873 1.4013 0.0140 0.0002 #DIV/0! 
C43-H49 1.0756 1.0806 0.0050 0.0000 #DIV/0! 
Largest absolute error 0.0288 0.0008 #DIV/0! 
RMS error 0.0129 #DIV/0! 
 
The same was done for pyroglutamate-NMA’s bond lengths before and after recursively 
optimizing bonds and angles, then dihedrals, and listing the bond lengths outside the 
margin of error as highlighted olive, boxed, and italicized, with the pyroglutamate-NMA 
bond lengths before this optimization shown in Table 20.4,158,159,160,161,162,163,164,165,166,167   
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Table 20 
 
Pyroglutamate-NMA Bond Lengths Prior to Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Pyroglutamate-NMA Length Test Before CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
OE -CD 1.1933 1.2251 0.0318 0.0010 100549.45055 
CD -N  1.3636 1.3754 0.0118 0.0001 #DIV/0! 
N  -HN  0.9963 0.9957 -0.0006 0.0000 #DIV/0! 
N  -CA 1.4463 1.4692 0.0229 0.0005 #DIV/0! 
CD -CG 1.5185 1.5253 0.0068 0.0000 #DIV/0! 
CG -HG2 1.0811 1.0979 0.0168 0.0003 #DIV/0! 
CG -HG3 1.0862 1.0985 0.0123 0.0002 #DIV/0! 
CG -CB 1.5328 1.5252 -0.0076 0.0001 #DIV/0! 
CB -HB1 1.0799 1.1001 0.0201 0.0004 #DIV/0! 
CB -HB2 1.0835 1.1031 0.0196 0.0004 #DIV/0! 
CB -CA 1.5493 1.5276 -0.0217 0.0005 #DIV/0! 
CA -HA  1.0821 1.1015 0.0194 0.0004 #DIV/0! 
CA -C  1.5294 1.5208 -0.0086 0.0001 #DIV/0! 
C  -O  1.2030 1.2279 0.0249 0.0006 #DIV/0! 
C  -N8 1.3415 1.3478 0.0063 0.0000 #DIV/0! 
N8 -H16 0.9924 0.9966 0.0042 0.0000 #DIV/0! 
N8 -C9 1.4475 1.4442 -0.0033 0.0000 #DIV/0! 
C9 -H17 1.0815 1.1124 0.0309 0.0010 101111.11111 
C9 -H18 1.0816 1.1141 0.0325 0.0011 100404.85830 
C9 -H19 1.0833 1.1141 0.0308 0.0009 101282.05128 
Largest absolute error 0.0325 0.0011 100404.85830 
RMS error 0.0195 #DIV/0! 
 
The pyroglutamate-NMA bond lengths after this optimization, with MM bond lengths 
more closely approximating the QM bond lengths, were compiled in Table 
21.4,158,159,160,161,162,163,164,165,166,167   
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Table 21 
 
Pyroglutamate-NMA Bond Lengths After Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Pyroglutamate-NMA Length Test After CHARMM Optimization 
Bond 
QM MM 
Difference Square Check 
Length Length 
(atoms) (angstroms) (angstroms) (angstroms) (sq. Å) (angstroms–1) 
OE -CD 1.1933 1.1908 -0.0025 0.0000 #DIV/0! 
CD -N  1.3636 1.3764 0.0128 0.0002 #DIV/0! 
N  -HN  0.9963 0.9960 -0.0003 0.0000 #DIV/0! 
N  -CA 1.4463 1.4678 0.0215 0.0005 #DIV/0! 
CD -CG 1.5185 1.5282 0.0096 0.0001 #DIV/0! 
CG -HG2 1.0811 1.0978 0.0167 0.0003 #DIV/0! 
CG -HG3 1.0862 1.0984 0.0121 0.0001 #DIV/0! 
CG -CB 1.5328 1.5276 -0.0052 0.0000 #DIV/0! 
CB -HB1 1.0799 1.0999 0.0200 0.0004 #DIV/0! 
CB -HB2 1.0835 1.1031 0.0196 0.0004 #DIV/0! 
CB -CA 1.5493 1.5238 -0.0255 0.0006 #DIV/0! 
CA -HA  1.0821 1.1002 0.0181 0.0003 #DIV/0! 
CA -C  1.5294 1.5228 -0.0066 0.0000 #DIV/0! 
C  -O  1.2030 1.2280 0.0250 0.0006 #DIV/0! 
C  -N8 1.3415 1.3479 0.0064 0.0000 #DIV/0! 
N8 -H16 0.9924 0.9976 0.0052 0.0000 #DIV/0! 
N8 -C9 1.4475 1.4447 -0.0028 0.0000 #DIV/0! 
C9 -H17 1.0815 1.0821 0.0006 0.0000 #DIV/0! 
C9 -H18 1.0816 1.0833 0.0017 0.0000 #DIV/0! 
C9 -H19 1.0833 1.0833 0.0000 0.0000 #DIV/0! 
Largest absolute error 0.0255 0.0006 #DIV/0! 
RMS error 0.0136 #DIV/0! 
 
Similar measurement comparisons for the bond angles before and after recursively 
optimizing bonds and angles, then dihedrals, were done for SB-674042, and listing the 
bond angles outside the margin of error as highlighted olive, boxed, and italicized, with 
its bond angles before this optimization listed in Table 22.137,158,159,160,161,162,163,164,165,166,167   
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Table 22 
 
SB-674042 Bond Angles Before Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 Angle Test Before CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C2 -C1 -H8 120.31 119.95 -0.36 0.13 #DIV/0! 
C6 -C1 -H8 119.69 120.19 0.50 0.25 #DIV/0! 
C2 -C1 -C6 120.00 119.86 -0.14 0.02 #DIV/0! 
C1 -C2 -H9 120.31 119.76 -0.56 0.31 #DIV/0! 
C1 -C6 -H11 121.99 120.65 -1.34 1.79 #DIV/0! 
C1 -C2 -C3 119.85 120.48 0.63 0.40 #DIV/0! 
C1 -C6 -C5 118.97 119.13 0.16 0.03 #DIV/0! 
H9 -C2 -C3 119.83 119.76 -0.07 0.00 #DIV/0! 
H11-C6 -C5 119.04 120.22 1.17 1.38 #DIV/0! 
C2 -C3 -C4 121.30 120.12 -1.18 1.39 #DIV/0! 
C6 -C5 -C4 122.76 121.87 -0.89 0.79 #DIV/0! 
C2 -C3 -H10 119.71 120.06 0.35 0.12 #DIV/0! 
C6 -C5 -F7 118.08 117.91 -0.18 0.03 #DIV/0! 
H10-C3 -C4 118.98 119.82 0.84 0.70 #DIV/0! 
F7 -C5 -C4 119.16 120.22 1.06 1.13 #DIV/0! 
C3 -C4 -C18 121.36 120.42 -0.95 0.89 #DIV/0! 
C5 -C4 -C18 121.50 121.05 -0.46 0.21 #DIV/0! 
C3 -C4 -C5 117.12 118.54 1.41 1.99 #DIV/0! 
C4 -C18-C14 130.62 129.78 -0.83 0.69 #DIV/0! 
C4 -C18-S17 121.03 120.04 -0.99 0.98 #DIV/0! 
C14-C18-S17 108.34 109.92 1.58 2.48 #DIV/0! 
C18-S17-C16 89.59 90.34 0.75 0.56 #DIV/0! 
S17-C16-N15 113.87 116.44 2.57 6.58 #DIV/0! 
S17-C16-C19 122.23 123.18 0.95 0.91 #DIV/0! 
N15-C16-C19 123.90 120.24 -3.66 13.42 100001.50830 
C16-N15-C14 111.99 109.00 -2.99 8.94 #DIV/0! 
C16-C19-H20 108.63 109.90 1.26 1.60 #DIV/0! 
C16-C19-H21 110.90 109.54 -1.36 1.86 #DIV/0! 
C16-C19-H22 111.19 110.41 -0.78 0.61 #DIV/0! 
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Table 22 
Cont. 
SB-674042 Angle Test Before CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
H20-C19-H21 109.04 108.82 -0.22 0.05 #DIV/0! 
H20-C19-H22 109.07 108.74 -0.33 0.11 #DIV/0! 
H21-C19-H22 107.96 109.41 1.45 2.09 #DIV/0! 
N15-C14-C18 116.19 114.21 -1.98 3.91 #DIV/0! 
C12-C14-C18 124.80 126.24 1.44 2.07 #DIV/0! 
N15-C14-C12 118.90 119.40 0.50 0.25 #DIV/0! 
C14-C12-O13 120.09 119.16 -0.93 0.86 #DIV/0! 
N27-C12-O13 122.65 121.18 -1.47 2.17 #DIV/0! 
C14-C12-N27 117.24 119.66 2.41 5.83 #DIV/0! 
C12-N27-C23 119.33 121.99 2.66 7.07 #DIV/0! 
C12-N27-C26 125.79 125.06 -0.73 0.54 #DIV/0! 
C23-N27-C26 112.28 112.50 0.22 0.05 #DIV/0! 
N27-C26-C25 102.82 103.23 0.41 0.17 #DIV/0! 
N27-C26-H33 110.98 112.27 1.29 1.67 #DIV/0! 
N27-C26-H34 110.60 108.11 -2.49 6.19 #DIV/0! 
C25-C26-H33 112.68 113.14 0.46 0.21 #DIV/0! 
C25-C26-H34 111.53 111.84 0.32 0.10 #DIV/0! 
H33-C26-H34 108.20 108.14 -0.06 0.00 #DIV/0! 
C26-C25-C24 102.89 102.71 -0.18 0.03 #DIV/0! 
C26-C25-H31 112.49 113.40 0.91 0.83 #DIV/0! 
C26-C25-H32 109.63 109.95 0.32 0.10 #DIV/0! 
C24-C25-H31 113.15 113.34 0.20 0.04 #DIV/0! 
C24-C25-H32 110.48 110.18 -0.30 0.09 #DIV/0! 
H31-C25-H32 108.14 107.24 -0.90 0.81 #DIV/0! 
C25-C24-C23 104.01 104.79 0.78 0.60 #DIV/0! 
C25-C24-H29 113.30 113.10 -0.19 0.04 #DIV/0! 
C25-C24-H30 110.10 109.37 -0.73 0.54 #DIV/0! 
C23-C24-H29 111.39 112.95 1.56 2.44 #DIV/0! 
C23-C24-H30 110.39 110.16 -0.23 0.05 #DIV/0! 
H29-C24-H30 107.66 106.49 -1.18 1.38 #DIV/0! 
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Table 22 
Cont. 
SB-674042 Angle Test Before CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
N27-C23-C24 103.72 104.55 0.83 0.68 #DIV/0! 
N27-C23-C35 113.26 111.82 -1.44 2.08 #DIV/0! 
N27-C23-H28 108.58 110.38 1.80 3.25 #DIV/0! 
C24-C23-C35 114.20 112.97 -1.23 1.52 #DIV/0! 
C24-C23-H28 110.41 108.12 -2.29 5.27 #DIV/0! 
C35-C23-H28 106.60 108.89 2.29 5.25 #DIV/0! 
C23-C35-C38 114.23 112.56 -1.67 2.78 #DIV/0! 
C23-C35-H36 109.09 108.79 -0.30 0.09 #DIV/0! 
C23-C35-H37 108.53 110.27 1.75 3.05 #DIV/0! 
C38-C35-H36 108.76 107.40 -1.36 1.85 #DIV/0! 
C38-C35-H37 107.60 109.48 1.88 3.54 #DIV/0! 
H36-C35-H37 108.49 108.20 -0.29 0.08 #DIV/0! 
C35-C38-O42 119.36 124.57 5.21 27.17 100000.45196 
C35-C38-N39 129.00 122.13 -6.87 47.18 100000.25850 
O42-C38-N39 111.65 113.13 1.48 2.19 #DIV/0! 
C38-O42-C41 103.39 100.83 -2.56 6.57 #DIV/0! 
C38-N39-N40 106.72 106.77 0.05 0.00 #DIV/0! 
N39-N40-C41 106.45 108.11 1.66 2.76 #DIV/0! 
N40-C41-O42 111.79 111.15 -0.64 0.41 #DIV/0! 
N40-C41-C46 128.58 125.09 -3.49 12.21 100002.02347 
O42-C41-C46 119.62 123.75 4.13 17.07 100000.88355 
C41-C46-C45 120.72 120.18 -0.54 0.29 #DIV/0! 
C41-C46-C47 119.27 121.57 2.29 5.26 #DIV/0! 
C45-C46-C47 120.01 118.25 -1.76 3.10 #DIV/0! 
C46-C45-H51 119.95 119.78 -0.17 0.03 #DIV/0! 
C46-C45-C44 119.78 120.88 1.10 1.20 #DIV/0! 
H51-C45-C44 120.27 119.34 -0.93 0.86 #DIV/0! 
C46-C47-H52 119.39 119.65 0.26 0.07 #DIV/0! 
C46-C47-C48 119.90 120.85 0.94 0.89 #DIV/0! 
H52-C47-C48 120.71 119.51 -1.20 1.45 #DIV/0! 
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Table 22 
Cont. 
SB-674042 Angle Test Before CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C45-C44-C43 120.19 119.99 -0.20 0.04 #DIV/0! 
C45-C44-H50 119.66 120.00 0.34 0.12 #DIV/0! 
H50-C44-C43 120.15 120.02 -0.13 0.02 #DIV/0! 
C47-C48-C43 120.10 120.01 -0.09 0.01 #DIV/0! 
C47-C48-H53 119.79 119.95 0.16 0.02 #DIV/0! 
H53-C48-C43 120.11 120.05 -0.07 0.00 #DIV/0! 
C44-C43-C48 120.02 120.03 0.01 0.00 #DIV/0! 
C44-C43-H49 119.99 120.01 0.03 0.00 #DIV/0! 
C48-C43-H49 119.99 119.96 -0.04 0.00 #DIV/0! 
Largest absolute error 6.87 47.18 100000.25850 
RMS error 1.59 #DIV/0! 
 
The SB-674042 bond angles after this optimization, with MM bond angles that more 
closely match the QM bond angles, were compiled as follows in Table 
23.137,158,159,160,161,162,163,164,165,166,167   
 
Table 23 
 
SB-674042 Bond Angles After Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C2 -C1 -H8 120.31 120.00 -0.31 0.10 #DIV/0! 
C6 -C1 -H8 119.69 120.25 0.56 0.31 #DIV/0! 
C2 -C1 -C6 120.00 119.75 -0.25 0.06 #DIV/0! 
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Table 23 
 
Cont.  
 
SB-674042 Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C1 -C2 -H9 120.31 119.79 -0.52 0.27 #DIV/0! 
C1 -C6 -H11 121.99 120.61 -1.38 1.92 #DIV/0! 
C1 -C2 -C3 119.85 120.42 0.57 0.32 #DIV/0! 
C1 -C6 -C5 118.97 119.18 0.21 0.04 #DIV/0! 
H9 -C2 -C3 119.83 119.79 -0.04 0.00 #DIV/0! 
H11-C6 -C5 119.04 120.22 1.17 1.38 #DIV/0! 
C2 -C3 -C4 121.30 120.78 -0.52 0.27 #DIV/0! 
C6 -C5 -C4 122.76 122.36 -0.40 0.16 #DIV/0! 
C2 -C3 -H10 119.71 119.71 0.00 0.00 #DIV/0! 
C6 -C5 -F7 118.08 117.25 -0.84 0.70 #DIV/0! 
H10-C3 -C4 118.98 119.51 0.53 0.28 #DIV/0! 
F7 -C5 -C4 119.16 120.34 1.19 1.41 #DIV/0! 
C3 -C4 -C18 121.36 120.45 -0.92 0.84 #DIV/0! 
C5 -C4 -C18 121.50 121.91 0.41 0.17 #DIV/0! 
C3 -C4 -C5 117.12 117.50 0.37 0.14 #DIV/0! 
C4 -C18-C14 130.62 130.88 0.27 0.07 #DIV/0! 
C4 -C18-S17 121.03 121.41 0.38 0.14 #DIV/0! 
C14-C18-S17 108.34 107.49 -0.86 0.74 #DIV/0! 
C18-S17-C16 89.59 90.89 1.29 1.67 #DIV/0! 
S17-C16-N15 113.87 113.63 -0.24 0.06 #DIV/0! 
S17-C16-C19 122.23 122.30 0.08 0.01 #DIV/0! 
N15-C16-C19 123.90 124.07 0.17 0.03 #DIV/0! 
C16-N15-C14 111.99 111.48 -0.51 0.26 #DIV/0! 
C16-C19-H20 108.63 110.06 1.42 2.03 #DIV/0! 
C16-C19-H21 110.90 109.68 -1.23 1.50 #DIV/0! 
C16-C19-H22 111.19 109.71 -1.48 2.19 #DIV/0! 
H20-C19-H21 109.04 109.00 -0.04 0.00 #DIV/0! 
H20-C19-H22 109.07 108.85 -0.23 0.05 #DIV/0! 
H21-C19-H22 107.96 109.54 1.57 2.47 #DIV/0! 
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Table 23 
 
Cont. 
 
SB-674042 Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
N15-C14-C18 116.19 116.51 0.32 0.10 #DIV/0! 
C12-C14-C18 124.80 122.65 -2.15 4.64 #DIV/0! 
N15-C14-C12 118.90 120.65 1.74 3.04 #DIV/0! 
C14-C12-O13 120.09 119.02 -1.07 1.14 #DIV/0! 
N27-C12-O13 122.65 121.40 -1.25 1.55 #DIV/0! 
C14-C12-N27 117.24 119.56 2.32 5.36 #DIV/0! 
C12-N27-C23 119.33 122.16 2.83 8.03 #DIV/0! 
C12-N27-C26 125.79 124.01 -1.78 3.18 #DIV/0! 
C23-N27-C26 112.28 111.89 -0.39 0.15 #DIV/0! 
N27-C26-C25 102.82 103.35 0.53 0.28 #DIV/0! 
N27-C26-H33 110.98 112.47 1.50 2.25 #DIV/0! 
N27-C26-H34 110.60 108.07 -2.53 6.41 #DIV/0! 
C25-C26-H33 112.68 112.96 0.28 0.08 #DIV/0! 
C25-C26-H34 111.53 111.80 0.28 0.08 #DIV/0! 
H33-C26-H34 108.20 108.09 -0.11 0.01 #DIV/0! 
C26-C25-C24 102.89 102.64 -0.25 0.06 #DIV/0! 
C26-C25-H31 112.49 113.26 0.77 0.59 #DIV/0! 
C26-C25-H32 109.63 110.03 0.40 0.16 #DIV/0! 
C24-C25-H31 113.15 113.34 0.20 0.04 #DIV/0! 
C24-C25-H32 110.48 110.29 -0.19 0.04 #DIV/0! 
H31-C25-H32 108.14 107.27 -0.87 0.75 #DIV/0! 
C25-C24-C23 104.01 103.56 -0.45 0.20 #DIV/0! 
C25-C24-H29 113.30 113.26 -0.04 0.00 #DIV/0! 
C25-C24-H30 110.10 109.67 -0.43 0.18 #DIV/0! 
C23-C24-H29 111.39 113.07 1.68 2.84 #DIV/0! 
C23-C24-H30 110.39 110.52 0.13 0.02 #DIV/0! 
H29-C24-H30 107.66 106.78 -0.88 0.77 #DIV/0! 
N27-C23-C24 103.72 103.89 0.16 0.03 #DIV/0! 
N27-C23-C35 113.26 114.39 1.12 1.26 #DIV/0! 
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Table 23 
 
Cont. 
 
SB-674042 Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
N27-C23-H28 108.58 107.74 -0.85 0.72 #DIV/0! 
C24-C23-C35 114.20 113.62 -0.58 0.34 #DIV/0! 
C24-C23-H28 110.41 110.17 -0.25 0.06 #DIV/0! 
C35-C23-H28 106.60 106.93 0.33 0.11 #DIV/0! 
C23-C35-C38 114.23 112.84 -1.39 1.92 #DIV/0! 
C23-C35-H36 109.09 109.66 0.56 0.32 #DIV/0! 
C23-C35-H37 108.53 109.35 0.82 0.67 #DIV/0! 
C38-C35-H36 108.76 108.48 -0.29 0.08 #DIV/0! 
C38-C35-H37 107.60 108.53 0.94 0.87 #DIV/0! 
H36-C35-H37 108.49 107.86 -0.63 0.39 #DIV/0! 
C35-C38-O42 119.36 119.39 0.03 0.00 #DIV/0! 
C35-C38-N39 129.00 127.32 -1.68 2.81 #DIV/0! 
O42-C38-N39 111.65 113.29 1.64 2.70 #DIV/0! 
C38-O42-C41 103.39 102.78 -0.61 0.38 #DIV/0! 
C38-N39-N40 106.72 105.43 -1.28 1.65 #DIV/0! 
N39-N40-C41 106.45 106.32 -0.13 0.02 #DIV/0! 
N40-C41-O42 111.79 112.16 0.37 0.13 #DIV/0! 
N40-C41-C46 128.58 128.57 -0.02 0.00 #DIV/0! 
O42-C41-C46 119.62 119.27 -0.35 0.12 #DIV/0! 
C41-C46-C45 120.72 120.72 0.00 0.00 #DIV/0! 
C41-C46-C47 119.27 119.26 -0.01 0.00 #DIV/0! 
C45-C46-C47 120.01 120.01 0.00 0.00 #DIV/0! 
C46-C45-H51 119.95 120.79 0.84 0.70 #DIV/0! 
C46-C45-C44 119.78 119.67 -0.12 0.01 #DIV/0! 
H51-C45-C44 120.27 119.54 -0.73 0.53 #DIV/0! 
C46-C47-H52 119.39 120.48 1.10 1.20 #DIV/0! 
C46-C47-C48 119.90 119.68 -0.22 0.05 #DIV/0! 
H52-C47-C48 120.71 119.83 -0.88 0.77 #DIV/0! 
C45-C44-C43 120.19 120.19 0.00 0.00 #DIV/0! 
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Table 23 
 
Cont. 
 
SB-674042 Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C45-C44-H50 119.66 119.84 0.19 0.03 #DIV/0! 
H50-C44-C43 120.15 119.97 -0.18 0.03 #DIV/0! 
C47-C48-C43 120.10 120.20 0.10 0.01 #DIV/0! 
C47-C48-H53 119.79 119.87 0.08 0.01 #DIV/0! 
H53-C48-C43 120.11 119.93 -0.18 0.03 #DIV/0! 
C44-C43-C48 120.02 120.25 0.23 0.05 #DIV/0! 
C44-C43-H49 119.99 119.90 -0.08 0.01 #DIV/0! 
C48-C43-H49 119.99 119.85 -0.14 0.02 #DIV/0! 
Largest absolute error 2.83 8.03 #DIV/0! 
RMS error 0.90 #DIV/0! 
 
The same was done for the angles of pyroglutamate-NMA before and after recursively 
optimizing bonds and angles, then dihedrals, and listing the bond angles outside the 
margin of error as highlighted olive, boxed, and italicized, with its bond angles prior to 
this optimization shown in Table 24.4,158,159,160,161,162,163,164,165,166,167   
 
Table 24 
 
Pyroglutamate-NMA Bond Angles Prior to Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Pyroglutamate-NMA Angle Test Before CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
CD -N  -HN  119.74 120.62 0.88 0.78 #DIV/0! 
CD -N  -CA 115.43 115.40 -0.04 0.00 #DIV/0! 
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Table 24 
 
Cont. 
 
Pyroglutamate-NMA Angle Test Before CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
CA -N  -HN  123.42 123.95 0.53 0.28 #DIV/0! 
N  -CD -CG 106.82 106.13 -0.69 0.47 #DIV/0! 
N  -CD -OE  125.49 125.77 0.28 0.08 #DIV/0! 
CG -CD -OE  127.68 128.03 0.35 0.13 #DIV/0! 
CD -CG -CB 103.99 103.15 -0.85 0.71 #DIV/0! 
CD -CG -HG2 110.30 111.40 1.11 1.23 #DIV/0! 
CD -CG -HG3 108.19 109.55 1.36 1.85 #DIV/0! 
CB -CG -HG2 114.25 113.16 -1.09 1.19 #DIV/0! 
CB -CG -HG3 112.21 112.07 -0.13 0.02 #DIV/0! 
HG2-CG -HG3 107.75 107.50 -0.25 0.06 #DIV/0! 
CG -CB -CA 104.19 105.89 1.69 2.86 #DIV/0! 
CG -CB -HB1 114.26 112.52 -1.74 3.04 #DIV/0! 
CG -CB -HB2 109.87 109.84 -0.03 0.00 #DIV/0! 
CA -CB -HB1 111.68 113.16 1.48 2.18 #DIV/0! 
CA -CB -HB2 108.83 109.43 0.60 0.36 #DIV/0! 
HB1-CB -HB2 107.89 106.01 -1.88 3.53 #DIV/0! 
CB -CA -N  102.71 101.22 -1.48 2.20 #DIV/0! 
CB -CA -C  111.35 114.48 3.12 9.76 100008.02568 
CB -CA -HA  110.80 109.89 -0.91 0.83 #DIV/0! 
N  -CA -C  115.26 114.46 -0.80 0.64 #DIV/0! 
N  -CA -HA  111.33 109.43 -1.89 3.59 #DIV/0! 
C  -CA -HA  105.53 107.24 1.72 2.94 #DIV/0! 
CA -C  -O  119.14 119.21 0.07 0.01 #DIV/0! 
CA -C  -N8 117.45 118.36 0.91 0.83 #DIV/0! 
N8 -C  -O  123.42 122.43 -0.98 0.97 #DIV/0! 
C  -N8 -C9 121.37 122.13 0.77 0.59 #DIV/0! 
C  -N8 -H16 118.88 119.14 0.26 0.07 #DIV/0! 
C9 -N8 -H16 119.71 118.61 -1.10 1.22 #DIV/0! 
N8 -C9 -H17 108.63 110.59 1.96 3.84 #DIV/0! 
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Pyroglutamate-NMA Angle Test Before CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
N8 -C9 -H18 110.50 110.73 0.23 0.05 #DIV/0! 
N8 -C9 -H19 111.26 110.72 -0.54 0.29 #DIV/0! 
H17-C9 -H18 109.10 108.31 -0.80 0.63 #DIV/0! 
H17-C9 -H19 109.01 108.30 -0.72 0.51 #DIV/0! 
H18-C9 -H19 108.30 108.10 -0.19 0.04 #DIV/0! 
Largest absolute error 3.12 9.76 100008.02568 
RMS error 1.15 #DIV/0! 
 
The pyroglutamate-NMA bond angles, which have the MM angle measurements more 
closely approximate the QM angle measurements, after this optimization of bond lengths, 
bond angles, and dihedral torsion angles, were compiled in Table 
25.4,158,159,160,161,162,163,164,165,166,167   
 
Table 25 
 
Pyroglutamate-NMA Bond Angles After Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Pyroglutamate-NMA Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
CD -N  -HN  119.74 120.15 0.41 0.17 #DIV/0! 
CD -N  -CA 115.43 114.43 -1.00 1.00 #DIV/0! 
CA -N  -HN  123.42 123.83 0.41 0.17 #DIV/0! 
N  -CD -CG 106.82 106.07 -0.75 0.57 #DIV/0! 
N  -CD -OE  125.49 125.83 0.34 0.12 #DIV/0! 
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Pyroglutamate-NMA Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
CG -CD -OE  127.68 128.05 0.37 0.14 #DIV/0! 
CD -CG -CB 103.99 102.83 -1.16 1.35 #DIV/0! 
CD -CG -HG2 110.30 111.42 1.13 1.27 #DIV/0! 
CD -CG -HG3 108.19 109.68 1.50 2.24 #DIV/0! 
CB -CG -HG2 114.25 113.15 -1.10 1.21 #DIV/0! 
CB -CG -HG3 112.21 112.16 -0.05 0.00 #DIV/0! 
HG2-CG -HG3 107.75 107.58 -0.17 0.03 #DIV/0! 
CG -CB -CA 104.19 104.79 0.60 0.36 #DIV/0! 
CG -CB -HB1 114.26 112.73 -1.53 2.34 #DIV/0! 
CG -CB -HB2 109.87 109.91 0.04 0.00 #DIV/0! 
CA -CB -HB1 111.68 113.78 2.10 4.41 #DIV/0! 
CA -CB -HB2 108.83 109.55 0.72 0.52 #DIV/0! 
HB1-CB -HB2 107.89 106.10 -1.80 3.23 #DIV/0! 
CB -CA -N  102.71 102.24 -0.47 0.22 #DIV/0! 
CB -CA -C  111.35 111.28 -0.07 0.00 #DIV/0! 
CB -CA -HA  110.80 112.12 1.32 1.74 #DIV/0! 
N  -CA -C  115.26 112.90 -2.36 5.57 #DIV/0! 
N  -CA -HA  111.33 112.94 1.62 2.61 #DIV/0! 
C  -CA -HA  105.53 105.57 0.04 0.00 #DIV/0! 
CA -C  -O  119.14 119.21 0.08 0.01 #DIV/0! 
CA -C  -N8 117.45 118.30 0.85 0.72 #DIV/0! 
N8 -C  -O  123.42 122.49 -0.92 0.86 #DIV/0! 
C  -N8 -C9 121.37 122.46 1.09 1.19 #DIV/0! 
C  -N8 -H16 118.88 118.58 -0.30 0.09 #DIV/0! 
C9 -N8 -H16 119.71 118.93 -0.78 0.61 #DIV/0! 
N8 -C9 -H17 108.63 110.45 1.81 3.29 #DIV/0! 
N8 -C9 -H18 110.50 110.64 0.14 0.02 #DIV/0! 
N8 -C9 -H19 111.26 110.64 -0.62 0.38 #DIV/0! 
H17-C9 -H18 109.10 108.40 -0.71 0.50 #DIV/0! 
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Table 25 
 
Cont. 
 
Pyroglutamate-NMA Angle Test After CHARMM Optimization 
Angle 
QM MM 
Difference Square Check 
Angle Angle 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
H17-C9 -H19 109.01 108.39 -0.62 0.39 #DIV/0! 
H18-C9 -H19 108.30 108.25 -0.05 0.00 #DIV/0! 
Largest absolute error 2.36 5.57 #DIV/0! 
RMS error 1.02 #DIV/0! 
 
The resulting bond length parameters, with the repaired force constants and equilibrium 
lengths highlighted for increased visibility, and the parameters for pyroglutamate and SB-
674042 listed after the parameters to connect pyroglutamate to peptides, are listed in 
Table 26.4,137,158,159,160,161,162,163,164,165,166,167   
 
Table 26 
 
Bond Length Parameters, with Repaired Parameters 
Highlighted.4,137,158,159,160,161,162,163,164,165,166,167   
 
Bond Length Parameters 
Atom Type 1 Atom Type 2 Kb (kcal mol–1Å–2) b0 length (Å) 
NH1 C 370.00 1.3450 
NH1 CT1 320.00 1.4300 
NH1 H 440.00 0.9970 
O C 620.00 1.2300 
N C 260.00 1.3000 
N CP1 320.00 1.4340 
N CP3 320.00 1.4550 
C53 C61 492.73 1.4366 
C53 N50 400.00 1.3200 
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Bond Length Parameters 
Atom Type 1 Atom Type 2 Kb (kcal mol–1Å–2) b0 length (Å) 
C53 N50X 911.70 1.2644 
C53 O50 450.00 1.3710 
C53 O50X 643.62 1.3313 
C53 HG52 340.00 1.0900 
C61 C61 305.00 1.3750 
C61 H61 340.00 1.0800 
N50 N50 340.00 1.2900 
N50X N50X 497.43 1.3833 
CO1 NG0 430.00 1.3500 
CO1 OD1 1138.69 1.2091 
CO1 HG52 317.13 1.1000 
C53 C21 454.61 1.4935 
C21 C11 222.50 1.5280 
C21 HG2 309.00 1.1110 
C11 C215 195.00 1.5180 
C11 NG0 420.16 1.4710 
C11 HG1 307.00 1.1000 
C215 C215 195.00 1.5300 
C215 NG0 320.00 1.4550 
C215 HG2 307.00 1.1000 
CO1 C51 488.45 1.4678 
C51 C51 725.64 1.3275 
C51 N50Y 565.70 1.3501 
C51 S50Y 300.00 1.7300 
C51 HG52 375.00 1.0830 
C53 C31 499.48 1.5000 
C53 N50Y 893.91 1.2808 
C53 S50Y 313.19 1.7920 
C31 C11 222.50 1.5280 
C31 HG3 322.00 1.0810 
C51 C61 478.71 1.4652 
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Bond Length Parameters 
Atom Type 1 Atom Type 2 Kb (kcal mol–1Å–2) b0 length (Å) 
C61 C66 305.00 1.3700 
C61 H62 340.00 1.0800 
C66 FR1 638.80 1.3319 
C CTY1 250.00 1.4900 
CCY CTY2 300.00 1.5300 
CCY NH1 460.00 1.3800 
CCY O 1400.00 1.1949 
CTY3 NH1 320.00 1.4300 
CTY3 HG3 480.00 1.0803 
CTY1 CTY2 195.00 1.5180 
CTY1 NH1 370.00 1.4500 
CTY1 HBY 307.00 1.1000 
CTY2 CTY2 195.00 1.5300 
CTY2 HAY 307.00 1.1000 
NH1 H5 440.00 0.9970 
CO1 NG2 430.00 1.3600 
NG2 HP1 480.00 1.0000 
 
The resulting bond angle parameters, are listed in Table 27, highlighting the force 
constants and equilibrium angles similarly.4,137,158,159,160,161,162,163,164,165,166,167   
 
Table 27 
 
Bond Angle Parameters, with Repaired Parameters 
Highlighted.4,137,158,159,160,161,162,163,164,165,166,167   
 
Angle Parameters 
Atom Atom Atom 
Kθ (kcal mol–1radian–2) θ0 angle (degrees) Type 1 Type 2 Type 3 
CP1 N C 60.000 117.0000 
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Angle Parameters 
Atom Atom Atom 
Kθ (kcal mol–1radian–2) θ0 angle (degrees) Type 1 Type 2 Type 3 
CP3 N C 60.000 117.0000 
CP3 N CP1 100.000 114.2000 
CT1 NH1 C 50.000 120.0000 
H NH1 C 34.000 123.0000 
H NH1 CT1 35.000 117.0000 
O C N 80.000 122.5000 
O C NH1 80.000 122.5000 
C61 C53 N50 65.000 127.8000 
C61 C53 N50X 44.980 129.0600 
C61 C53 O50 65.000 127.8000 
C61 C53 O50X 59.030 118.6900 
N50 C53 O50 120.000 115.7000 
N50X C53 O50X 120.000 115.7000 
N50 C53 HG52 39.000 124.8000 
N50X C53 HG52 46.950 129.5600 
O50 C53 HG52 25.000 119.5000 
O50X C53 HG52 32.210 118.6900 
C53 C61 C61 47.240 109.8400 
C61 C61 C61 40.000 120.0000 
C61 C61 H61 30.000 120.0000 
C53 N50 N50 110.000 106.8000 
C53 N50X N50X 110.000 106.8000 
C53 O50 C53 140.000 104.0000 
C53 O50X C53 140.000 104.0000 
NG0 CO1 OD1 80.000 124.0000 
NG0 CO1 HG52 43.000 115.0000 
OD1 CO1 HG52 44.000 122.0000 
C21 C53 N50X 44.460 128.5100 
C21 C53 O50X 68.770 119.6900 
C53 C21 C11 82.720 113.4100 
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Angle Parameters 
Atom Atom Atom 
Kθ (kcal mol–1radian–2) θ0 angle (degrees) Type 1 Type 2 Type 3 
C53 C21 HG2 55.000 109.5000 
C11 C21 HG2 34.600 110.1000 
HG2 C21 HG2 35.500 109.0000 
C21 C11 C215 58.000 115.0000 
C21 C11 NG0 94.330 113.1100 
C21 C11 HG1 34.600 106.6000 
C215 C11 NG0 70.000 112.0000 
C215 C11 HG1 48.720 111.7700 
NG0 C11 HG1 88.230 108.5300 
C11 C215 C215 58.000 109.5000 
C11 C215 HG2 35.000 111.4000 
C215 C215 C215 58.000 109.5000 
C215 C215 NG0 70.000 110.5000 
C215 C215 HG2 35.000 111.4000 
NG0 C215 HG2 48.000 108.0000 
HG2 C215 HG2 38.500 106.8000 
CO1 NG0 C11 60.000 115.9000 
CO1 NG0 C215 60.000 115.0000 
C11 NG0 C215 100.000 114.2000 
C51 CO1 NG0 80.000 116.5000 
C51 CO1 OD1 30.000 121.0000 
CO1 C51 C51 90.510 122.1700 
CO1 C51 N50Y 35.280 119.9100 
C51 C51 N50Y 132.060 104.5500 
C51 C51 S50Y 141.280 99.7100 
C51 C51 HG52 22.000 130.0000 
S50Y C51 HG52 45.000 121.0000 
C31 C53 N50Y 63.360 125.3200 
C31 C53 S50Y 49.780 121.8800 
N50Y C53 S50Y 110.000 117.2000 
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Angle Parameters 
Atom Atom Atom 
Kθ (kcal mol–1radian–2) θ0 angle (degrees) Type 1 Type 2 Type 3 
N50 C53 S50 110.000 117.2000 
C53 C31 HG3 55.000 109.5000 
C11 C31 HG3 34.600 110.1000 
HG3 C31 HG3 35.500 108.4000 
C31 C11 C215 58.000 115.0000 
C31 C11 NG0 94.330 111.1100 
C31 C11 HG1 34.600 110.1000 
C51 N50Y C53 119.130 102.9500 
C51 S50Y C53 110.000 97.0000 
C51 C51 C61 49.150 127.1700 
C61 C51 S50Y 49.690 121.2800 
N50Y C51 HG52 25.000 120.0000 
N50 C51 HG52 25.000 120.0000 
C51 C61 C61 84.170 121.8300 
C51 C61 C66 52.270 122.7800 
C61 C61 C66 40.000 119.0000 
C61 C61 H62 30.000 120.0000 
C66 C61 H62 30.000 121.5000 
C61 C66 C61 40.000 122.5000 
C61 C66 FR1 60.000 118.7500 
CTY1 C N 80.000 116.5000 
CTY1 C NH1 80.000 116.5000 
CTY1 C O 80.000 118.0000 
CTY2 CCY NH1 120.000 105.5000 
CTY2 CCY O 65.000 126.7000 
NH1 CCY O 65.000 127.8000 
NH1 CTY3 HG3 51.500 109.5000 
HG3 CTY3 HG3 35.500 108.4000 
C CTY1 CTY2 48.750 103.9500 
C CTY1 NH1 47.920 105.9200 
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Angle Parameters 
Atom Atom Atom 
Kθ (kcal mol–1radian–2) θ0 angle (degrees) Type 1 Type 2 Type 3 
C CTY1 HBY 51.000 106.9500 
CTY2 CTY1 NH1 90.000 104.5000 
CTY2 CTY1 HBY 35.000 111.4000 
NH1 CTY1 HBY 59.000 111.0000 
CCY CTY2 CTY2 70.000 106.5000 
CCY CTY2 HAY 58.000 111.0000 
CTY1 CTY2 CTY2 58.000 109.5000 
CTY1 CTY2 HAY 35.000 111.4000 
CTY2 CTY2 HAY 35.000 111.4000 
HAY CTY2 HAY 38.500 106.8000 
CCY NH1 CTY1 75.000 111.0000 
CCY NH1 H 38.000 119.5000 
CTY1 NH1 H 38.000 116.0000 
C NH1 CTY3 50.000 120.0000 
C NH1 H5 34.000 123.0000 
CTY3 NH1 H5 35.000 117.0000 
C51 CO1 NG2 50.000 110.2300 
NG2 CO1 OD1 75.000 122.5000 
CO1 NG2 HP1 50.000 120.0000 
HP1 NG2 HP1 23.000 120.0000 
 
The resulting Urey-Bradley parameters, with no necessary repairs determined or required 
to be made, are listed in Table 28.4,137,158,159,160,161,162,163,164,165,166,167  
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Table 28 
 
Urey-Bradley Parameters.4,137,158,159,160,161,162,163,164,165,166,167   
 
Urey-Bradley Parameters 
Atom Atom Atom 
KUB(kcal mol–1Å–2) s0length (Å) 
Type 1 Type 2 Type 3 
O50 C53 HG52 20.00 2.14000 
O50X C53 HG52 20.00 2.14000 
C61 C61 C61 35.00 2.41620 
C61 C61 H61 22.00 2.15250 
C11 C21 HG2 22.53 2.17900 
HG2 C21 HG2 5.40 1.80200 
C21 C11 C215 8.00 2.56100 
C21 C11 HG1 22.53 2.17900 
C215 C11 HG1 22.53 2.17900 
C11 C215 C215 11.16 2.56100 
C11 C215 HG2 22.53 2.17900 
C215 C215 C215 11.16 2.56100 
C215 C215 HG2 22.53 2.17900 
HG2 C215 HG2 5.40 1.80200 
C51 C51 HG52 15.00 2.21500 
C11 C31 HG3 22.53 2.17900 
HG3 C31 HG3 5.40 1.80200 
C31 C11 C215 8.00 2.56100 
C31 C11 HG1 22.53 2.17900 
N50Y C51 HG52 20.00 2.14000 
N50 C51 HG52 20.00 2.14000 
C61 C61 C66 35.00 2.41620 
C61 C61 H62 22.00 2.15250 
C66 C61 H62 22.00 2.15250 
C61 C66 C61 35.00 2.41620 
HG3 CTY3 HG3 5.40 1.80200 
CTY2 CTY1 HBY 22.53 2.17900 
CTY1 CTY2 CTY2 11.16 2.56100 
CTY1 CTY2 HAY 22.53 2.17900 
CTY2 CTY2 HAY 22.53 2.17900 
HAY CTY2 HAY 5.40 1.80200 
NG2 CO1 OD1 50.00 2.37000 
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Measurement comparisons for the dihedral angles, in a similar fashion as was done for 
the bond lengths and bond angles, were made for SB-674042 before and after recursively 
optimizing bonds and angles, then dihedrals, with the dihedral check formula modified to 
add only 10000 for the purposes of space, and the SB-674042 dihedral angles prior to this 
optimization listed in Table 29.137,158,159,160,161,162,163,164,165,166,167   
 
Table 29 
 
SB-674042 Dihedral Angles Prior to Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
H8 -C1 -C2 -H9 0.24 0.09 -0.15 0.02 #DIV/0! 
H8 -C1 -C2 -C3 179.80 179.81 0.01 0.00 #DIV/0! 
C6 -C1 -C2 -H9 -179.71 -179.75 -0.04 0.00 #DIV/0! 
C6 -C1 -C2 -C3 -0.15 -0.02 0.12 0.02 #DIV/0! 
H8 -C1 -C6 -H11 0.17 0.04 -0.14 0.02 #DIV/0! 
H8 -C1 -C6 -C5 -179.88 -179.79 0.09 0.01 #DIV/0! 
C2 -C1 -C6 -H11 -179.88 179.87 -0.26 0.07 #DIV/0! 
C2 -C1 -C6 -C5 0.07 0.04 -0.03 0.00 #DIV/0! 
C1 -C2 -C3 -C4 0.01 -0.01 -0.02 0.00 #DIV/0! 
C1 -C2 -C3 -H10 -179.09 -179.48 -0.39 0.15 #DIV/0! 
H9 -C2 -C3 -C4 179.58 179.71 0.13 0.02 #DIV/0! 
H9 -C2 -C3 -H10 0.48 0.24 -0.24 0.06 #DIV/0! 
C1 -C6 -C5 -C4 0.15 -0.02 -0.17 0.03 #DIV/0! 
C1 -C6 -C5 -F7 -179.26 -179.14 0.12 0.01 #DIV/0! 
H11-C6 -C5 -C4 -179.90 -179.85 0.05 0.00 #DIV/0! 
H11-C6 -C5 -F7 0.68 1.03 0.34 0.12 #DIV/0! 
C2 -C3 -C4 -C5 0.20 0.03 -0.17 0.03 #DIV/0! 
C2 -C3 -C4 -C18 178.91 -179.54 1.56 2.42 #DIV/0! 
H10-C3 -C4 -C5 179.30 179.50 0.20 0.04 #DIV/0! 
H10-C3 -C4 -C18 -1.99 -0.07 1.92 3.69 #DIV/0! 
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SB-674042 Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C6 -C5 -C4 -C3 -0.28 -0.02 0.27 0.07 #DIV/0! 
C6 -C5 -C4 -C18 -178.99 179.55 -1.46 2.13 #DIV/0! 
F7 -C5 -C4 -C3 179.13 179.09 -0.04 0.00 #DIV/0! 
F7 -C5 -C4 -C18 0.42 -1.35 -1.77 3.12 #DIV/0! 
C3 -C4 -C18-C14 132.30 123.56 -8.74 76.35 10001.35520
C5 -C4 -C18-C14 -49.04 -55.99 -6.95 48.29 #DIV/0! 
C3 -C4 -C18-S17 -48.96 -62.87 -13.92 193.64 10000.16904
C5 -C4 -C18-S17 129.70 117.57 -12.13 147.06 10000.24232
C4 -C18-S17-C16 -179.66 -177.56 2.09 4.38 #DIV/0! 
C14-C18-S17-C16 -0.66 -2.82 -2.16 4.66 #DIV/0! 
C18-S17-C16-N15 1.00 2.18 1.18 1.39 #DIV/0! 
C18-S17-C16-C19 -179.50 177.80 -2.70 7.30 #DIV/0! 
S17-C16-C19-H20 174.15 148.38 -25.77 664.04 10000.05628
S17-C16-C19-H21 -66.03 -92.12 -26.09 680.76 10000.05527
S17-C16-C19-H22 54.11 28.43 -25.68 659.56 10000.05656
N15-C16-C19-H20 -6.40 -36.16 -29.76 885.70 10000.04595
N15-C16-C19-H21 113.42 83.34 -30.08 904.99 10000.04528
N15-C16-C19-H22 -126.44 -156.11 -29.67 880.52 10000.04614
S17-C16-N15-C14 -1.03 -0.83 0.19 0.04 #DIV/0! 
C19-C16-N15-C14 179.48 -176.59 3.93 15.45 #DIV/0! 
C16-N15-C14-C12 -175.94 -177.35 -1.42 2.00 #DIV/0! 
C16-N15-C14-C18 0.50 -1.45 -1.95 3.79 #DIV/0! 
C4 -C18-C14-N15 179.12 177.07 -2.05 4.20 #DIV/0! 
C4 -C18-C14-C12 -4.68 -7.35 -2.67 7.15 #DIV/0! 
S17-C18-C14-N15 0.26 3.00 2.74 7.51 #DIV/0! 
S17-C18-C14-C12 176.45 178.57 2.11 4.47 #DIV/0! 
C18-C14-C12-O13 -44.92 -42.00 2.93 8.58 #DIV/0! 
C18-C14-C12-N27 136.72 137.25 0.53 0.28 #DIV/0! 
N15-C14-C12-O13 131.18 133.37 2.19 4.80 #DIV/0! 
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SB-674042 Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
N15-C14-C12-N27 -47.18 -47.39 -0.21 0.05 #DIV/0! 
C14-C12-N27-C26 -20.09 -18.68 1.41 2.00 #DIV/0! 
C14-C12-N27-C23 179.66 169.67 -9.99 99.77 10000.50294
O13-C12-N27-C26 161.60 160.55 -1.05 1.10 #DIV/0! 
O13-C12-N27-C23 1.35 -11.10 -12.45 155.07 10000.22459
C12-N27-C26-C25 -141.22 -149.60 -8.38 70.26 10002.61780
C12-N27-C26-H33 -20.50 -27.43 -6.92 47.95 #DIV/0! 
C12-N27-C26-H34 99.60 91.78 -7.82 61.18 #DIV/0! 
C23-N27-C26-C25 20.22 22.74 2.52 6.37 #DIV/0! 
C23-N27-C26-H33 140.93 144.91 3.98 15.84 #DIV/0! 
C23-N27-C26-H34 -98.97 -95.88 3.08 9.51 #DIV/0! 
N27-C26-C25-C24 -34.73 -33.44 1.29 1.67 #DIV/0! 
N27-C26-C25-H31 -156.82 -156.14 0.68 0.46 #DIV/0! 
N27-C26-C25-H32 82.82 83.82 1.00 1.00 #DIV/0! 
H33-C26-C25-C24 -154.27 -155.03 -0.75 0.57 #DIV/0! 
H33-C26-C25-H31 83.64 82.28 -1.36 1.86 #DIV/0! 
H33-C26-C25-H32 -36.72 -37.76 -1.05 1.09 #DIV/0! 
H34-C26-C25-C24 83.80 82.56 -1.25 1.55 #DIV/0! 
H34-C26-C25-H31 -38.28 -40.14 -1.86 3.45 #DIV/0! 
H34-C26-C25-H32 -158.64 -160.18 -1.54 2.37 #DIV/0! 
C26-C25-C24-C23 37.07 32.94 -4.12 17.01 #DIV/0! 
C26-C25-C24-H29 158.17 156.38 -1.79 3.21 #DIV/0! 
C26-C25-C24-H30 -81.21 -85.13 -3.92 15.39 #DIV/0! 
H31-C25-C24-C23 158.71 155.68 -3.03 9.17 #DIV/0! 
H31-C25-C24-H29 -80.18 -80.88 -0.70 0.49 #DIV/0! 
H31-C25-C24-H30 40.44 37.61 -2.83 8.00 #DIV/0! 
H32-C25-C24-C23 -79.89 -84.15 -4.27 18.20 #DIV/0! 
H32-C25-C24-H29 41.22 39.29 -1.93 3.74 #DIV/0! 
H32-C25-C24-H30 161.84 157.78 -4.07 16.53 #DIV/0! 
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SB-674042 Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C25-C24-C23-N27 -24.80 -19.67 5.13 26.32 #DIV/0! 
C25-C24-C23-C35 -148.54 -141.48 7.06 49.91 #DIV/0! 
C25-C24-C23-H28 91.37 97.95 6.59 43.38 #DIV/0! 
H29-C24-C23-N27 -147.17 -143.20 3.97 15.74 #DIV/0! 
H29-C24-C23-C35 89.08 94.98 5.90 34.82 #DIV/0! 
H29-C24-C23-H28 -31.01 -25.59 5.42 29.41 #DIV/0! 
H30-C24-C23-N27 93.28 97.87 4.59 21.05 #DIV/0! 
H30-C24-C23-C35 -30.47 -23.94 6.52 42.53 #DIV/0! 
H30-C24-C23-H28 -150.56 -144.51 6.04 36.54 #DIV/0! 
C12-N27-C23-C35 -70.06 -66.73 3.33 11.06 #DIV/0! 
C12-N27-C23-C24 165.59 170.71 5.12 26.23 #DIV/0! 
C12-N27-C23-H28 48.14 54.65 6.51 42.41 #DIV/0! 
C26-N27-C23-C35 127.17 120.66 -6.51 42.44 #DIV/0! 
C26-N27-C23-C24 2.82 -1.90 -4.72 22.26 #DIV/0! 
C26-N27-C23-H28 -114.63 -117.96 -3.33 11.07 #DIV/0! 
N27-C23-C35-C38 -53.31 -36.48 16.83 283.24 10000.11326
N27-C23-C35-H36 68.62 82.43 13.80 190.46 10000.17239
N27-C23-C35-H37 -173.34 -159.06 14.28 204.02 10000.15915
C24-C23-C35-C38 65.13 81.14 16.00 256.15 10000.12493
C24-C23-C35-H36 -172.93 -159.95 12.98 168.37 10000.20098
C24-C23-C35-H37 -54.90 -41.44 13.46 181.13 10000.18320
H28-C23-C35-C38 -172.66 -158.73 13.93 194.00 10000.16868
H28-C23-C35-H36 -50.72 -39.82 10.90 118.80 10000.34489
H28-C23-C35-H37 67.31 78.69 11.38 129.56 10000.29565
C23-C35-C38-N39 -94.43 -84.07 10.36 107.34 10000.42362
C23-C35-C38-O42 85.55 90.79 5.24 27.43 #DIV/0! 
H36-C35-C38-N39 143.45 156.21 12.76 162.91 10000.20993
H36-C35-C38-O42 -36.57 -28.93 7.64 58.38 #DIV/0! 
H37-C35-C38-N39 26.12 38.95 12.83 164.70 10000.20689
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SB-674042 Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
H37-C35-C38-O42 -153.90 -146.19 7.71 59.44 #DIV/0! 
C35-C38-O42-C41 -179.67 -174.13 5.54 30.66 #DIV/0! 
N39-C38-O42-C41 0.32 1.14 0.82 0.67 #DIV/0! 
C35-C38-N39-N40 179.66 174.66 -5.00 25.00 #DIV/0! 
O42-C38-N39-N40 -0.33 -0.75 -0.41 0.17 #DIV/0! 
C38-N39-N40-C41 0.20 -0.03 -0.23 0.05 #DIV/0! 
N39-N40-C41-C46 179.80 -178.70 1.49 2.23 #DIV/0! 
N39-N40-C41-O42 0.00 0.77 0.77 0.60 #DIV/0! 
C38-O42-C41-C46 179.99 178.35 -1.64 2.68 #DIV/0! 
C38-O42-C41-N40 -0.19 -1.13 -0.94 0.89 #DIV/0! 
N40-C41-C46-C45 174.40 177.17 2.77 7.69 #DIV/0! 
N40-C41-C46-C47 -5.54 -1.77 3.77 14.20 #DIV/0! 
O42-C41-C46-C45 -5.81 -2.24 3.57 12.75 #DIV/0! 
O42-C41-C46-C47 174.25 178.82 4.57 20.85 #DIV/0! 
C41-C46-C45-C44 179.91 -179.04 1.06 1.11 #DIV/0! 
C41-C46-C45-H51 -0.57 0.24 0.80 0.65 #DIV/0! 
C47-C46-C45-C44 -0.16 -0.06 0.09 0.01 #DIV/0! 
C47-C46-C45-H51 179.37 179.21 -0.16 0.02 #DIV/0! 
C41-C46-C47-C48 -179.95 179.07 -0.98 0.96 #DIV/0! 
C41-C46-C47-H52 -0.11 -0.78 -0.67 0.45 #DIV/0! 
C45-C46-C47-C48 0.11 0.11 0.00 0.00 #DIV/0! 
C45-C46-C47-H52 179.96 -179.74 0.31 0.09 #DIV/0! 
C46-C45-C44-C43 0.04 -0.03 -0.07 0.00 #DIV/0! 
C46-C45-C44-H50 -179.73 179.96 -0.32 0.10 #DIV/0! 
H51-C45-C44-C43 -179.48 -179.31 0.18 0.03 #DIV/0! 
H51-C45-C44-H50 0.75 0.68 -0.07 0.00 #DIV/0! 
C46-C47-C48-C43 0.05 -0.07 -0.12 0.01 #DIV/0! 
C46-C47-C48-H53 179.91 179.94 0.02 0.00 #DIV/0! 
H52-C47-C48-C43 -179.80 179.78 -0.43 0.18 #DIV/0! 
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SB-674042 Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
H52-C47-C48-H53 0.07 -0.22 -0.29 0.08 #DIV/0! 
C47-C48-C43-C44 -0.17 -0.03 0.14 0.02 #DIV/0! 
C47-C48-C43-H49 179.83 179.95 0.12 0.01 #DIV/0! 
H53-C48-C43-C44 179.97 179.97 0.00 0.00 #DIV/0! 
H53-C48-C43-H49 -0.03 -0.06 -0.02 0.00 #DIV/0! 
C45-C44-C43-C48 0.12 0.08 -0.04 0.00 #DIV/0! 
C45-C44-C43-H49 -179.88 -179.90 -0.02 0.00 #DIV/0! 
H50-C44-C43-C48 179.88 -179.91 0.20 0.04 #DIV/0! 
H50-C44-C43-H49 -0.11 0.11 0.22 0.05 #DIV/0! 
Largest absolute error 30.08310 904.99291 10000.04528
RMS error 7.76708 #DIV/0! 
 
The SB-674042 dihedral angles, after optimizing bond lengths, bond angles, and dihedral 
angles, were listed in Table 30.137,158,159,160,161,162,163,164,165,166,167   
 
Table 30 
 
SB-674042 Dihedrals After Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
SB-674042 Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1)
H8 -C1 -C2 -H9 0.24 -0.02 -0.26 0.07 #DIV/0! 
H8 -C1 -C2 -C3 179.80 -179.93 0.26 0.07 #DIV/0! 
C6 -C1 -C2 -H9 -179.71 179.70 -0.59 0.35 #DIV/0! 
C6 -C1 -C2 -C3 -0.15 -0.21 -0.06 0.00 #DIV/0! 
H8 -C1 -C6 -H11 0.17 0.37 0.20 0.04 #DIV/0! 
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SB-674042 Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1)
H8 -C1 -C6 -C5 -179.88 -179.79 0.09 0.01 #DIV/0! 
C2 -C1 -C6 -H11 -179.88 -179.35 0.52 0.28 #DIV/0! 
C2 -C1 -C6 -C5 0.07 0.48 0.42 0.17 #DIV/0! 
C1 -C2 -C3 -C4 0.01 -0.80 -0.81 0.66 #DIV/0! 
C1 -C2 -C3 -H10 -179.09 179.83 -1.08 1.17 #DIV/0! 
H9 -C2 -C3 -C4 179.58 179.29 -0.29 0.08 #DIV/0! 
H9 -C2 -C3 -H10 0.48 -0.08 -0.56 0.31 #DIV/0! 
C1 -C6 -C5 -C4 0.15 0.25 0.10 0.01 #DIV/0! 
C1 -C6 -C5 -F7 -179.26 -177.16 2.11 4.44 #DIV/0! 
H11-C6 -C5 -C4 -179.90 -179.91 -0.01 0.00 #DIV/0! 
H11-C6 -C5 -F7 0.68 2.68 2.00 3.99 #DIV/0! 
C2 -C3 -C4 -C5 0.20 1.48 1.28 1.65 #DIV/0! 
C2 -C3 -C4 -C18 178.91 177.19 -1.72 2.96 #DIV/0! 
H10-C3 -C4 -C5 179.30 -179.15 1.55 2.40 #DIV/0! 
H10-C3 -C4 -C18 -1.99 -3.44 -1.45 2.12 #DIV/0! 
C6 -C5 -C4 -C3 -0.28 -1.22 -0.94 0.88 #DIV/0! 
C6 -C5 -C4 -C18 -178.99 -176.86 2.13 4.54 #DIV/0! 
F7 -C5 -C4 -C3 179.13 176.11 -3.02 9.12 #DIV/0! 
F7 -C5 -C4 -C18 0.42 0.47 0.05 0.00 #DIV/0! 
C3 -C4 -C18-C14 132.30 132.59 0.29 0.08 #DIV/0! 
C5 -C4 -C18-C14 -49.04 -51.90 -2.86 8.15 #DIV/0! 
C3 -C4 -C18-S17 -48.96 -53.56 -4.60 21.19 #DIV/0! 
C5 -C4 -C18-S17 129.70 121.95 -7.75 60.00 #DIV/0! 
C4 -C18-S17-C16 -179.66 -175.93 3.73 13.90 #DIV/0! 
C14-C18-S17-C16 -0.66 -0.80 -0.14 0.02 #DIV/0! 
C18-S17-C16-N15 1.00 0.51 -0.50 0.25 #DIV/0! 
C18-S17-C16-C19 -179.50 -179.51 -0.01 0.00 #DIV/0! 
S17-C16-C19-H20 174.15 177.11 2.96 8.78 #DIV/0! 
S17-C16-C19-H21 -66.03 -62.98 3.05 9.30 #DIV/0! 
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SB-674042 Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1)
S17-C16-C19-H22 54.11 57.37 3.26 10.63 #DIV/0! 
N15-C16-C19-H20 -6.40 -2.91 3.50 12.22 #DIV/0! 
N15-C16-C19-H21 113.42 117.00 3.58 12.84 #DIV/0! 
N15-C16-C19-H22 -126.44 -122.65 3.79 14.39 #DIV/0! 
S17-C16-N15-C14 -1.03 -0.04 0.98 0.97 #DIV/0! 
C19-C16-N15-C14 179.48 179.97 0.49 0.24 #DIV/0! 
C16-N15-C14-C12 -175.94 -175.68 0.26 0.07 #DIV/0! 
C16-N15-C14-C18 0.50 -0.64 -1.13 1.28 #DIV/0! 
C4 -C18-C14-N15 179.12 175.48 -3.65 13.30 #DIV/0! 
C4 -C18-C14-C12 -4.68 -9.59 -4.91 24.13 #DIV/0! 
S17-C18-C14-N15 0.26 0.97 0.72 0.51 #DIV/0! 
S17-C18-C14-C12 176.45 175.91 -0.55 0.30 #DIV/0! 
C18-C14-C12-O13 -44.92 -43.20 1.72 2.97 #DIV/0! 
C18-C14-C12-N27 136.72 135.29 -1.43 2.05 #DIV/0! 
N15-C14-C12-O13 131.18 131.53 0.35 0.12 #DIV/0! 
N15-C14-C12-N27 -47.18 -49.98 -2.80 7.86 #DIV/0! 
C14-C12-N27-C26 -20.09 -18.63 1.47 2.15 #DIV/0! 
C14-C12-N27-C23 179.66 178.53 -1.13 1.27 #DIV/0! 
O13-C12-N27-C26 161.60 159.83 -1.77 3.13 #DIV/0! 
O13-C12-N27-C23 1.35 -3.02 -4.36 19.04 #DIV/0! 
C12-N27-C26-C25 -141.22 -147.62 -6.40 41.01 #DIV/0! 
C12-N27-C26-H33 -20.50 -25.48 -4.98 24.77 #DIV/0! 
C12-N27-C26-H34 99.60 93.76 -5.84 34.10 #DIV/0! 
C23-N27-C26-C25 20.22 16.77 -3.45 11.91 #DIV/0! 
C23-N27-C26-H33 140.93 138.91 -2.02 4.10 #DIV/0! 
C23-N27-C26-H34 -98.97 -101.85 -2.89 8.34 #DIV/0! 
N27-C26-C25-C24 -34.73 -33.46 1.27 1.63 #DIV/0! 
N27-C26-C25-H31 -156.82 -156.03 0.78 0.61 #DIV/0! 
N27-C26-C25-H32 82.82 83.92 1.10 1.21 #DIV/0! 
205 
 
 
Table 30 
 
Cont. 
 
SB-674042 Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1)
H33-C26-C25-C24 -154.27 -155.28 -1.00 1.01 #DIV/0! 
H33-C26-C25-H31 83.64 82.15 -1.50 2.24 #DIV/0! 
H33-C26-C25-H32 -36.72 -37.90 -1.18 1.39 #DIV/0! 
H34-C26-C25-C24 83.80 82.54 -1.27 1.60 #DIV/0! 
H34-C26-C25-H31 -38.28 -40.04 -1.76 3.09 #DIV/0! 
H34-C26-C25-H32 -158.64 -160.08 -1.44 2.07 #DIV/0! 
C26-C25-C24-C23 37.07 38.24 1.18 1.38 #DIV/0! 
C26-C25-C24-H29 158.17 161.09 2.92 8.50 #DIV/0! 
C26-C25-C24-H30 -81.21 -79.74 1.47 2.15 #DIV/0! 
H31-C25-C24-C23 158.71 160.76 2.06 4.22 #DIV/0! 
H31-C25-C24-H29 -80.18 -76.39 3.80 14.41 #DIV/0! 
H31-C25-C24-H30 40.44 42.78 2.35 5.50 #DIV/0! 
H32-C25-C24-C23 -79.89 -78.95 0.93 0.87 #DIV/0! 
H32-C25-C24-H29 41.22 43.90 2.68 7.16 #DIV/0! 
H32-C25-C24-H30 161.84 163.07 1.22 1.50 #DIV/0! 
C25-C24-C23-N27 -24.80 -28.05 -3.25 10.59 #DIV/0! 
C25-C24-C23-C35 -148.54 -152.96 -4.42 19.51 #DIV/0! 
C25-C24-C23-H28 91.37 87.10 -4.26 18.16 #DIV/0! 
H29-C24-C23-N27 -147.17 -151.02 -3.85 14.81 #DIV/0! 
H29-C24-C23-C35 89.08 84.07 -5.01 25.12 #DIV/0! 
H29-C24-C23-H28 -31.01 -35.87 -4.86 23.58 #DIV/0! 
H30-C24-C23-N27 93.28 89.34 -3.94 15.51 #DIV/0! 
H30-C24-C23-C35 -30.47 -35.57 -5.10 26.03 #DIV/0! 
H30-C24-C23-H28 -150.56 -155.51 -4.95 24.47 #DIV/0! 
C12-N27-C23-C35 -70.06 -63.70 6.36 40.45 #DIV/0! 
C12-N27-C23-C24 165.59 171.89 6.30 39.72 #DIV/0! 
C12-N27-C23-H28 48.14 55.02 6.88 47.38 #DIV/0! 
C26-N27-C23-C35 127.17 131.58 4.41 19.43 #DIV/0! 
C26-N27-C23-C24 2.82 7.17 4.35 18.93 #DIV/0! 
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SB-674042 Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1)
C26-N27-C23-H28 -114.63 -109.70 4.93 24.32 #DIV/0! 
N27-C23-C35-C38 -53.31 -49.37 3.95 15.58 #DIV/0! 
N27-C23-C35-H36 68.62 71.67 3.04 9.27 #DIV/0! 
N27-C23-C35-H37 -173.34 -170.26 3.09 9.53 #DIV/0! 
C24-C23-C35-C38 65.13 69.70 4.56 20.83 #DIV/0! 
C24-C23-C35-H36 -172.93 -169.27 3.66 13.41 #DIV/0! 
C24-C23-C35-H37 -54.90 -51.19 3.70 13.72 #DIV/0! 
H28-C23-C35-C38 -172.66 -168.55 4.11 16.92 #DIV/0! 
H28-C23-C35-H36 -50.72 -47.51 3.21 10.31 #DIV/0! 
H28-C23-C35-H37 67.31 70.57 3.25 10.59 #DIV/0! 
C23-C35-C38-N39 -94.43 -99.66 -5.22 27.26 #DIV/0! 
C23-C35-C38-O42 85.55 81.08 -4.47 20.02 #DIV/0! 
H36-C35-C38-N39 143.45 138.64 -4.81 23.11 #DIV/0! 
H36-C35-C38-O42 -36.57 -40.63 -4.06 16.49 #DIV/0! 
H37-C35-C38-N39 26.12 21.70 -4.42 19.53 #DIV/0! 
H37-C35-C38-O42 -153.90 -157.57 -3.67 13.49 #DIV/0! 
C35-C38-O42-C41 -179.67 -179.20 0.47 0.22 #DIV/0! 
N39-C38-O42-C41 0.32 1.44 1.11 1.24 #DIV/0! 
C35-C38-N39-N40 179.66 179.62 -0.04 0.00 #DIV/0! 
O42-C38-N39-N40 -0.33 -1.08 -0.75 0.56 #DIV/0! 
C38-N39-N40-C41 0.20 0.24 0.04 0.00 #DIV/0! 
N39-N40-C41-C46 179.80 -178.94 1.25 1.57 #DIV/0! 
N39-N40-C41-O42 0.00 0.66 0.67 0.44 #DIV/0! 
C38-O42-C41-C46 179.99 178.40 -1.59 2.54 #DIV/0! 
C38-O42-C41-N40 -0.19 -1.25 -1.07 1.14 #DIV/0! 
N40-C41-C46-C45 174.40 173.31 -1.08 1.17 #DIV/0! 
N40-C41-C46-C47 -5.54 -5.87 -0.33 0.11 #DIV/0! 
O42-C41-C46-C45 -5.81 -6.27 -0.46 0.21 #DIV/0! 
O42-C41-C46-C47 174.25 174.55 0.30 0.09 #DIV/0! 
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SB-674042 Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1)
C41-C46-C45-C44 179.91 -179.40 0.69 0.47 #DIV/0! 
C41-C46-C45-H51 -0.57 0.02 0.58 0.34 #DIV/0! 
C47-C46-C45-C44 -0.16 -0.23 -0.07 0.01 #DIV/0! 
C47-C46-C45-H51 179.37 179.19 -0.18 0.03 #DIV/0! 
C41-C46-C47-C48 -179.95 179.52 -0.53 0.28 #DIV/0! 
C41-C46-C47-H52 -0.11 -0.49 -0.39 0.15 #DIV/0! 
C45-C46-C47-C48 0.11 0.33 0.22 0.05 #DIV/0! 
C45-C46-C47-H52 179.96 -179.68 0.36 0.13 #DIV/0! 
C46-C45-C44-C43 0.04 -0.01 -0.05 0.00 #DIV/0! 
C46-C45-C44-H50 -179.73 179.95 -0.32 0.10 #DIV/0! 
H51-C45-C44-C43 -179.48 -179.43 0.05 0.00 #DIV/0! 
H51-C45-C44-H50 0.75 0.52 -0.23 0.05 #DIV/0! 
C46-C47-C48-C43 0.05 -0.20 -0.26 0.07 #DIV/0! 
C46-C47-C48-H53 179.91 179.88 -0.03 0.00 #DIV/0! 
H52-C47-C48-C43 -179.80 179.81 -0.40 0.16 #DIV/0! 
H52-C47-C48-H53 0.07 -0.11 -0.17 0.03 #DIV/0! 
C47-C48-C43-C44 -0.17 -0.03 0.14 0.02 #DIV/0! 
C47-C48-C43-H49 179.83 -179.97 0.20 0.04 #DIV/0! 
H53-C48-C43-C44 179.97 179.88 -0.09 0.01 #DIV/0! 
H53-C48-C43-H49 -0.03 -0.06 -0.02 0.00 #DIV/0! 
C45-C44-C43-C48 0.12 0.14 0.02 0.00 #DIV/0! 
C45-C44-C43-H49 -179.88 -179.93 -0.05 0.00 #DIV/0! 
H50-C44-C43-C48 179.88 -179.82 0.29 0.09 #DIV/0! 
H50-C44-C43-H49 -0.11 0.12 0.23 0.05 #DIV/0! 
Largest absolute error 7.74580 59.99742 #DIV/0! 
RMS error 2.75208 #DIV/0! 
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Measurement comparisons for the dihedral angles were made for pyroglutamate-NMA 
with dihedral angles before optimization listed in Table 31.4,158,159,160,161,162,163,164,165,166,167   
 
Table 31 
 
Pyroglutamate-NMA Dihedral Angles Prior to 
Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Pyroglutamate-NMA Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
C9 -N8 -C  -CA -178.90 -179.55 -0.65 0.42 #DIV/0! 
C9 -N8 -C  -O  0.64 0.28 -0.35 0.12 #DIV/0! 
H16-N8 -C  -CA -1.20 -3.48 -2.28 5.19 #DIV/0! 
H16-N8 -C  -O  178.34 176.35 -1.99 3.94 #DIV/0! 
N8 -C  -CA -N  -5.64 -2.59 3.05 9.31 #DIV/0! 
N8 -C  -CA -CB 110.82 112.89 2.07 4.27 #DIV/0! 
N8 -C  -CA -HA  -128.89 -124.97 3.92 15.40 #DIV/0! 
O  -C  -CA -N  174.81 177.58 2.77 7.68 #DIV/0! 
O  -C  -CA -CB -68.73 -66.95 1.79 3.19 #DIV/0! 
O  -C  -CA -HA  51.55 55.19 3.65 13.29 #DIV/0! 
C  -CA -CB -CG -101.17 -98.56 2.61 6.83 #DIV/0! 
C  -CA -CB -HB1 22.65 25.29 2.64 6.98 #DIV/0! 
C  -CA -CB -HB2 141.66 143.26 1.61 2.58 #DIV/0! 
N  -CA -CB -CG 22.73 24.48 1.75 3.07 #DIV/0! 
N  -CA -CB -HB1 146.55 148.33 1.78 3.16 #DIV/0! 
N  -CA -CB -HB2 -94.44 -93.70 0.74 0.55 #DIV/0! 
HA -CA -CB -CG 141.71 140.79 -0.92 0.84 #DIV/0! 
HA -CA -CB -HB1 -94.47 -95.36 -0.89 0.79 #DIV/0! 
HA -CA -CB -HB2 24.53 22.61 -1.92 3.70 #DIV/0! 
C  -CA -N  -CD 109.92 110.01 0.08 0.01 #DIV/0! 
C  -CA -N  -HN  -83.69 -72.58 11.11 123.48 10000.32131
CB -CA -N  -CD -11.35 -11.94 -0.59 0.35 #DIV/0! 
CB -CA -N  -HN  155.04 165.47 10.43 108.88 10000.41076
HA -CA -N  -CD -129.95 -128.71 1.25 1.55 #DIV/0! 
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Table 31 
 
Cont. 
 
Pyroglutamate-NMA Dihedral Test Before CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) (degrees–1) 
HA -CA -N  -HN  36.44 48.71 12.27 150.67 10000.23393
CA -CB -CG -CD -25.96 -28.21 -2.25 5.06 #DIV/0! 
CA -CB -CG -HG3 90.72 89.55 -1.17 1.37 #DIV/0! 
CA -CB -CG -HG2 -146.25 -148.76 -2.50 6.27 #DIV/0! 
HB1-CB -CG -CD -148.10 -152.63 -4.53 20.51 #DIV/0! 
HB1-CB -CG -HG3 -31.41 -34.86 -3.45 11.91 #DIV/0! 
HB1-CB -CG -HG2 91.61 86.83 -4.78 22.88 #DIV/0! 
HB2-CB -CG -CD 90.49 89.69 -0.80 0.64 #DIV/0! 
HB2-CB -CG -HG3 -152.83 -152.55 0.28 0.08 #DIV/0! 
HB2-CB -CG -HG2 -29.80 -30.86 -1.05 1.11 #DIV/0! 
CA -N  -CD -CG -5.30 -5.71 -0.41 0.17 #DIV/0! 
CA -N  -CD -OE  175.90 177.25 1.35 1.81 #DIV/0! 
HN -N  -CD -CG -172.22 176.78 -11.00 120.93 10000.33369
HN -N  -CD -OE  8.97 -0.26 -9.24 85.36 10000.80723
N  -CD -CG -CB 19.80 20.91 1.11 1.22 #DIV/0! 
N  -CD -CG -HG3 -99.66 -98.61 1.05 1.10 #DIV/0! 
N  -CD -CG -HG2 142.72 142.64 -0.08 0.01 #DIV/0! 
OE -CD -CG -CB -161.43 -162.13 -0.71 0.50 #DIV/0! 
OE -CD -CG -HG3 79.11 78.35 -0.76 0.58 #DIV/0! 
OE -CD -CG -HG2 -38.51 -40.41 -1.90 3.59 #DIV/0! 
Largest absolute error 12.27 150.67 10000.23393
RMS error 4.16 #DIV/0! 
 
The pyroglutamate-NMA dihedral angles, after optimizing its bond lengths, bond angles, 
and dihedral torsion angles as had been done for SB-674042, were compiled in Table 
32.4,158,159,160,161,162,163,164,165,166,167   
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Table 32 
 
Pyroglutamate-NMA Dihedral Angles After Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Pyroglutamate-NMA Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) 
(degrees–
1) 
C9 -N8 -C  -CA -178.90 -179.49 -0.59 0.35 #DIV/0! 
C9 -N8 -C  -O  0.64 0.05 -0.59 0.35 #DIV/0! 
H16-N8 -C  -CA -1.20 -1.45 -0.25 0.06 #DIV/0! 
H16-N8 -C  -O  178.34 178.09 -0.25 0.06 #DIV/0! 
N8 -C  -CA -N  -5.64 -6.37 -0.73 0.54 #DIV/0! 
N8 -C  -CA -CB 110.82 107.92 -2.90 8.41 #DIV/0! 
N8 -C  -CA -HA  -128.89 -130.21 -1.32 1.73 #DIV/0! 
O  -C  -CA -N  174.81 174.07 -0.73 0.54 #DIV/0! 
O  -C  -CA -CB -68.73 -71.63 -2.90 8.40 #DIV/0! 
O  -C  -CA -HA  51.55 50.24 -1.31 1.73 #DIV/0! 
C  -CA -CB -CG -101.17 -94.39 6.78 46.02 #DIV/0! 
C  -CA -CB -HB1 22.65 29.19 6.54 42.76 #DIV/0! 
C  -CA -CB -HB2 141.66 147.74 6.09 37.03 #DIV/0! 
N  -CA -CB -CG 22.73 26.39 3.66 13.40 #DIV/0! 
N  -CA -CB -HB1 146.55 149.97 3.42 11.66 #DIV/0! 
N  -CA -CB -HB2 -94.44 -91.48 2.96 8.78 #DIV/0! 
HA -CA -CB -CG 141.71 147.63 5.93 35.14 #DIV/0! 
HA -CA -CB -HB1 -94.47 -88.79 5.68 32.29 #DIV/0! 
HA -CA -CB -HB2 24.53 29.76 5.23 27.35 #DIV/0! 
C  -CA -N  -CD 109.92 107.75 -2.17 4.71 #DIV/0! 
C  -CA -N  -HN  -83.69 -86.63 -2.94 8.64 #DIV/0! 
CB -CA -N  -CD -11.35 -11.90 -0.55 0.31 #DIV/0! 
CB -CA -N  -HN  155.04 153.72 -1.32 1.75 #DIV/0! 
HA -CA -N  -CD -129.95 -132.57 -2.62 6.88 #DIV/0! 
HA -CA -N  -HN  36.44 33.04 -3.39 11.50 #DIV/0! 
CA -CB -CG -CD -25.96 -31.07 -5.11 26.07 #DIV/0! 
CA -CB -CG -HG3 90.72 86.69 -4.04 16.29 #DIV/0! 
CA -CB -CG -HG2 -146.25 -151.39 -5.14 26.40 #DIV/0! 
HB1-CB -CG -CD -148.10 -155.32 -7.22 52.06 #DIV/0! 
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Table 32 
 
Cont. 
 
Pyroglutamate-NMA Dihedral Test After CHARMM Optimization 
Dihedral 
QM MM 
Difference Square Check 
Twist Twist 
(atoms) (degrees) (degrees) (degrees) (sq. deg.) 
(degrees–
1) 
HB1-CB -CG -HG3 -31.41 -37.56 -6.15 37.77 #DIV/0! 
HB1-CB -CG -HG2 91.61 84.37 -7.25 52.54 #DIV/0! 
HB2-CB -CG -CD 90.49 86.56 -3.93 15.41 #DIV/0! 
HB2-CB -CG -HG3 -152.83 -155.68 -2.86 8.16 #DIV/0! 
HB2-CB -CG -HG2 -29.80 -33.76 -3.96 15.66 #DIV/0! 
CA -N  -CD -CG -5.30 -7.78 -2.49 6.18 #DIV/0! 
CA -N  -CD -OE  175.90 174.60 -1.30 1.69 #DIV/0! 
HN -N  -CD -CG -172.22 -173.98 -1.76 3.09 #DIV/0! 
HN -N  -CD -OE  8.97 8.41 -0.57 0.32 #DIV/0! 
N  -CD -CG -CB 19.80 24.04 4.24 17.96 #DIV/0! 
N  -CD -CG -HG3 -99.66 -95.46 4.21 17.70 #DIV/0! 
N  -CD -CG -HG2 142.72 145.54 2.82 7.94 #DIV/0! 
OE -CD -CG -CB -161.43 -158.42 3.01 9.08 #DIV/0! 
OE -CD -CG -HG3 79.11 82.09 2.98 8.89 #DIV/0! 
OE -CD -CG -HG2 -38.51 -36.92 1.59 2.54 #DIV/0! 
Largest absolute error 7.25 52.54 #DIV/0! 
RMS error 3.80 #DIV/0! 
 
The resulting dihedral parameters, with repaired force constants (listed as Kχ in the 
parameter file), multiplicities (n), and offset constants (δ) highlighted for increased 
visibility, some extra parameters added with newer multiplicities for better optimization 
of these compounds, and the parameters for pyroglutamate and SB-674042 listed after the 
parameters used to connect pyroglutamate to peptides, are listed in Table 
33.4,137,158,159,160,161,162,163,164,165,166,167   
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Table 33 
 
Dihedral Parameters, with Repaired Parameters 
Highlighted.4,137,158,159,160,161,162,163,164,165,166,167   
 
Dihedral Parameters as listed in the parameter file 
Atom Atom Atom Atom 
Kχ(kcal mol–1) n (multiplicity) δ (degrees) Type 
1 
Type 
2 
Type 
3 
Type 
4 
CTY1 C N CP1 2.7500 2 180.00 
CTY1 C N CP1 0.3000 4 0.00 
CTY1 C N CP3 2.7500 2 180.00 
CTY1 C N CP3 0.3000 4 0.00 
CTY1 C NH1 CT1 1.6000 1 0.00 
CTY1 C NH1 CT1 2.5000 2 180.00 
H NH1 C CTY1 2.5000 2 180.00 
NH1 C CTY1 NH1 0.6000 1 0.00 
NH1 CTY1 C N 0.4000 1 0.00 
O C CTY1 NH1 0.0000 1 0.00 
O C N CP1 2.7500 2 180.00 
O C N CP1 0.3000 4 0.00 
O C N CP3 2.7500 2 180.00 
O C N CP3 0.3000 4 0.00 
O C NH1 CT1 2.5000 2 180.00 
O C NH1 H 2.5000 2 180.00 
N50 C53 C61 C61 1.0000 2 180.00 
N50X C53 C61 C61 1.1156 2 180.00 
O50 C53 C61 C61 1.0000 2 180.00 
O50X C53 C61 C61 1.1156 2 180.00 
C61 C53 N50 N50 8.5000 2 180.00 
C61 C53 N50X N50X 6.5616 2 180.00 
O50 C53 N50 N50 14.0000 2 180.00 
O50X C53 N50X N50X 13.9271 2 180.00 
HG52 C53 N50 N50 3.3000 2 180.00 
HG52 C53 N50X N50X 3.3000 2 180.00 
C61 C53 O50 C53 8.5000 2 180.00 
C61 C53 O50X C53 6.5280 2 180.00 
N50 C53 O50 C53 8.5000 2 180.00 
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Table 33 
 
Cont. 
 
Dihedral Parameters as listed in the parameter file 
Atom Atom Atom Atom 
Kχ(kcal mol–1) n (multiplicity) δ (degrees) Type 
1 
Type 
2 
Type 
3 
Type 
4 
N50X C53 O50X C53 8.5000 2 180.00 
HG52 C53 O50 C53 3.8000 2 180.00 
HG52 C53 O50X C53 3.8000 2 180.00 
C53 C61 C61 C61 5.2810 2 180.00 
C53 C61 C61 H61 3.9265 2 180.00 
C61 C61 C61 C61 3.1000 2 180.00 
C61 C61 C61 H61 4.2000 2 180.00 
H61 C61 C61 H61 2.4000 2 180.00 
C53 N50 N50 C53 14.0000 2 180.00 
C53 N50X N50X C53 12.9127 2 180.00 
OD1 CO1 NG0 C11 2.7500 2 180.00 
OD1 CO1 NG0 C11 0.3000 4 0.00 
OD1 CO1 NG0 C215 2.7500 2 180.00 
OD1 CO1 NG0 C215 0.3000 4 0.00 
HG52 CO1 NG0 C11 2.6000 2 180.00 
HG52 CO1 NG0 C215 2.6000 2 180.00 
N50X C53 C21 C11 0.3000 2 0.00 
N50X C53 C21 C11 -0.7000 4 0.00 
N50X C53 C21 C11 1.5000 3 180.00 
N50X C53 C21 C11 -1.3000 1 0.00 
N50X C53 C21 HG2 0.0000 3 0.00 
O50X C53 C21 C11 0.0000 1 180.00 
O50X C53 C21 HG2 0.0000 3 0.00 
C21 C53 N50X N50X 4.4143 2 180.00 
C21 C53 O50X C53 11.2830 2 180.00 
C53 C21 C11 C215 0.7000 3 0.00 
C53 C21 C11 NG0 0.3000 1 0.00 
C53 C21 C11 HG1 0.0000 3 0.00 
HG2 C21 C11 C215 0.0000 3 0.00 
HG2 C21 C11 NG0 0.0000 3 0.00 
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Table 33 
 
Cont. 
 
Dihedral Parameters as listed in the parameter file 
Atom Atom Atom Atom 
Kχ(kcal mol–1) n (multiplicity) δ (degrees) Type 
1 
Type 
2 
Type 
3 
Type 
4 
HG2 C21 C11 HG1 0.0000 3 0.00 
C21 C11 C215 C215 1.7900 3 0.00 
C21 C11 C215 HG2 0.1900 3 0.00 
NG0 C11 C215 C215 0.1400 3 0.00 
NG0 C11 C215 HG2 0.1400 3 0.00 
HG1 C11 C215 C215 0.1900 3 0.00 
HG1 C11 C215 HG2 0.1900 3 0.00 
C21 C11 NG0 CO1 0.8000 3 0.00 
C21 C11 NG0 CO1 0.0800 6 0.00 
C21 C11 NG0 C215 0.1000 3 0.00 
C21 C11 NG0 C215 0.0100 6 0.00 
C215 C11 NG0 CO1 0.8000 3 0.00 
C215 C11 NG0 CO1 0.0800 6 0.00 
C215 C11 NG0 C215 0.1000 3 0.00 
C215 C11 NG0 C215 0.0100 6 0.00 
HG1 C11 NG0 CO1 0.8000 3 0.00 
HG1 C11 NG0 CO1 0.0800 6 0.00 
HG1 C11 NG0 C215 0.1000 3 0.00 
HG1 C11 NG0 C215 0.0100 6 0.00 
C11 C215 C215 C215 0.4100 3 180.00 
C11 C215 C215 HG2 0.1900 3 0.00 
C215 C215 C215 NG0 0.1400 3 0.00 
C215 C215 C215 HG2 0.1900 3 0.00 
NG0 C215 C215 HG2 0.1400 3 0.00 
HG2 C215 C215 HG2 0.1900 3 0.00 
C215 C215 NG0 CO1 0.0000 3 180.00 
C215 C215 NG0 CO1 0.1000 6 180.00 
C215 C215 NG0 C11 0.1000 3 0.00 
HG2 C215 NG0 CO1 0.1000 6 180.00 
HG2 C215 NG0 CO1 0.0000 3 180.00 
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Table 33 
 
Cont. 
 
Dihedral Parameters as listed in the parameter file 
Atom Atom Atom Atom 
Kχ(kcal mol–1) n (multiplicity) δ (degrees) Type 
1 
Type 
2 
Type 
3 
Type 
4 
HG2 C215 NG0 C11 0.1000 3 0.00 
NG0 CO1 C51 C51 1.0000 2 180.00 
NG0 CO1 C51 N50Y 1.0000 2 180.00 
OD1 CO1 C51 C51 1.0000 2 180.00 
OD1 CO1 C51 N50Y 1.0000 2 180.00 
C51 CO1 NG0 C11 1.6000 1 0.00 
C51 CO1 NG0 C11 4.0000 2 180.00 
C51 CO1 NG0 C215 -6.3000 2 0.00 
C51 CO1 NG0 C215 0.8000 4 0.00 
C51 CO1 NG0 C215 0.4000 6 180.00 
CO1 C51 C51 S50Y 4.7453 2 180.00 
CO1 C51 C51 HG52 1.5000 2 180.00 
N50Y C51 C51 S50Y 27.9668 2 180.00 
N50Y C51 C51 HG52 3.0000 2 180.00 
CO1 C51 N50Y C53 5.7385 2 180.00 
C51 C51 N50Y C53 23.3184 2 180.00 
C51 C51 S50Y C53 31.8457 2 180.00 
HG52 C51 S50Y C53 5.5000 2 180.00 
N50Y C53 C31 HG3 0.0000 3 0.00 
S50Y C53 C31 HG3 0.0837 3 0.00 
C31 C53 N50Y C51 4.8178 2 180.00 
S50Y C53 N50Y C51 6.0000 2 180.00 
C31 C53 S50Y C51 10.4678 2 180.00 
N50Y C53 S50Y C51 8.5000 2 180.00 
HG3 C31 C11 C215 0.1600 3 0.00 
HG3 C31 C11 NG0 0.1950 3 0.00 
HG3 C31 C11 HG1 0.1600 3 0.00 
C31 C11 C215 C215 0.1900 3 0.00 
C31 C11 C215 HG2 0.1900 3 0.00 
C31 C11 NG0 CO1 0.8000 3 0.00 
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Table 33 
 
Cont. 
 
Dihedral Parameters as listed in the parameter file 
Atom Atom Atom Atom 
Kχ(kcal mol–1) n (multiplicity) δ (degrees) Type 
1 
Type 
2 
Type 
3 
Type 
4 
C31 C11 NG0 C215 0.1000 3 0.00 
C61 C51 C51 N50Y 6.2321 2 180.00 
C61 C51 C51 HG52 2.8000 2 180.00 
S50Y C51 C51 HG52 5.5000 2 180.00 
C51 C51 C61 C61 -4.6000 2 0.00 
C51 C51 C61 C61 0.1000 4 0.00 
C51 C51 C61 C61 0.3000 6 180.00 
C51 C51 C61 C61 0.5000 1 180.00 
C51 C51 C61 C61 0.0000 3 0.00 
C51 C51 C61 C66 0.0000 2 180.00 
S50Y C51 C61 C61 0.0000 2 180.00 
S50Y C51 C61 C66 0.0000 2 180.00 
HG52 C51 N50Y C53 3.0000 2 180.00 
C61 C51 S50Y C53 7.9685 2 180.00 
C51 C61 C61 C61 4.7027 2 180.00 
C51 C61 C61 H61 3.0813 2 180.00 
C61 C61 C61 C66 10.5440 2 180.00 
C61 C61 C61 H62 4.2000 2 180.00 
C66 C61 C61 H61 4.2000 2 180.00 
H61 C61 C61 H62 2.4000 2 180.00 
C51 C61 C66 C61 4.2284 2 180.00 
C51 C61 C66 FR1 5.9321 2 180.00 
C61 C61 C66 C61 13.6398 2 180.00 
C61 C61 C66 FR1 4.5000 2 180.00 
H62 C61 C66 C61 4.2000 2 180.00 
H62 C61 C66 FR1 2.4000 2 180.00 
NH1 C CTY1 CTY2 0.0000 1 0.00 
NH1 C CTY1 CTY2 0.0000 2 0.00 
NH1 C CTY1 HBY 0.0000 1 180.00 
NH1 C CTY1 HBY 0.0000 2 0.00 
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Table 33 
 
Cont. 
 
Dihedral Parameters as listed in the parameter file 
Atom Atom Atom Atom 
Kχ(kcal mol–1) n (multiplicity) δ (degrees) Type 
1 
Type 
2 
Type 
3 
Type 
4 
N C CTY1 CTY2 0.0000 1 0.00 
N C CTY1 CTY2 0.0000 2 0.00 
N C CTY1 HBY 0.0000 1 180.00 
N C CTY1 HBY 0.0000 2 0.00 
O C CTY1 CTY2 0.0000 1 180.00 
O C CTY1 CTY2 0.0000 2 0.00 
O C CTY1 CTY2 0.2000 6 180.00 
O C CTY1 HBY 0.0000 1 0.00 
O C CTY1 HBY 0.0000 2 0.00 
CTY1 C NH1 CTY3 1.6000 1 0.00 
CTY1 C NH1 CTY3 2.5000 2 180.00 
CTY1 C NH1 H5 2.5000 2 180.00 
O C NH1 CTY3 2.5000 2 180.00 
O C NH1 H5 2.5000 2 180.00 
NH1 CCY CTY2 CTY2 1.0500 3 180.00 
NH1 CCY CTY2 HAY 0.0000 3 180.00 
O CCY CTY2 CTY2 0.0800 3 0.00 
O CCY CTY2 HAY 0.0000 3 0.00 
CTY2 CCY NH1 CTY1 0.4000 2 180.00 
CTY2 CCY NH1 H 7.2700 2 180.00 
O CCY NH1 CTY1 2.5900 2 180.00 
O CCY NH1 H 0.8600 2 180.00 
HG3 CTY3 NH1 C 0.0000 3 0.00 
HG3 CTY3 NH1 H5 0.0000 3 0.00 
C CTY1 CTY2 CTY2 0.1400 3 0.00 
C CTY1 CTY2 HAY 0.1400 3 0.00 
NH1 CTY1 CTY2 CTY2 2.1300 3 0.00 
NH1 CTY1 CTY2 HAY 0.0000 3 180.00 
HBY CTY1 CTY2 CTY2 0.1900 3 0.00 
HBY CTY1 CTY2 HAY 0.1900 3 0.00 
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Table 33 
 
Cont. 
 
Dihedral Parameters as listed in the parameter file 
Atom Atom Atom Atom 
Kχ(kcal mol–1) n (multiplicity) δ (degrees) Type 
1 
Type 
2 
Type 
3 
Type 
4 
C CTY1 NH1 CCY 1.3478 3 180.00 
C CTY1 NH1 H 0.7600 3 0.00 
CTY2 CTY1 NH1 CCY 1.8314 3 180.00 
CTY2 CTY1 NH1 H 0.7600 3 180.00 
HBY CTY1 NH1 CCY 0.0000 3 0.00 
HBY CTY1 NH1 H 0.0000 3 180.00 
CCY CTY2 CTY2 CTY1 0.3400 3 180.00 
CCY CTY2 CTY2 HAY 0.0000 3 0.00 
CTY1 CTY2 CTY2 HAY 0.1900 3 0.00 
HAY CTY2 CTY2 HAY 0.1900 3 0.00 
CO1 C51 C51 C61 4.2491 2 180.00 
NG2 CO1 C51 C51 1.0000 2 180.00 
NG2 CO1 C51 N50Y 1.0000 2 180.00 
C51 CO1 NG2 HP1 1.0000 2 180.00 
OD1 CO1 NG2 HP1 1.4000 2 180.00 
 
The resulting improper dihedral parameters, with no necessary repairs determined or 
required to be made, are listed in Table 34.4,137,158,159,160,161,162,163,164,165,166,167   
 
Table 34 
 
Improper Dihedral Parameters.4,137,158,159,160,161,162,163,164,165,166,167   
 
Improper Parameters 
Atom Atom Atom Atom 
Kψ(kcal mol–1rad–2) ψ0(degrees) Type 1 Type 2 Type 3 Type 4 
N C CP1 CP3 0.0000 0.0000 
CO1 NG0 OD1 HG52 50.0000 0.0000 
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Table 34 
 
Cont. 
 
Improper Parameters 
Atom Atom Atom Atom 
Kψ(kcal mol–1rad–2) ψ0(degrees) Type 1 Type 2 Type 3 Type 4 
CO1 C51 NG0 OD1 120.0000 0.0000 
C CTY1 NH1 O 120.0000 0.0000 
CCY CTY2 NH1 O 90.0000 0.0000 
CO1 C51 NG2 OD1 120.0000 0.0000 
 
In the process of optimizing these bond, angle, and dihedral parameters, potential energy 
surfaces of these bonds, angles, and dihedrals were made, with the C1-C12 bond in SB-
674042 BAT Model Compound 1 illustrated in Figure 115, and the CD-OE bond in 
pyroglutamate illustrated as examples in Figure 116.4,137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 115. SB-674042 BAT Model Compound 1, with Bond C1-C12 Highlighted 
Green.137,158,159,160,161,162,163,164,165,166,167   
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Figure 116. Pyroglutamate-NMA, with Bond CD-OE Highlighted 
Green.4,158,159,160,161,162,163,164,165,166,167   
 
Since that bond connects the two rings of a compound that is absent from the 
CGenFF force field, and said bond was in need of repair, the potential energy surface of 
that same bond in SB-674042 BAT Model Compound 1 prior to parameter repair 
(namely the C51-C61 bond stretch parameter which atoms C12 and C1 represent, 
respectively) is shown in Figure 117, with a wide mismatch between the QM and MM 
energetic curves and minima.137,158,159,160,161,162,163,164,165,166,167   
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Figure 117. SB-674042 BAT Model Compound 1 Energy Profile for Bond C1-C12 
Before Parameter Optimization, with a Notably Differing Mismatch Between the QM and 
MM Energetic Minima.137,158,159,160,161,162,163,164,165,166,167   
 
The energy profile for the same C1-C12 bond in SB-674042 BAT Model Compound 1, 
but after bond length, bond angle, and dihedral angle optimization, with an improved 
energetic match between the QM minimum and the MM minimum, as well as the 
energetic curves of each, allowing both to line up almost perfectly, is shown in Figure 
118.137,158,159,160,161,162,163,164,165,166,167   
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Figure 118. SB-674042 BAT Model Compound 1 Energy Profile for Bond C1-C12 After 
Parameter Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
More energy profiles were created for pyroglutamate-NMA’s CD-OE bond representing 
the CCY-O bond stretch parameter, showing the mismatch of QM and MM energetic 
minima before, and a good lineup of QM and MM energetic minima after, bond length, 
bond angle, and dihedral angle parameter optimization.4,158,159,160,161,162,163,164,165,166,167  
The pyroglutamate-NMA bond CD-OE from before parameter optimization was 
performed shown in Figure 119.4,158,159,160,161,162,163,164,165,166,167   
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Figure 119. Pyroglutamate-NMA Energy Profile for Bond CD-OE Before Parameter 
Optimization, with a Notable Mismatch Between the QM and MM Energetic 
Minima.4,158,159,160,161,162,163,164,165,166,167   
 
As was shown in Figure 117 for SB-674042 BAT Model Compound 1’s C1-C12 bond 
and in Figure 119 for the pyroglutamate-NMA bond CD-OE, in both cases, the MM bond 
length was longer than the QM bond length, long enough to be outside the margin of 
QM-MM error, and the potential energy well to each side of the MM minimum was far 
shallower than that of the QM minimum, which allowed the MM compound to be more 
capable of deviating from its minimum, with these repaired bond parameters remedying 
that problem, and the potential energy surface for the pyroglutamate bond CD-OE after 
parameter optimization is shown in Figure 120.4,158,159,160,161,162,163,164,165,166,167   
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Figure 120. Pyroglutamate-NMA Energy Profile for Bond CD-OE After Parameter 
Optimization, with an Excellent Match Between the QM and MM Energetic 
Minima.4,158,159,160,161,162,163,164,165,166,167   
 
As was seen in Figures 118 and 120, the implications of parameter repair are quite 
important, as not only does parameter optimization improve how well the QM and MM 
minima match up, it also improves the energetic wells’ depth, allowing the MM 
compounds to be kept closer to their energetic minima, which already match up with the 
QM minima.4,137,158,159,160,161,162,163,164,165,166,167  With that point made very clear, the 
example angles’ potential energy surfaces will be shown, with SB-674042 BAT Model 
Compound 1’s Bond Angle C1-C12-N13 and its energy profile prior to optimization 
illustrated in Figures 121 and 122.137,158,159,160,161,162,163,164,165,166,167   
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Figure 121. SB-674042 BAT Model Compound 1, with Angle C1-C12-N13 Highlighted 
Green.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 122. SB-674042 BAT Model Compound 1 Energy Profile for Angle C1-C12-N13 
Before Parameter Optimization.137,158,159,160,161,162,163,164,165,166,167   
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The minima prior to parameter optimization did not line up well, but such is not the case 
after optimization, as shown in Figure 123 for that same angle, which did line up both the 
QM and MM minima and energetic wells quite well.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 123. SB-674042 BAT Model Compound 1 Energy Profile for Angle C1-C12-N13 
After Parameter Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
This angle optimization was also important in the pyroglutamate-NMA compound, as it 
would also be important to optimize any angle that connects atoms within a ring, unlike 
SB-674042 BAT Model Compound 1’s C1-C12 bond or C1-C12-N13 angle, which each 
connect the two rings of that compound, or the CD-OE bond in pyroglutamate-NMA, 
which connects a ring carbon (CD) with its carbonyl oxygen (OE), with pyroglutamate-
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NMA’s Bond Angle C-CA-CB and its energy profile prior to optimization illustrated in 
Figures 124 and 125.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 124. Pyroglutamate-NMA, with Angle C-CA-CB Highlighted 
Green.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 125. Pyroglutamate-NMA Energy Profile for Angle C-CA-CB Before Parameter 
Optimization.4,158,159,160,161,162,163,164,165,166,167   
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That MM bond angle energy profile was very different from the corresponding QM 
profile, as would be expected, but after parameter optimization, the energy profiles match 
extremely well, as seen in Figure 126.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 126. Pyroglutamate-NMA Energy Profile for Angle C-CA-CB After Parameter 
Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Lastly, it is important that the dihedral minima match up, with less regard to the energetic 
peaks, as the minima would be the most populated areas on an energy profile, especially 
if the dihedral in question is an amide bond.137,158,159,160,161,162,163,164,165,166,167  This would 
be the case, especially due to its high (at least 18 kcal/mol) energy barriers, for SB-
674042 BAT Model Compound 3’s amide bond C3-C11-N24-C16 (with intent to 
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resemble that of a proline)3,137 and its corresponding energy profile prior to parameter 
optimization, as shown in Figures 127 and 128.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 127. SB-674042 BAT Model Compound 3, with Dihedral C3-C11-N24-C16 
Highlighted Green.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 128. SB-674042 BAT Model Compound 3 Energy Profile for Dihedral C3-C11-
N24-C16 Before Parameter Optimization.137,158,159,160,161,162,163,164,165,166,167   
230 
 
 
With 10-degree increments between each dihedral measurement, the minimum at a 
certain dihedral measurement would have to be between the two lowest energy values, 
thus showing that the global minimum has to be moved closer to 0°, as opposed to ~+5° 
as seen in Figure 128.137,158,159,160,161,162,163,164,165,166,167  Figure 129 illustrates the tradeoff 
of raising the energy barriers to cis/trans conversion for this dihedral in exchange for 
centering the minima at 0° and 180°, after optimization.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 129. SB-674042 BAT Model Compound 3 Energy Profile for Dihedral C3-C11-
N24-C16 After Parameter Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
That repair allowed all of the amide-centered dihedrals of SB-674042 BAT Model 
Compound 3, and by extension SB-674042, to fall within the margin of error for a 
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dihedral measurement.137,158,159,160,161,162,163,164,165,166,167  Another example of a dihedral 
potential energy surface is Figures 130 and 131.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 130. Pyroglutamate-NMA, with Dihedral CB-CA-N-HN Highlighted 
Green.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 131. Pyroglutamate-NMA Energy Profile for Dihedral CB-CA-N-HN Before 
Parameter Optimization.4,158,159,160,161,162,163,164,165,166,167   
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The resulting MM energy profile had a minimum that was very far from the QM 
minimum, and the misplacement of HN was responsible for all of the MM dihedral 
measurements that were outside the margin of error, but repair of the adjacent CTY2-
CCY-NH1-H dihedral parameter (representing the CG-CD-N-HN dihedral) beneficially 
impacted this dihedral and the other four that needed repair, as shown in Figure 
132.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 132. Pyroglutamate-NMA Energy Profile for Dihedral CB-CA-N-HN After 
Parameter Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
The difference between the QM and MM energetic minima was reduced to well within 
the acceptable margin of error, and both of the energetic wells were deep enough to allow 
the cis-amide to maintain its planarity in any situation.4,158,159,160,161,162,163,164,165,166,167  As 
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a result, the parameters were created, and were ready to test on the global and local 
minima of SB-674042, and the global minimum of pyroglutamate-NMA using the “eye 
test.”4,137,158,159,160,161,162,163,164,165,166,167   
Eye Test of Parameters Using Local and Global Minima of SB-674042 
  Two local minima of SB-674042 were used alongside the global minimum of SB-
674042 as part of an eye test to determine the overall appearance of SB-674042 once 
minimized with the new CHARMM parameters, with the QM global minimum and its 
pre-optimized MM counterpart shown in Figure 133.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 133. SB-674042 QM Global Minimum (Magenta Carbons) and the MM Global 
Minimum (Teal Carbons), the Latter Using the Bond Length, Bond Angle, and Dihedral 
Torsion Angle Parameters Prior to Their Optimization.137,158,159,160,161,162,163,164,165,166,167   
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A notable improvement in MM parameters became apparent with the newer optimized 
MM global minimum of SB-674042 being closer all-around to the QM global minimum 
than the pre-optimized MM global minimum was, especially within the tail phenyl and 
1,3,4-oxadiazole end of SB-674042, with the QM global minimum and its optimized MM 
counterpart shown in Figure 134.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 134. SB-674042 QM Global Minimum (Magenta Carbons) and the MM Global 
Minimum (Teal Carbons), the Latter Using the Bond Length, Bond Angle, and Dihedral 
Torsion Angle Parameters After Their Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
With a large improvement of parameters apparent in the global minimum, the local 
minima had to be consulted as well to show how the parameters improved their 
structures, with the two local minima being the “unpopped” global minimum of SB-
674042 (the global minimum of the “unpopped” conformational search that still had a 
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higher energy than the true global minimum) and a local minimum of the conformational 
search of the “popped” SB-674042, and the first of these is the QM “unpopped” global 
minimum and its MM-pre-optimized counterpart, as is shown in Figure 
135.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 135. SB-674042 QM “Unpopped” Global Minimum (Magenta Carbons) 
and the MM “Unpopped” Global Minimum (Teal Carbons), the Latter Using the  
Bond Length, Bond Angle, and Dihedral Torsion Angle Parameters Prior to Their 
Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
The overall structure SB-674042 showed an on-average improvement, and individual 
parts improved as well, especially the head fluorophenyl and 1,3-thiazole end of SB-
674042, when the newer optimized bond length, bond angle, and dihedral torsion angle 
parameters were used in place of the older pre-optimized parameters to minimize the MM 
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“unpopped” global minimum and superimpose it on the QM “unpopped” global 
minimum, with those two structures shown in Figure 136.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 136. SB-674042 QM “Unpopped” Global Minimum (Magenta Carbons) 
and the MM “Unpopped” Global Minimum (Teal Carbons), the Latter Using the  
Bond Length, Bond Angle, and Dihedral Torsion Angle Parameters After Their 
Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
The last local minimum that had to be consulted was a local minimum of the “popped” 
SB-674042 conformational search, and the QM structure and its pre-optimized MM 
counterpart were superimposed, with a notable difference in structure between the QM 
and MM structures.137,158,159,160,161,162,163,164,165,166,167  The MM structure especially had a 
greatly errant tail phenyl and 1,3,4-oxadiazole end of SB-674042, with the MM structure 
237 
 
 
having a C23-C35-C38-O42 dihedral angle that was ~50° less than that of the QM 
structure, as both structures are shown in Figure 137.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 137. SB-674042 QM “Popped” Local Minimum (Magenta Carbons) and the MM 
“Popped” Local Minimum (Teal Carbons), the Latter Using the Bond Length, Bond 
Angle, and Dihedral Torsion Angle Parameters Before 
Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
When the optimized bond length, bond angle, and dihedral torsion angle parameters were 
used to minimize the “popped” local minimum, virtually everything in the MM structure 
improved, as the C23-C35-C38-O42 dihedral angle error between the MM and QM 
structures was reduced to as little as ~3°, and the optimized MM head fluorophenyl and 
1,3-thiazole end fit much more closely together with their QM counterparts than the 
corresponding pre-optimized MM parts did.137,158,159,160,161,162,163,164,165,166,167  This is 
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shown by superimposing the MM “popped” local minimum with optimized parameters 
on its QM counterpart, as is shown in Figure 138.137,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 138. SB-674042 QM “Popped” Local Minimum (Magenta Carbons) and the MM 
“Popped” Local Minimum (Teal Carbons), the Latter Using the Bond Length, Bond 
Angle, and Dihedral Torsion Angle Parameters After Their 
Optimization.137,158,159,160,161,162,163,164,165,166,167   
 
Eye Test of Parameters Using the Global Minimum of Pyroglutamate-NMA 
  A similar eye test to that of SB-674042 was performed on pyroglutamate-NMA 
using the global minimum of pyroglutamate-NMA, and since it was a far smaller 
molecule than SB-674042, pyroglutamate-NMA’s global minimum was used for this 
experiment.4,158,159,160,161,162,163,164,165,166,167  This global minimum was minimized first 
with the pre-optimized bond length, bond angle, and dihedral torsion angle parameters, 
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then with the optimized parameters, and the pre-optimized MM global minimum of 
pyroglutamate-NMA was superimposed on its QM counterpart, as shown in Figure 
139.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 139. Pyroglutamate-NMA QM Global Minimum (Magenta Carbons) and the MM 
Global Minimum (Teal Carbons), the Latter Using the Bond Length, Bond Angle, and 
Dihedral Torsion Angle Parameters Prior to Their 
Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
Very little was required to be fixed, namely the HN that was pointed slightly differently 
in the pre-optimized MM structure, as well as CD-OE being too long and C-CA-CB 
being spread too wide, and using the optimized bond length, bond angle, and dihedral 
torsion angle parameters allowed all of those issues to be properly addressed for the MM 
structure.4,158,159,160,161,162,163,164,165,166,167  The MM global minimum was minimized using 
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these newer optimized parameters and superimposed onto the QM global minimum, as is 
shown in Figure 140.4,158,159,160,161,162,163,164,165,166,167   
 
 
 
Figure 140. Pyroglutamate-NMA QM Global Minimum (Magenta Carbons) and the MM 
Global Minimum (Teal Carbons), the Latter Using the Bond Length, Bond Angle, and 
Dihedral Torsion Angle Parameters After Their 
Optimization.4,158,159,160,161,162,163,164,165,166,167   
 
 The newly optimized parameters were then ready to use in MD 
simulations.4,137,158,159,160,161,162,163,164,165,166,167   
Molecular Dynamics RMSD, Dihedral, and Distance Measurements Results 
  The MD experiments produced two successful orexin-1 receptor models, with one 
of them an R model with SB-674042 bound,3,7,24,175,176 and the other an R* model with 
orexin-A bound.3,4,7,22,24,175,176  These bundles had RMSD measurement graphs of the 
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protein backbone and of the TMH Cαs, distance measurement graphs, dihedral 
measurement graphs, and component interaction energy comparison tables taken, along 
with pictures and videos of the structures.   
  The RMSD of the R state ox1r backbone was ~3.2, showing the bundle’s overall 
stability as it settled at this number very early on as seen in Figure 141.3,7,24,175,176   
 
 
Figure 141. Graph of the RMSD for the Ox1r R Simulation Protein Backbone.3,7,24,175,176   
 
This is due to the ox2r crystal structure being used as a basis for the R structure, allowing 
for a vast improvement in structural stability as the ox2r crystal structure was already a 
stable structure.3,7,24  It also would not be as likely to rip apart as a “pull-apart-and-
minimize” ox1r model, as the higher identity and homology of the ox2r crystal structure 
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made it a better basis for the ox1r models than the CM output and the corresponding 
superposition templates did.3,7,24,133,147,188   
  The RMSD of the R state’s transmembrane Cαs was ~1.4, showing its stability in 
the transmembrane core as it settled at this number early in the trajectory.3,7,24,175,176  This 
is also due to the use of the ox2r crystal structure as the ox1r R model’s structural basis, 
and is visible in Figure 142.3,7,24,175,176   
 
 
Figure 142. Graph of the RMSD for the Ox1r R Simulation Transmembrane Helix Cα 
Atoms.3,7,24,175,176   
 
  These RMSD measurements were as predicted, thus leading to the next phase of 
analysis:  dihedral and distance measurement, with the hypothesis that the measurements 
would correspond to experimental data.3,7,24,124,125,126,127,128,129,130,175,176   
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  The ox1r R structure had the Y6.48 χ1 dihedral measured, with the measurement 
and graph as shown in Figures 143 and 144.3,7,24,124,125,126,127,128,129,130,175,176   
 
 
 
Figure 143. The Y6.48 χ1 Dihedral from the R Simulation.3,7,24,124,125,126,127,128,129,130,175,176   
 
 
 
Figure 144. Graph of the Y6.48 χ1 Dihedral for the R 
Simulation.3,7,24,124,125,126,127,128,129,130,175,176   
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Y6.48 never deviated from its g+ conformation throughout the simulation, consistent with 
an inactive GPCR’s X6.48 χ1 dihedral.3,7,24,124,125,126,127,128,129,130,175,176   
  The ox1r R3.50-R6.30 Cα-Cα distance in the R simulation is shown in Figure 
145.3,7,24,124,125,126,127,128,129,130,175,176   
 
 
 
Figure 145. Picture of the R3.50-R6.30 Cα-Cα Distance from the R 
Simulation.3,7,24,124,125,126,127,128,129,130,175,176   
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  The ox1r R3.50-R6.30 Cα-Cα distance in the R simulation is graphed in Figure 
146.3,7,24,124,125,126,127,128,129,130,175,176   
 
 
Figure 146. Graph of the R3.50-R6.30 Cα-Cα Distance for the R 
Simulation.3,7,24,124,125,126,127,128,129,130,175,176   
 
The R3.50-R6.30 Cα-Cα distance was ~9.2 Å for much of the trajectory, consistent with 
an inactive GPCR’s R3.50-X6.30 Cα-Cα distance.3,7,24,124,125,126,127,128,129,130,175,176   
  Three of the R simulation’s newest interactions formed between F5.42 and the 
head fluorophenyl of SB-674042, between F5.42 and the thiazole group, and between 
H7.39 and SB-674042’s 1,3,4-oxadiazole group, since at the start of the simulation F5.42 
interacted by van der Waals and by π-π T-stacks with both groups, and Y6.48 only by 
van der Waals with the thiazole group.3,7,24,175,176  Hence, new measurements must be 
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collected from this trajectory.3,7,24,175,176  The ox1r I3.28-SB-674042 Cβ-C43 distance in 
the R simulation is shown and graphed in Figures 147 and 148.3,7,24,175,176   
 
 
 
Figure 147. The R Simulation’s I3.28-SB-674042 Cβ-C43 Distance.3,7,24,175,176   
 
 
Figure 148. Graph of the R Simulation’s I3.28-SB-674042 Cβ-C43 Distance.3,7,24,175,176   
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The ox1r F5.42-SB-674042 Cγ-C1 distance in the R simulation is shown and graphed in 
Figures 149 and 150.3,7,24,175,176   
 
 
 
Figure 149. The R Simulation’s F5.42-SB-674042 Cγ-C1 Distance.3,7,24,175,176   
 
 
 
Figure 150. Graph of the R Simulation’s F5.42-SB-674042 Cγ-C1 Distance.3,7,24,175,176 
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The ox1r H7.39-SB-674042 Cδ2-C25 distance in the R simulation is shown and graphed 
in Figures 151 and 152.3,7,24,175,176   
 
 
 
Figure 151. The R Simulation’s H7.39-SB-674042 Cδ2-C25 Distance.3,7,24,175,176   
 
 
 
Figure 152. Graph of the R Simulation’s H7.39-SB-674042 Cδ2-C25 Distance.3,7,24,175,176   
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The I3.28-SB-674042 Cβ-C43 distance in the R simulation was ~4.3 Å, consistent with 
SB-674042’s ability to use its phenyl ring to interact by van der Waals from the nearby 
I3.28.3,7,24,175,176  The F5.42-SB-674042 Cγ-C1 distance in the R simulation was ~5.7 Å, 
consistent with SB-674042’s ability to use its fluorophenyl ring to interact by van der 
Waals with the nearby F5.42.3,7,24,175,176  The H7.39-SB-674042 Cδ2-C25 distance in the 
R simulation was ~3.9 Å, consistent with SB-674042’s ability to use its proline-like ring 
to interact by van der Waals with the nearby H7.39.3,7,24,137,175,176   
  The ox1r Y6.48-SB-674042 Cζ-S17 distance in the R simulation is graphed in 
Figure 153.3,7,24,175,176   
 
 
 
Figure 153. Graph of the Y6.48-SB-674042 Cζ-S17 Distance for the R 
Simulation.3,7,24,175,176   
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  The ox1r Y6.48-SB-674042 Cζ-S17 distance in the R simulation is shown in 
Figure 154.3,7,24,175,176   
 
 
 
Figure 154. The Y6.48-SB-674042 Cζ-S17 Distance from the R Simulation.3,7,24,175,176   
 
The Y6.48-SB-674042 Cζ-S17 distance in the R simulation was ~4.8 Å, consistent with 
SB-674042’s ability to use its thiazole ring to interact by numerous van der Waals 
contacts with the nearby Y6.48, as well as the ability of that part of SB-674042 to hold 
Y6.48 in g+.3,7,24,124,125,126,127,128,129,130,175,176   
251 
 
 
  The interaction between Q3.32 and SB-674042 at the start and end of the R 
simulation are shown in Figures 155 and 156.3,7,24,175,176   
 
 
 
Figure 155. The Q3.32-SB-674042 Interaction at the Start of the R Simulation.3,7,24,175,176   
 
 
 
Figure 156. The Q3.32-SB-674042 Interaction at the End of the R Simulation.3,7,24,175,176   
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The distance in the R simulation between Q3.32’s Nε2 and SB-674042’s oxadiazole ring 
nitrogen N40 was steady at ~3.2 Å, and SB-674042 got no farther away from Q3.32.3,7,24  
The interaction between the two was excellent, as the original interaction was a hydrogen 
bond between the two, as well as having SB-674042 additionally draped around Q3.32 at 
the end, interacting heavily by van der Waals contacts over a large surface area, with the 
distance illustrated in Figure 157.3,7,24,175,176   
 
 
Figure 157. Graph of the Q3.32-SB-674042 Nε2-N40 Distance for the R 
Simulation.3,7,24,175,176   
 
  The R model’s Q3.32 had a good binding energy with SB-674042, which had 
several π-stacking interactions with F5.42 and with H7.39, as the former (especially via 
the thiazole) kept Y6.48 in g+.3,7,24,124,125,126,127,128,129,130,175,176   
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  The RMSD of the R* state ox1r backbone was ~4.5, showing the bundle’s overall 
stability during its run as it settled at this number very early on as seen in Figure 
158.3,4,7,22,24,175,176   
 
 
 
Figure 158. Graph of the RMSD for the Ox1r R* Simulation Protein 
Backbone.3,4,7,22,24,175,176   
 
This is due to the ox2r crystal structure being used as a basis for the R* structure, 
allowing for a vast improvement in structural stability as the ox2r crystal structure was 
already a stable structure.3,4,7,22,24  It also would not be as likely to rip apart as a “pull-
apart-and-minimize” ox1r model, as the higher identity and homology of the ox2r crystal 
structure made it a better basis for the ox1r models than the CM output and the 
corresponding superposition templates did, even if the R* model of ox1r requires a partial 
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replacement of TMH6 with CM output as part of its 
structure.3,4,7,22,24,124,125,126,127,128,129,130,133,143,147,188   
  The RMSD of the R* state’s transmembrane Cαs was ~1.4, showing its stability 
in the transmembrane core as it settled at this number early in the trajectory.3,4,7,22,24,175,176  
This is also due to the use of the ox2r crystal structure as the ox1r R* model’s structural 
basis, and is visible in Figure 159.3,4,7,22,24,175,176   
 
 
Figure 159. Graph of the RMSD for the Ox1r R* Simulation  
Transmembrane Helix Cα Atoms.3,4,7,22,24,175,176   
 
  These RMSD measurements were as predicted, thus leading to the next phase of 
analysis:  dihedral and distance measurement, with the hypothesis that the measurements 
would correspond to experimental data.3,4,7,22,24,124,125,126,127,128,129,130,175,176   
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  The R* structure had its Y6.48 χ1 dihedral measured, as shown in Figures 160 
and 161.3,4,7,22,24,124,125,126,127,128,129,130,175,176   
 
 
 
Figure 160. The Y6.48 χ1 Dihedral from the R* 
Simulation.3,4,7,22,24,124,125,126,127,128,129,130,175,176   
 
 
 
Figure 161. Graph of the Y6.48 χ1 Dihedral for the R* 
Simulation.3,4,7,22,24,124,125,126,127,128,129,130,175,176   
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The R* structure’s Y6.48 χ1 dihedral was in a trans conformation throughout the 
simulation, consistent with an active GPCR’s X6.48 χ1 
dihedral.3,4,7,22,24,124,125,126,127,128,129,130,175,176   
  The R3.50-R6.30 Cα-Cα distance in the R* simulation was ~13.6 Å, as shown in 
Figure 162.3,4,7,22,24,124,125,126,127,128,129,130,139,141,143,175,176   
 
 
 
Figure 162. The R3.50-R6.30 Cα-Cα Distance from the R* 
Simulation.3,4,7,22,24,124,125,126,127,128,129,130,139,141,143,175,176   
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 The ox1r R3.50-R6.30 Cα-Cα distance in the R* simulation is graphed in Figure 
163.3,4,7,22,24,124,125,126,127,128,129,130,139,141,143,175,176   
 
 
 
Figure 163. Graph of the R3.50-R6.30 Cα-Cα Distance for the R* 
Simulation.3,4,7,22,24,124,125,126,127,128,129,130,139,141,143,175,176   
 
This R3.50-R6.30 distance measurement was consistent with an active GPCR’s R3.50-
X6.30 Cα-Cα distance, as it would be far enough apart to neither permit T6.33 to accept a 
hydrogen bond from R3.50, nor permit R6.30 to accept an arginine-arginine T-stack from 
R3.50.3,4,7,22,24,124,125,126,127,128,129,130,139,141,143,175,176   
  Two unique interactions are the van der Waals interactions between F5.42 and 
orexin-A’s L33, along with Y6.48 and orexin-A’s L33, with measurements of the 
distances between F5.42’s Cζ and L33’s Cγ, and between Y6.48’s Cζ and L33’s Cγ, 
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respectively.  The ox1r F5.42-orexin-A L33 Cζ-Cγ distance in the R* simulation is 
shown and graphed in Figures 164 and 165.3,4,7,22,24,175,176   
 
 
 
Figure 164. The R* Simulation’s F5.42-orexin-A L33 Cζ-Cγ Distance.3,4,7,22,24,175,176   
 
 
 
Figure 165. Graph of the R* Simulation’s F5.42-orexin-A L33 Cζ-Cγ 
Distance.3,4,7,22,24,175,176   
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The F5.42-orexin-A L33 Cζ-Cγ distance was ~5.0 Å, consistent with orexin-A L33’s 
ability to interact by a van der Waals interaction with the nearby F5.42, but though that 
interaction breaks, L33 can find other residues with which it can interact, and F5.42 
remains an important residue for other reasons, such as maintaining ox1r 
stability.3,4,7,22,24,175,176   
  The ox1r Y6.48-orexin-A L33 Cζ-Cγ distance in the R* simulation is shown in 
Figure 166.3,4,7,22,24,175,176   
 
 
 
Figure 166. The R* Simulation’s Y6.48-orexin-A L33 Cζ-Cγ Distance.3,4,7,22,24,175,176   
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 The ox1r Y6.48-orexin-A L33 Cζ-Cγ distance in the R* simulation is graphed in 
Figure 167.3,4,7,22,24,175,176   
 
 
Figure 167. Graph of the R* Simulation’s Y6.48-orexin-A L33 Cζ-Cγ 
Distance.3,4,7,22,24,175,176   
 
The Y6.48-orexin-A L33 Cζ-Cγ distance in the R* simulation was ~6 Å, consistent with 
orexin-A’s ability to use its L33 to interact by van der Waals contacts with the nearby 
Y6.48, as well as its ability to hold Y6.48 in 
trans.3,4,7,22,24,124,125,126,127,128,129,130,133,142,143,175,176   
  Nine more distances in the R* simulation were measured:  H7.39-orexin-A L31 
Nε2-O, orexin-A L33-orexin-A T32 N-Oγ1, D45.51-orexin-A H26 Cγ-Nδ1, C45.50-
orexin-A H26 O-Nδ1, I3.28-orexin-A L31 Cβ-Cγ, C45.50-orexin-A L31 Sγ-Cγ, P3.29-
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orexin-A L33 O-NT, R6.59-orexin-A L33 Cζ-O, and V45.49-orexin-A L20 Cβ-
Cγ.3,4,7,22,24,175,176  The first of these distances measures an interaction that is hypothesized 
to be the reason for H7.39’s role in orexin-A binding in the ox1r, and the atoms involved 
in the R* simulation’s H7.39-orexin-A L31 Nε2-O distance are shown in Figure 
168.3,4,7,22,24,175,176   
 
 
 
Figure 168. The R* Simulation’s H7.39-orexin-A L31 Nε2-O Distance.3,4,7,22,24,175,176   
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The measurement, which was ~3.5 Å, of the R* simulation’s H7.39-orexin-A L31 Nε2-O 
distance is shown in Figure 169.3,4,7,22,24,175,176   
 
 
Figure 169. Graph of the R* Simulation’s H7.39-orexin-A L31 Nε2-O 
Distance.3,4,7,22,24,175,176   
 
This measurement shows that H7.39 changes its hydrogen bond acceptor partner from the 
backbone oxygen of oxA’s T32 to that of oxA’s L31 amidst competition from water and 
from S2.61.3,4,7,22,24,175,176   
  The orexin-A residue T32 faced competition from water and R6.59 for E45.52’s 
carboxylate side chain, and the interaction broke as a result, but it was nevertheless 
important.3,4,7,22,24,175,176  This is because T32 accepts an internal hydrogen bond from 
L33’s amide hydrogen that stabilized orexin-A’s C-terminus so that it could interact by 
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three hydrogen bonds:  one with R6.59’s guanidinium side chain, one with P3.29’s amide 
oxygen, and one with Q3.32’s amide side chain.3,4,7,22,24,175,176  If T32 is mutated to an 
alanine, this internal hydrogen bond is lost completely, and the C-terminal orexin-A 
backbone has no energetic reason to attain this conformation.3,4,7,22,24,175,176  If T32 is 
chirally inverted, this internal hydrogen bond flipped around, and the C-terminal orexin-
A backbone attains a different conformation that is not amenable to binding in the 
ox1r.3,4,7,22,24,175,176  The measurements in the orexin-A L33-orexin-A T32 N-Oγ1 
measurement in the R* simulation are shown in Figure 170, with the measurement being 
~3.0 Å.3,4,7,22,24,175,176   
 
 
 
Figure 170. Graph of the R* Simulation’s orexin-A L33-orexin-A T32 N-Oγ1 
Distance.3,4,7,22,24,175,176   
 
264 
 
 
The atoms in the orexin-A L33-orexin-A T32 N-Oγ1 measurement in the R* simulation 
are shown in Figure 171.3,4,7,22,24,175,176   
 
 
 
Figure 171. The R* Simulation’s Orexin-A L33-orexin-A T32 N-Oγ1 
Distance.3,4,7,22,24,175,176   
 
  The next two distances concern the residue H26, which is hypothesized to donate 
a hydrogen bond to D45.51, as that bond could be a reason for D45.51’s and H26’s 
respective roles in oxA binding in the ox1r, yet H26 transitions to donate a hydrogen 
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bond to C45.50’s backbone oxygen at the end, keeping it involved.3,4,7,22,24,175,176  The 
atoms in the D45.51-orexin-A H26 Cγ-Nδ1 measurement in the R* simulation are shown 
in Figure 172, with the measurements in Figure 173.3,4,7,22,24,175,176   
 
 
 
Figure 172. The R* Simulation’s D45.51-oxA H26 Cγ-Nδ1 Distance.3,4,7,22,24,175,176   
 
 
 
Figure 173. Graph of the R* Simulation’s D45.51-oxA H26 Cγ-Nδ1 
Distance.3,4,7,22,24,175,176   
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The atoms in the C45.50-orexin-A H26 O-Nδ1 measurement in the R* simulation are 
shown in Figure 174, with the measurements in Figure 175.3,4,7,22,24,175,176   
 
 
 
Figure 174. The R* Simulation’s C45.50-oxA H26 O-Nδ1 Distance.3,4,7,22,24,175,176   
 
 
 
Figure 175. Graph of the R* Simulation’s C45.50-oxA H26 O-Nδ1 
Distance.3,4,7,22,24,175,176   
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The measurement of D45.51-orexin-A H26 Cγ-Nδ1 was ~3.5 Å, while the measurement 
of C45.50-orexin-A H26 O-Nδ1 was ~3.8 Å at the end, showing that H26 faced 
competition from water and from R45.53, and therefore shifted its hydrogen bond 
acceptor to the far less mobile C45.50 amide oxygen.3,4,7,22,24,175,176   
  The next two distances concern the residue L31, which is hypothesized to seat 
itself into the hydrophobic pocket formed between TMH2 and TMH3 and also involving 
residues in the EC1 loop, especially W112.3,4,7,22,24,175,176  The measurement of the I3.28-
orexin-A L31 Cβ-Cγ distance in the R* simulation is shown in Figure 176, as I3.28 is 
central to this binding pocket.3,4,7,22,24,175,176   
 
 
Figure 176. Graph of the R* Simulation’s I3.28-orexin-A L31 Cβ-Cγ 
Distance.3,4,7,22,24,175,176   
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The atoms in the I3.28-orexin-A L31 Cβ-Cγ measurement in the R* simulation are shown 
in Figure 177.3,4,7,22,24,175,176   
 
 
 
Figure 177. The R* Simulation’s I3.28-orexin-A L31 Cβ-Cγ Distance.3,4,7,22,24,175,176   
 
Over the course of the simulation, at about 36 ns in, the distance jumps from ~6.0 Å to 
~7.0 Å, signifying the residue L31 shifting to a new hydrophobic pocket formed with the 
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EC2 loop and TMH3, with M45.31 and C45.50 key to this binding pocket.3,4,7,22,24,175,176  
As C45.50 is central to this new binding pocket, the atoms in the C45.50-orexin-A L31 
Sγ-Cγ measurement in the R* simulation are shown in Figure 178.3,4,7,22,24,175,176   
 
 
 
Figure 178. Picture of the R* Simulation’s C45.50-orexin-A L31 Sγ-Cγ 
Distance.3,4,7,22,24,175,176   
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The measurement of the C45.50-orexin-A L31 Sγ-Cγ atoms in the R* simulation are 
shown in Figure 179.3,4,7,22,24,175,176   
 
 
Figure 179. Graph of the R* Simulation’s C45.50-orexin-A L31 Sγ-Cγ 
Distance.3,4,7,22,24,175,176   
 
The measurement of C45.50-orexin-A L31 Sγ-Cγ falls from ~9.0 Å to ~5.0 Å at the end, 
showing that L31 not only found a new binding pocket, it actually stayed there, showing 
its importance as a key residue on orexin-A.3,4,7,22,24,175,176   
  The next two measurements concern the L33 amide cap and its ability to find 
specific hydrogen binding partners, one the almost immobile P3.29 backbone oxygen, 
and another the R6.59 guanidium, which interact with the amide cap’s HT1 hydrogen and 
backbone oxygen, respectively.3,4,7,22,24,175,176  Even though this does not involve L33’s 
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side chain, these remain important.3,4,7,22,24,175,176  The measurement of P3.29-orexin-A 
L33 O-NT and the atoms involved are shown in Figures 180 and 181.3,4,7,22,24,175,176   
 
 
 
Figure 180. The R* Simulation’s P3.29-orexin-A L33 O-NT Distance.3,4,7,22,24,175,176   
 
 
Figure 181. Graph of the R* Simulation’s P3.29-orexin-A L33 O-NT 
Distance.3,4,7,22,24,175,176   
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The atoms in the R6.59-orexin-A L33 Cζ-O measurement in the R* simulation are shown 
in Figure 182, with the measurements in Figure 183.3,4,7,22,24,175,176   
 
 
 
Figure 182. The R* Simulation’s R6.59-orexin-A L33 Cζ-O Distance.3,4,7,22,24,175,176   
 
 
Figure 183. Graph of the R* Simulation’s R6.59-orexin-A L33 Cζ-O 
Distance.3,4,7,22,24,175,176   
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The distances for P3.29-orexin-A L33 O-NT and R6.59-orexin-A L33 Cζ-O were ~3.0 Å 
and ~4.0 Å, consistent with strong hydrogen bonds between oxA and the ox1r, especially 
when it came to oxA binding to ox1r residues that were either immobile or charged, and 
also due to R6.59 supplanting Q4.60 as a hydrogen bond donor.3,4,7,22,24,175,176  In fact, 
L33’s bulky side chain immobilizes these interactions further still, and prevents water 
molecules from interfering with these hydrogen bonds.3,4,7,22,24,175,176   
  The last of these distances is V45.49-orexin-A L20 Cβ-Cγ, and the atoms 
involved are shown in Figure 184.3,4,7,22,24,175,176   
 
 
 
Figure 184. The R* Simulation’s V45.49-orexin-A L20 Cβ-Cγ Distance.3,4,7,22,24,175,176   
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  The measurement of the V45.49-orexin-A L20 Cβ-Cγ distance is shown in Figure 
185.3,4,7,22,24,175,176   
 
 
Figure 185. Graph of the R* Simulation’s V45.49-orexin-A L20 Cβ-Cγ 
Distance.3,4,7,22,24,175,176   
 
The distance between V45.49’s Cβ and orexin-A’s L20 Cγ is ~6.5 Å, showing a 
consistent interaction between L20 and a hydrophobic binding pocket formed by the ox1r 
EC1 and EC2 loops that also interacts with L16 and with L19.3,4,7,22,24,175,176   
Molecular Dynamics Component Interaction Energy Measurements Results 
  Two energy comparison tables were created, each using the R model’s 
interactions with SB-674042 in the first and last frames of its MD simulation so that each 
of those two structures’ component interaction energies between the six parts of SB-
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674042 and the residues of ox1r within 7 Å of each of those parts are calculated with the 
OPLS_2005 force field (as OPLS3 was unavailable for this calculation script), no 
solvent, extended cutoff, and force field charges were used for both “wet” and “dry” 
dielectric conditions, with “wet” as a constant dielectric of 80, and “dry” as a distance-
dependent dielectric of 3.3,7,24,175,176  Four different energy sets were made:  “before dry,” 
“before wet,” “after dry,” and “after wet.”  One of these tables was created to display the 
interaction energies between ox1r and each of the six parts of SB-674042, including a 
total energy for each, as shown in Table 35.3,7,24,137,175,176   
 
Table 35 
 
Interaction Energies between Ox1r and the Six Component Parts of SB-
674042.3,7,24,137,175,176   
 
Before Energy (kcal/mol) Part of SB-674042 After Energy (kcal/mol) 
Dry Wet (with description) Dry Wet 
-45.86 -43.93 Part 1 (fluorophenyl) -26.41 -24.55 
-37.30 -38.81 
Part 2 (1,3-thiazole  
with methyl and C=O) 
-59.64 -56.93 
-25.29 -25.68 Part 3 (proline-like part) -19.55 -19.59 
-3.04 -3.12 Part 4 (methylene) -3.86 -3.88 
-13.59 -5.93 Part 5 (1,3,4-oxadiazole) -23.49 -15.82 
-45.77 -46.81 Part 6 (phenyl) -55.53 -55.86 
-170.86 -164.28 Whole SB-674042 -188.49 -176.64 
 
The energies in Table 35 show which parts of SB-674042 had the most vital interaction 
energies with ox1r, namely the 1,3-thiazole part, which was one of the principal parts 
holding Y6.48 in g+, and the 1,3,4-oxadiazole, which was the part that accepted the 
hydrogen bond from Q3.32.3,7,24,175,176  Furthermore, the phenyl group tucked itself into 
276 
 
 
the TMH2-3 hydrophobic pocket quite well.3,7,24,175,176  The other table was created to 
display the interaction energies between SB-674042 and selected individual residues of 
ox1r, along with binding data, as shown in Table 36.3,7,24,175,176   
 
Table 36 
 
Interaction Energies between SB-674042 and Key Individual Residues of Ox1r.3,7,24,175,176   
 
Before Energy (kcal/mol) Residue of Ox1r After Energy (kcal/mol) 
Dry Wet Kd (Mutant) / Kd (WT) Dry Wet 
-23.44 -14.08 Q3.32 → A 50.9*** -44.77 -34.58 
-2.02 -1.86 A3.33 → T 20.2** -5.46 -5.53 
0.11 -0.10 V3.36 → A 2.1 -8.91 -8.83 
-2.73 -3.04 Y5.47 → A 1.8 -0.32 -0.33 
-9.51 -9.25 Y6.48 → A 10.8** -8.52 -8.53 
-11.26 -11.60 H7.39 → A 22.7*** -6.84 -7.45 
-4.13 -4.80 Y7.43 → A 9.3*** -10.77 -9.03 
Note. *p < 0.05, **p < 0.01, ***p < 0.001, N.D.B. means no detectable binding because of high nonspecific 
binding.3   
 
The energies in Table 36 show a consistency with the main important residues of 
interaction in ox1r interacting with SB-674042, with Q3.32 and Y6.48 each with strong 
energetic interactions, the latter being necessary to keep the ox1r in the R 
state.3,7,24,124,125,126,127,128,129,130,175,176  Q3.32 gained a more significant role by having SB-
674042 wrap around it, in addition to its strong electrostatic role.3,7,24,175,176   
  Two more energy comparison tables were created, each with the R* model’s 
interactions with orexin-A in the first and last frames of the MD simulation, with the 
component interaction energy calculated between oxA and ox1r the same way as between 
SB-674042 and ox1r, for the same total of four different energy sets for each table:  
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“before wet,” “before dry,” “after wet,” and “after dry.”3,4,7,22,24,155,175,176  One of these 
tables was created to display the interaction energies between ox1r and each individual 
residue of orexin-A, along with the sums of the energies for residues 16, 19, 20, and 26-
33 of orexin-A (listed as “Majors”) and for all of orexin-A’s residues, as well as the total 
interaction energies and normalized efficacy for orexin-A, as shown in Table 
37.3,4,7,22,24,155,175,176   
 
Table 37 
 
Interaction Energies between Ox1r and Each Residue of Orexin-A.3,4,7,22,24,155,175,176   
 
Before Energy (kcal/mol) Whole Orexin-A Residue After Energy (kcal/mol) 
Dry Wet 
WT oxA (15-33) 
(pEC50 6.45 ± 0.06, =) 
Dry Wet 
-6.34 -5.88 Pyr1 (n/a, n/a) -17.03 -15.51 
-14.93 -15.20 P2 (n/a, n/a) -14.51 -15.15 
-6.82 -7.06 L3 (n/a, n/a) -1.22 -1.54 
-2.67 -3.31 P4 (n/a, n/a) -23.41 -20.77 
-48.67 -9.02 D5 (n/a, n/a) 9.95 0.09 
-10.28 -10.46 C6 (n/a, n/a) -3.00 -3.33 
-3.52 -3.55 C7 (n/a, n/a) -1.21 -1.21 
6.54 0.92 R8 (n/a, n/a) -7.18 -1.31 
-1.83 -2.57 Q9 (n/a, n/a) 0.78 0.13 
-5.40 -1.86 K10 (n/a, n/a) -0.41 -0.11 
-1.15 -1.37 T11 (n/a, n/a) -0.18 -0.15 
-17.48 -13.35 C12 (n/a, n/a) -0.97 -1.23 
-12.76 -10.22 S13 (n/a, n/a) -17.06 -10.80 
-5.43 -5.94 C14 (n/a, n/a) -8.24 -6.72 
-46.02 -30.39 R15 (→A 6.46 ± 0.03, =) -15.67 -10.51 
-20.95 -20.63 
L16 (→A 71% of  
10 μM oxA, ↓) 
-23.71 -22.88 
-38.42 -16.31 Y17 (→A 6.11 ± 0.03, =) -39.64 -32.48 
2.02 -1.18 E18 (→A 6.71 ± 0.04, =) -6.48 -8.85 
-11.77 -12.19 
L19 (→A 60% of  
10 μM oxA, ↓↓) 
-20.86 -21.24 
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Table 37 
 
Cont. 
 
Before Energy (kcal/mol) Whole Orexin-A Residue After Energy (kcal/mol) 
Dry Wet 
WT oxA (15-33) 
(pEC50 6.45 ± 0.06, =) 
Dry Wet 
-17.81 -17.60 
L20 (→A 37% of  
10 μM oxA, ↓↓) 
-16.56 -16.14 
-39.30 -30.00 H21 (→A 5.89 ± 0.02, =) -29.55 -24.40 
-7.04 -6.56 G22 (→A 6.19 ± 0.09, =) -15.56 -15.39 
-1.84 -1.77 A23 (n/a, =) -13.03 -12.85 
-12.68 -8.16 G24 (→A 6.08 ± 0.03, =) -28.38 -23.13 
-3.25 -5.34 N25 (→A 6.00 ± 0.09, =) -18.52 -9.84 
-67.77 -30.25 
H26 (→A 61% of  
10 μM oxA, ↓↓) 
-49.07 -38.64 
-35.30 -29.01 A27 (→G n/a, ↓↓) -26.11 -20.80 
-15.26 -16.64 A28 (→G n/a, ↓↓) -10.56 -8.85 
-16.43 -15.60 
G29 (→A 15% of  
10 μM oxA, ↓↓↓) 
-15.61 -12.49 
-34.72 -33.79 
I30 (→A inactive at  
10 μM, ↓↓↓) 
-28.22 -28.29 
-49.80 -47.30 
L31 (→A 12% of 10  
μM oxA, ↓↓↓) 
-45.17 -34.87 
-42.47 -19.50 
T32 (→A 39% of 10 μM 
oxA, ↓↓↓) (→D-T inactive 
at 10 μM oxA, n/a) 
-28.60 -29.38 
-79.99 -53.80 
L33 (→A 15% of 10 μM 
oxA, ↓↓↓) (→D-L 18%  
of 10 μM oxA, n/a) 
-82.14 -67.46 
-392.26 -296.32 Majors -346.61 -301.04 
-669.51 -484.88 Totals -597.12 -516.09 
 
The energies in Table 37 show which parts of orexin-A had the most vital interaction 
energies with ox1r, showing a consistency with the most important residues of interaction 
oxA has with ox1r.3,4,7,22,24,155,175,176  The other table was created to display the interaction 
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energies between oxA and the individual residues of ox1r, as well as normalized EC50s 
for orexin-A, as shown in Table 38.3,4,7,22,24,155,175,176   
 
Table 38 
 
Interaction Energies between Orexin-A and the Important Residues of 
Ox1r.3,4,7,22,24,155,175,176   
 
Before Energy (kcal/mol) Orexin-1 Receptor After Energy (kcal/mol) 
Dry Wet EC50(Mutant) / EC50(WT) Dry Wet 
-18.75 -10.44 Q3.32 → A 2.4-fold -19.28 -16.57 
-3.86 -4.61 A3.33 → T 1.8-fold -7.89 -7.73 
-0.08 -0.24 V3.36 → A 30.6-fold -2.52 -2.67 
0.00 0.00 Y5.47 → A 84.4-fold 0.00 -0.01 
-0.25 -0.19 Y6.48 → A 163.9-fold -3.78 -3.71 
-22.45 -11.01 H7.39 → A 241.1-fold -17.79 -6.38 
-2.43 -2.29 Y7.43 → A 8.7-fold -0.64 -0.43 
 
The energies in Table 38 show a consistency with the important residues of interaction in 
ox1r interacting with orexin-A.3,4,7,22,24,155,175,176   
Orexin-B Dock in Ox1r Component Interaction Energy Measurements Results 
  Two more energy comparison tables were created, using the dock of orexin-A 
within the ox1r R* structure taken from the final frame of the MD simulation, and the 
dock of orexin-B in that same structure, with energies calculated as in Tables 37 and 
38.3,4,7,22,24,131,132,155,157,158,159,160,175,176  However, since the dock of orexin-B was 
minimized to clean it up, the orexin-A dock was minimized to the same energetic 
gradient of ~0.21 kJ/mol to improve dock-to-dock comparison, and the resulting data are 
shown in Table 39.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
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Table 39 
 
Interaction Energies between the Entire Ox1r and Each Residue of Orexin-A (Right) and 
Orexin-B (Left).3,4,7,22,24,131,132,155,157,158,159,160,175,176   
 
OxB Energy (kcal/mol) Orexin Residues OxA Energy (kcal/mol) 
Dry Wet Orexin-B vs. Orexin-A Dry Wet 
0.00 0.00 N/a vs. Pyr1 -24.92 -22.95 
0.00 0.00 N/a vs. P2 -15.13 -17.97 
0.00 0.00 N/a vs. L3 -1.50 -1.85 
0.00 0.00 N/a vs. P4 -23.68 -21.43 
0.00 0.00 N/a vs. D5 9.43 1.02 
-13.36 -5.83 R1 vs. C6 -3.71 -3.75 
-0.75 -0.14 S2 vs. C7 -1.37 -1.20 
0.01 0.00 G3 vs. R8 -6.62 -1.19 
0.16 -0.24 P4 vs. Q9 -0.56 -0.14 
0.61 -0.15 P5 vs. K10 -4.04 -1.68 
-0.43 -0.99 G6 vs. T11 0.31 -0.09 
-23.79 -24.34 L7 vs. C12 -1.11 -1.16 
-3.17 -4.23 Q8 vs. S13 -18.28 -7.31 
-5.31 -4.03 G9 vs. C14 -10.03 -9.95 
-26.06 -18.04 R10 vs. R15 -16.93 -11.32 
-29.91 -29.87 L11 vs. L16 -26.77 -25.59 
-23.47 -19.01 Q12 vs. Y17 -38.21 -26.78 
-12.85 -12.36 R13 vs. E18 -5.63 -8.54 
-20.99 -21.33 L14 vs. L19 -21.27 -21.65 
-32.36 -31.98 L15 vs. L20 -31.80 -31.32 
-31.79 -26.95 Q16 vs. H21 -28.84 -24.29 
-14.42 -13.74 A17 vs. G22 -7.02 -6.30 
-5.33 -5.65 S18 vs. A23 -15.07 -15.43 
-23.32 -18.99 G19 vs. G24 -34.11 -26.13 
-27.41 -18.83 N20 vs. N25 -30.56 -18.06 
-62.01 -45.62 H21 vs. H26 -54.47 -30.37 
-29.06 -19.84 A22 vs. A27 -26.80 -20.05 
-12.57 -11.67 A23 vs. A28 -11.80 -10.97 
-18.18 -16.00 G24 vs. G29 -16.63 -14.61 
-20.03 -20.44 I25 vs. I30 -20.25 -20.53 
-52.09 -43.90 L26 vs. L31 -52.79 -45.54 
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Table 39 
 
Cont. 
 
OxB Energy (kcal/mol) Orexin Residues OxA Energy (kcal/mol) 
Dry Wet Orexin-B vs. Orexin-A Dry Wet 
-38.83 -38.59 T27 vs. T32 -38.84 -38.53 
-97.36 -79.83 M28 vs. L33 -91.23 -72.54 
-413.41 -359.07 Majors -392.66 -331.71 
-624.11 -532.60 Total -670.24 -558.19 
 
The energies in Table 39 show a consistency with how orexin-A interacts better with 
ox1r than orexin-B does with ox1r, especially using the first four and last four residues of 
orexin-A in the process.3,4,7,22,24,131,132,155,157,158,159,160,175,176  The last four residues of both 
orexin-A and orexin-B both interact extremely well with the ox1r, but the first four 
residues of orexin-A combined have an interaction with the ox1r that is much stronger 
than that of orexin-B’s L7, as orexin-B lacks the first five residues and the two stabilizing 
disulfide bridges of orexin-A.3,4,7,22,24,131,132,155,157,158,159,160,175,176  Interaction energies 
between oxA and the individual residues of ox1r, as well as normalized EC50s for orexin-
A, are displayed in Table 40.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
 
Table 40 
 
Interaction Energies between Orexin-A (Right) and Orexin-B (Left) and the Important 
Residues of Ox1r.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
 
OxB Energy (kcal/mol) Orexin-1 Receptor OxA Energy (kcal/mol) 
Dry Wet EC50(Mutant) / EC50(WT) Dry Wet 
-25.36 -20.45 Q3.32 → A 2.4-fold -20.17 -15.71 
-7.75 -7.89 A3.33 → T 1.8-fold -5.84 -5.92 
-4.40 -4.86 V3.36 → A 30.6-fold -1.25 -1.35 
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Table 40 
 
Cont. 
 
OxB Energy (kcal/mol) Orexin-1 Receptor OxA Energy (kcal/mol) 
Dry Wet EC50(Mutant) / EC50(WT) Dry Wet 
0.00 0.00 Y5.47 → A 84.4-fold 0.00 -0.01 
-3.61 -3.44 Y6.48 → A 163.9-fold -3.43 -3.40 
-25.42 -16.18 H7.39 → A 241.1-fold -25.38 -17.05 
-0.76 -0.48 Y7.43 → A 8.7-fold -0.56 -0.31 
 
The data for Table 40 are consistent with experimental data that show that oxB activates 
the ox1r as well as oxA does at high enough concentrations, as the N-terminus of the oxB 
dock in the ox1r shown in Figure 186.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
 
 
 
Figure 186. The OxB N-terminus Interacting with the Ox1r R* 
Structure.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
 
The central helix of orexin-B (residues G6 to Q16) is shown in Figure 
187.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
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Figure 187. The Oxb Central Helix Interacting with the Ox1r R* 
Structure.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
 
The C-terminus of orexin-B (residues A17 to M28) is shown in Figure 
188.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
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Figure 188. OxB C-terminus Interacting with the Ox1r R* 
Structure.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
 
These previous three images further bolster the data that shows oxB activates the ox1r as 
well as oxA does at high enough concentrations.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
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Ox1r Crystal Structure Comparisons with the R and R* Structures 
  The recently released ox1r crystal structures, 4zj8 (with suvorexant bound) and 
4zjc (with SB-674042 bound),192 were compared with the orexin-1 receptor models 
before and after the MD simulations3,4,7,22,24,157,158,159,160,175,176 to see the various structural 
similarities and differences between them.3,4,7,22,24,192  First, the ox1r R* structure from 
the final frame of its MD experiment and the crystal structure 4zjc were superimposed, 
with the EC2 loops of both shown in Figure 189.3,4,7,22,24,157,158,159,160,175,176,192   
 
 
 
Figure 189. The EC2 Loops of the Ox1r R* Final Frame (Magenta) Superimposed on the 
Ox1r Crystal Structure 4zjc (Teal).3,4,7,22,24,157,158,159,160,175,176,192   
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Figure 189 shows that the residues on the ox1r R* final frame EC2 loop that bind L16, 
L19, and L20 on orexin-A were identical to those on 4zjc, and faced the same direction, 
into the orexin-A-binding hydrophobic pocket.3,4,7,22,24,157,158,159,160,175,176,192   
  Second, the crystal structure 4zjc and the ox1r R structure that was used as the 
input structure for the R model’s MD experiment were compared, as shown in Figure 
190.3,4,7,22,24,192   
 
 
 
Figure 190. The Ox1r R Model (Magenta) Superimposed on the Ox1r Crystal Structure 
4zjc (Teal).3,4,7,22,24,192   
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  Third, the RMSD of the transmembrane helices of the crystal structure 4zjc and of 
the ox1r R structure that was used as the input structure for the R model’s MD 
experiment was taken, and this was listed in Table 41.3,4,7,22,24,192   
 
Table 41 
 
RMSD between the Cαs of the Respective Transmembrane Helices of the Ox1r R 
Structure and of the Ox1r Crystal Structure 4zjc.3,4,7,22,24,192   
 
TMH# 1 2 3 4 5 6 7 8 
RMSD 0.5383 0.2374 0.3416 0.3731 0.3839 0.2851 0.3074 0.5060 
 
The data suggest that both ox1r models, as the R* model was based on the R model 
before equilibration via MD, line up well with the ox1r crystal structures in both the 
transmembrane and loop regions, especially due to their high homology and high identity, 
rendering the models to be valid for these experiments.3,4,7,22,24,157,158,159,160,175,176,188,192   
  It is further hypothesized that the α-helix in the ox1r crystal structure N-terminus 
binds to the EC2 loop to hold it, but it is a weak van der Waals interaction.3,4,7,22,24,192  
This allows the ox1r N-terminal α-helix to clear the way when orexin-A or orexin-B 
binds to the EC2 loop and “discharges” its C-terminus into the 
ox1r.3,4,7,22,24,140,146,180,181,182,183,184,185,186,187,192   
Ox1r Crystal Structure vs. R Model Component Interaction Energy Measurements 
  The last of these experiments involves the ox1r R model and the ox1r crystal 
structure 4zjc, both of which bind the ox1r antagonist SB-674042.3,7,24,137,192  First, the 
hydrogens on both of these structures, 4zjc and the ox1r R model’s final frame, were 
minimized to roughly the same gradient.3,7,24,137,157,158,159,160,175,176,192  This experiment is a 
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component interaction calculation that compares the “wet” and “dry” interaction energies 
of the six parts of SB-674042 with individual residues of the ox1r crystal 
structure.3,7,24,137,192  The resultant energies are added in a manner similar to Table 35, for 
ox1r’s interaction with SB-674042 and parts thereof, and Table 36, for SB-674042’s 
interaction with individual residues of the ox1r.3,7,24,137,192  Interaction energies between 
ox1r and each of the six parts of SB-674042, including a total energy for each, are shown 
in Table 42.3,7,24,137,157,158,159,160,175,176,192   
 
Table 42 
 
Interaction Energies between Ox1r’s Crystal Structure 4zjc, as Well as the Ox1r R 
Model’s Final Frame, and the Six Component Parts of SB-
674042.3,7,24,137,157,158,159,160,175,176,192   
 
4zjc Energy (kcal/mol) Part of SB-674042 R MD Energy (kcal/mol) 
Dry Wet (with description) Dry Wet 
-41.43 -40.87 Part 1 (fluorophenyl) -29.81 -28.27 
-50.18 -50.10 
Part 2 (1,3-thiazole  
with methyl and C=O) 
-59.77 -56.37 
-23.91 -25.75 Part 3 (proline-like part) -18.46 -18.59 
-11.82 -11.45 Part 4 (methylene) -3.87 -3.88 
-21.18 -22.01 Part 5 (1,3,4-oxadiazole) -24.48 -15.93 
-52.17 -51.03 Part 6 (phenyl) -56.58 -56.76 
-200.68 -201.20 Whole SB-674042 -192.97 -179.80 
 
The energies in Table 42 show that SB-674042 interacts with the ox1r crystal structure 
almost entirely by means of van der Waals interactions between its six parts and the 
ox1r.3,7,24,137,192  SB-674042’s interactions with the ox1r R model are mostly by van der 
Waals forces, with the exception of Q3.32’s electrostatic interactions with the 1,3-
thiazole and the 1,3,4-oxadiazole, which helped the SB-674042 interaction energy with 
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the ox1r R model grow even more favorable.3,7,24,137,192  However, the energies were, by 
and large, more favorable in the ox1r crystal structure than they were in the ox1r R 
model, with the exceptions of the thiazole and phenyl parts, because 4zjc’s SB-674042 
was able to achieve better hydrophobic contacts at the expense of those electrostatic 
interactions.3,7,24,137,192  The two structures used in this experiment are shown in Figure 
191, to show the position of SB-674042 in both.3,7,24,137,157,158,159,160,175,176,192   
 
 
 
Figure 191. The Ox1r R Final Frame (Magenta) Superimposed on the Ox1r Crystal 
Structure 4zjc (Teal).3,7,24,137,157,158,159,160,175,176,192   
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Another table was created to display the interaction energies between SB-674042 and 
selected individual residues of ox1r, along with binding data, as shown in Table 
43.3,7,24,157,158,159,160,175,176,192   
 
Table 43 
 
Interaction Energies between SB-674042 and Key Individual Residues of 
Ox1r.3,7,24,157,158,159,160,175,176,192   
 
4zjc Energy (kcal/mol) Residue of Ox1r R MD Energy (kcal/mol) 
Dry Wet Kd (Mutant) / Kd (WT) Dry Wet 
-33.21 -31.80 Q3.32 → A 50.9*** -46.12 -35.21 
-6.79 -7.36 A3.33 → T 20.2** -5.30 -5.37 
-2.91 -3.09 V3.36 → A 2.1 -9.78 -9.68 
-0.18 -0.21 Y5.47 → A 1.8 -0.32 -0.33 
-5.94 -5.89 Y6.48 → A 10.8** -8.66 -8.59 
-12.72 -13.68 H7.39 → A 22.7*** -7.01 -7.60 
-7.59 -8.41 Y7.43 → A 9.3*** -9.71 -7.91 
Note. *p < 0.05, **p < 0.01, ***p < 0.001, N.D.B. means no detectable binding because of high nonspecific 
binding.3,192 
 
The results of Table 43 show overall consistency with the crystal structure and with 
experimental data, with Q3.32 having the most favorable binding energy.3,7,24,192  
However, Q3.32 is able to have an extremely favorable energy of interaction with SB-
674042 in the crystal structure even without the aid of multiple electrostatic interactions 
as present in the R model.3,7,24,192  Despite having lower binding energy in 4zjc than in the 
ox1r R model, Y6.48 still interacts well with SB-674042 in the crystal structure.3,7,24,192   
  In summary, the above figure and two tables comparing the interaction energy of 
SB-674042 with both the ox1r R model and the ox1r crystal structure 4zjc bolster its role 
in keeping the ox1r in its R state.3,7,24,124,125,126,127,128,129,130,157,158,159,160,175,176,192 
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CHAPTER IV 
 
CONCLUSION 
 
Implications of GPCR Modeling Technique 
  The conclusion of these experiments reveals several facts.  These state that 
homology modeling of GPCRs works well, but the pull-apart homology modeling 
method that requires replacement of each transmembrane helix with its CM 
counterpart,133,147 pulling the helices apart, then minimizing, works best when no high-
homology crystal structures are available.144,145  Furthermore, since the release of the 
ox2r crystal structure7 and those of many peptide-bound GPCRs,46,180,181,182,183,184,185,186, 
187 improved homology modeling methods can be created.  This is because MD 
experiments157,158,159,160,175,176 in a simulated lipid bilayer cause homology models created 
using the pull-apart-and-minimize method to be ripped apart, especially when no 
information about peptide docking in GPCRs was known prior.146,180,181,182,183,184,185,186,187   
  Due to improved crystal structures,7,146,180,181,182,183,184,185,186,187 a GPCR crystal 
structure with closer homology—especially much higher identity7,188—with the GPCR 
sequence in question, would be used by direct mutation, with Modeller134,135,136 only used 
to create the IC3 loop that the co-crystallizing protein replaced,7 as well as the protein 
termini,7 and CM only used to replace the inactive TMH6 with an active 
one.124,125,126,127,128,129,130,133,142,143,144,145,147,148,149  Furthermore, this works best for the job 
as higher identity leads to an increased ability to predict overall structure,7,144,145,188 and 
crystallizing peptide-bound GPCRs allows the proper way to dock peptide ligands to 
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become apparent,146,180,181,182,183,184,185,186,187 e.g., using CM to create the docked part of a 
peptide ligand (in this case, orexin-A),4,22,133,147 then using the original NMR or crystal 
structure to fill in the rest of the ligand (here, orexin-A’s NMR structure).4,22  
Furthermore, Glide can be used to speed up ligand docking.3,7,24,189,190,191 
 Additionally, this method is easier to use as it starts by retaining as much of the 
crystal structure as possible,7 and this increased structural fidelity7,144,145,188 allows the 
creation of the EC1, EC2, EC3, IC1, or IC2 loops with Modeller,134,135,136 as well as the 
creation of any transmembrane helix (except for the R* TMH6) using 
CM124,125,126,127,128,129,130,133,143,144,145,147,148,149 to be obviated.   
  In fact, the extracellular half of TMH6 did not need to be replaced, as the top turn 
in the ox2r crystal structure TMH6 was wound less tightly than that of the CM TMH6, 
allowing for better interhelical packing, and only using residues 6.51-6.56 for 
superposition allowed improved alignment and also allowed the retention of the ox2r 
crystal structure TMH6 residues 6.51-6.61.7,133,144,145,147   
  To summarize modeling technique, as the ox1r crystal structures were released, 
they were shown to have a high enough identity with the ox2r that the residues in the 
EC2 loop that are pointed into the hypothesized orexin-A binding pocket, as well as all of 
the transmembrane helices, were lined up well enough with the respective R and R* 
models of the orexin-1 receptor that they were considered valid models for these 
experiments.3,4,7,22,24,157,158,159,160,175,176,188,192  The new crystal structures even give insight 
into how the EC2 loop and N-terminus would be predicted to interact in the absence of 
orexin-A.3,4,7,22,24,157,158,159,160,175,176,188,192   
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Implications of Ligand Parametrization Technique 
  Improved ligand parametrization techniques158,159,160,161,162,163,164,165,166,167,168 
allowed SB-674042 and pyroglutamate to have new CHARMM parameters made for 
them with far greater speed,158,159,160,161,162,163,164,165,166,167,168 by combining CHARMM 
scripts and spreadsheets in such a way as to immediately reveal problem parameters, 
determine how the parameter should act, and quickly repair that same parameter, at a 
much faster speed than the original scripts would have been able to do 
so.158,159,160,161,162,163,164,165,166,167,168  This leads to the limiting factor in ligand 
parametrization speed becoming the QM conformational searches and QM energy 
profiles, as performed in these experiments in Spartan (Wavefunction Inc., Irvine, 
CA),158,159,160,161,162,163,164,165,166,167,168 with parameters repaired quickly, and in many 
cases, a spreadsheet could be used to perfect one after one or two uses of a CHARMM 
script.158,159,160,161,162,163,164,165,166,167,168  This in turn means that ligand parameters can be 
quickly made, thus speeding up research.158,159,160,161,162,163,164,165,166,167,168   
Implications of R and R* Ox1r Model Results in a Ligand Binding Context 
  As for the ox1r models themselves, each one lends an improved insight as to how 
the orexin-1 receptor operates, since the R ox1r model has SB-674042 keep the ox1r in 
the R state,3,7,24 while the R* ox1r model has oxA keep the ox1r in the R* state.3,4,7,22,24   
  First of all, the ox1r R model binds one end of SB-674042 using Q3.32 and 
H7.39, and subsequently the other end of SB-674042, which binds to both F5.42 and 
Y6.48 by π-π interactions, holds Y6.48 in g+ and this holds TMH6 in an inactive 
conformation.3,7,24,124,125,126,127,128,129,130,139,141   
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  Secondly, the ox1r R* model binds the peptide orexin-A using the EC2 β-sheet to 
bind the hydrophobic side of oxA Helix I,3,4,7,22,24 then “discharges” the C-terminus into 
the receptor binding pocket,146,180,181,182,183,184,185,186,187 with H26 pulled down so it could 
initially interact with D45.51, then pursue the less mobile C45.50 amide oxygen,3,4,7,22,24 
where the final C-terminal residues reach deep enough for L33 can contact F5.42 and 
Y6.48 and hold the latter in trans.3,4,7,22,24,124,125,126,127,128,129,130,139,141,143  As L33 was 
forced deeper into the bundle, T32 (the C-terminal residue with the strongest available 
hydrogen bond donor) could bind to E45.52 and permit its backbone and L31’s to bind to 
H7.39, holding TMH6 in an active conformation long enough for a Gq protein to 
bind.3,4,7,10,11,12,,22,24,124,125,126,127,128,129,130,139,141,143,158,159,160,161,162,163,164,165,166,167,168   
  Thirdly, experiments were performed by comparing the binding of orexin-B to the 
ox1r to orexin-A’s binding to the ox1r, and the results show that orexin-A has superior 
binding energy to the ox1r with respect to orexin-B’s binding energy, yet orexin-B 
interacts with Y6.48 as well as orexin-A does, consistent with experimental results that 
show orexin-A to have better ability to bind to the ox1r at lower concentrations, as oxB 
binds just as well as oxA does at high concentrations.3,4,7,22,24,131,132,155,157,158,159,160,175,176   
  Fourthly, another experiment was performed that compared the binding energy of 
SB-674042 in the R model’s final frame to that of the 4zjc crystal structure, and the 
crystal structure had a superior binding energy with SB-674042 compared to the R 
model, despite depending almost entirely on van der Waals energy to acquire such 
interactions, as opposed to the R model, which still interacts well as it is aided by 
electrostatic interactions between Q3.32 and the 1,3-thiazole and 1,3,4-oxadiazole parts 
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of SB-674042, yet SB-674042 in both the R model and 4zjc keep the ox1r in its R 
state.3,7,24,124,125,126,127,128,129,130,137,157,158,159,160,175,176,192   
Implications of R and R* Ox1r Model Results in a Pharmaceutical Context 
  The pharmaceutical implications of this series of experiments is staggering, as not 
only can improved homology modeling tactics7,133,134,135,136,147,146,180,181,182,183,184,185,186,187 
and improved parametrization methods158,159,160,161,162,163,164,165,166,167,168 improve ligand 
and receptor construction and simulation (cite) and subsequently, improve drug 
design,3,4,5,6,10,13,18 the ox1r itself is an impressive target for drugs, as new 
agonists10,27,28,29,30,31,32,33,34,53,54,55,65,81,86,87,88,89,92,93,100,101,108,109,112,116 and 
antagonists28,36,39,46,47,48,49,50,51,52,53,54,55,59,62,67,69,78,79,90,107 could be designed based on these 
experiments, and side effects of other drugs can be avoided using the results of these 
experiments.60,83,102,120,121,122  In final conclusion, the results of this experiment will 
benefit the orexin drug design field, benefit other drug fields by removing side effects, 
and unlock knowledge about how to design drugs in many other drug fields in the same 
way.   
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